,Unnamed: 0,ID,Event,Item,Dictionary,Verbatim Term,Preferred Term,RXCUI,Drug Name,Normalized RxNorm Id,Approximate RxNorm Id,Best RxNorm Id,Requires Review,MESHPA,ATC1-4,DISPOS_isa_disposition,STRUCT_isa_structure,CHEM_has_ingredient,DISEASE_ci_with,DISEASE_may_treat,DISEASE_may_prevent,MOA_ci_moa,MOA_has_moa,PE_has_pe,EPC_has_epc,VA_has_VAClass,VA_has_VAClass_extended,TC_has_tc,PK_has_pk,THERAP_isa_therapeutic,CHEM_ci_chemclass,PK_site_of_metabolism,PE_ci_pe,DISEASE_induces,CHEM_has_chemical_structure,DISEASE_may_diagnose,SCHEDULE_has_schedule
0,0,1,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram 20 MG,353383.0,Escitalopram 20 MG,321988.0,321988.0,321988,False,Serotonin Agents;Selective Serotonin Reuptake Inhibitors;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzofurans;Amines;Escitalopram","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder, Major;Disease;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,,,
1,0,1,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram 20 MG,353383.0,Escitalopram 20 MG,321988.0,321988.0,321988,False,Serotonin Agents;Selective Serotonin Reuptake Inhibitors;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzofurans;Amines;Escitalopram","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder, Major;Disease;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,,,
2,101,30,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram,321988.0,Escitalopram,321988.0,321988.0,321988,False,Serotonin Agents;Selective Serotonin Reuptake Inhibitors;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzofurans;Amines;Escitalopram","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder, Major;Disease;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,,,
3,101,30,Concomitant Medications,Generic Name,RxNorm,escitalopram,Escitalopram,321988.0,Escitalopram,321988.0,321988.0,321988,False,Serotonin Agents;Selective Serotonin Reuptake Inhibitors;MeSH Pharmacologic Actions (MESHPA);Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Benzofuran-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzofurans;Amines;Escitalopram","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Depressive Disorder;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Depressive Disorder, Major;Disease;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,,,
4,1,1,Concomitant Medications,Generic Name,RxNorm,mirena,Mirena,152061.0,Mirena,152061.0,152061.0,152061,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal",SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Levonorgestrel;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Norgestrel;Polycyclic Compounds;Fused-Ring Compounds,"Kidney Diseases;Endometrial Neoplasms;Adenoma;Chemically-Induced Disorders;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Liver Neoplasms;Adenoma, Liver Cell;Neoplasms by Histologic Type;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Glucose Metabolism Disorders;Liver Diseases;Drug Hypersensitivity;Tobacco Use Disorder;Skin Manifestations;Cerebrovascular Disorders;Reproductive Physiological Phenomena;Urologic Diseases;Neoplasms, Glandular and Epithelial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Brain Diseases;Uterine Diseases;Uterine Neoplasms;Nutritional and Metabolic Diseases;Hemorrhage;Peripheral Vascular Diseases;Heart Diseases;Myocardial Ischemia;Thrombosis;Phlebitis;Vasculitis;Jaundice;Hyperbilirubinemia;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Pregnancy;Uterine Hemorrhage;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Mental Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Neoplasms;Female Urogenital Diseases;Reproduction;Embolism and Thrombosis;Endocrine System Diseases;Headache Disorders;Signs and Symptoms;Metabolic Diseases",,"Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Inhibit Ovum Fertilization;Ovum Fertilization Alteration,Progestin;Progestin-containing Intrauterine Device;Established Pharmacologic Class (EPC);Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Blood Pressure Alteration;Physiologic Effect (PE),"Urogenital Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Abortion, Spontaneous;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Complications;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Pregnancy Outcome;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
5,1,1,Concomitant Medications,Generic Name,RxNorm,mirena,Mirena,152061.0,Mirena,152061.0,152061.0,152061,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal",SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Levonorgestrel;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Norgestrel;Polycyclic Compounds;Fused-Ring Compounds,"Kidney Diseases;Endometrial Neoplasms;Adenoma;Chemically-Induced Disorders;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Liver Neoplasms;Adenoma, Liver Cell;Neoplasms by Histologic Type;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Glucose Metabolism Disorders;Liver Diseases;Drug Hypersensitivity;Tobacco Use Disorder;Skin Manifestations;Cerebrovascular Disorders;Reproductive Physiological Phenomena;Urologic Diseases;Neoplasms, Glandular and Epithelial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Brain Diseases;Uterine Diseases;Uterine Neoplasms;Nutritional and Metabolic Diseases;Hemorrhage;Peripheral Vascular Diseases;Heart Diseases;Myocardial Ischemia;Thrombosis;Phlebitis;Vasculitis;Jaundice;Hyperbilirubinemia;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Pregnancy;Uterine Hemorrhage;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Mental Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Neoplasms;Female Urogenital Diseases;Reproduction;Embolism and Thrombosis;Endocrine System Diseases;Headache Disorders;Signs and Symptoms;Metabolic Diseases",,"Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Inhibit Ovum Fertilization;Ovum Fertilization Alteration,Progestin;Progestin-containing Intrauterine Device;Established Pharmacologic Class (EPC);Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Blood Pressure Alteration;Physiologic Effect (PE),"Urogenital Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Abortion, Spontaneous;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Complications;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Pregnancy Outcome;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
6,37,16,Concomitant Medications,Generic Name,RxNorm,Mirena,Mirena Drug Implant Product,1181044.0,Mirena Drug Implant Product,152061.0,152061.0,152061,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal",SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Levonorgestrel;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Norgestrel;Polycyclic Compounds;Fused-Ring Compounds,"Kidney Diseases;Endometrial Neoplasms;Adenoma;Chemically-Induced Disorders;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Liver Neoplasms;Adenoma, Liver Cell;Neoplasms by Histologic Type;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Glucose Metabolism Disorders;Liver Diseases;Drug Hypersensitivity;Tobacco Use Disorder;Skin Manifestations;Cerebrovascular Disorders;Reproductive Physiological Phenomena;Urologic Diseases;Neoplasms, Glandular and Epithelial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Brain Diseases;Uterine Diseases;Uterine Neoplasms;Nutritional and Metabolic Diseases;Hemorrhage;Peripheral Vascular Diseases;Heart Diseases;Myocardial Ischemia;Thrombosis;Phlebitis;Vasculitis;Jaundice;Hyperbilirubinemia;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Pregnancy;Uterine Hemorrhage;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Mental Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Neoplasms;Female Urogenital Diseases;Reproduction;Embolism and Thrombosis;Endocrine System Diseases;Headache Disorders;Signs and Symptoms;Metabolic Diseases",,"Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Inhibit Ovum Fertilization;Ovum Fertilization Alteration,Progestin;Progestin-containing Intrauterine Device;Established Pharmacologic Class (EPC);Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Blood Pressure Alteration;Physiologic Effect (PE),"Urogenital Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Abortion, Spontaneous;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Complications;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Pregnancy Outcome;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
7,37,16,Concomitant Medications,Generic Name,RxNorm,Mirena,Mirena Drug Implant Product,1181044.0,Mirena Drug Implant Product,152061.0,152061.0,152061,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptive Agents;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal",SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Emergency contraceptives;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES,Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Levonorgestrel;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Norgestrel;Polycyclic Compounds;Fused-Ring Compounds,"Kidney Diseases;Endometrial Neoplasms;Adenoma;Chemically-Induced Disorders;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Liver Neoplasms;Adenoma, Liver Cell;Neoplasms by Histologic Type;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Glucose Metabolism Disorders;Liver Diseases;Drug Hypersensitivity;Tobacco Use Disorder;Skin Manifestations;Cerebrovascular Disorders;Reproductive Physiological Phenomena;Urologic Diseases;Neoplasms, Glandular and Epithelial;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Brain Diseases;Uterine Diseases;Uterine Neoplasms;Nutritional and Metabolic Diseases;Hemorrhage;Peripheral Vascular Diseases;Heart Diseases;Myocardial Ischemia;Thrombosis;Phlebitis;Vasculitis;Jaundice;Hyperbilirubinemia;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Pregnancy;Uterine Hemorrhage;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Mental Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Neoplasms;Female Urogenital Diseases;Reproduction;Embolism and Thrombosis;Endocrine System Diseases;Headache Disorders;Signs and Symptoms;Metabolic Diseases",,"Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Inhibit Ovum Fertilization;Ovum Fertilization Alteration,Progestin;Progestin-containing Intrauterine Device;Established Pharmacologic Class (EPC);Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Blood Pressure Alteration;Physiologic Effect (PE),"Urogenital Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Abortion, Spontaneous;Female Urogenital Diseases and Pregnancy Complications;Pregnancy Complications;Reproduction;Pregnancy;Reproductive Physiological Phenomena;Pregnancy Outcome;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
8,2,2,Concomitant Medications,Generic Name,RxNorm,norethindrone,,,,7514.0,7514.0,7514,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Contraceptives, Oral, Sequential;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal","SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Estren derivatives;PROGESTOGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Norethindrone;Norethindrone Acetate;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Polycyclic Compounds;Fused-Ring Compounds,"Embolism;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Liver Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Uterine Diseases;Hemorrhage;Peripheral Vascular Diseases;Thrombosis;Phlebitis;Vasculitis;Pathological Conditions, Signs and Symptoms;Neoplasms by Site;Uterine Hemorrhage;Pregnancy;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Skin and Connective Tissue Diseases;Female Urogenital Diseases and Pregnancy Complications;Pulmonary Embolism;Respiratory Tract Diseases;Female Urogenital Diseases;Reproduction;Digestive System Diseases;Neoplasms;Embolism and Thrombosis","Endometriosis;Skin Diseases;Gonadal Disorders;Endometrial Hyperplasia;Menorrhagia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Hemorrhage;Sebaceous Gland Diseases;Hypogonadism;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Urogenital Diseases;Skin and Connective Tissue Diseases;Acne Vulgaris;Female Urogenital Diseases and Pregnancy Complications;Acneiform Eruptions;Female Urogenital Diseases;Endocrine System Diseases","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Decreased Luteinizing Hormone Secretion;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Pituitary Gland Activity Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Gonadotropin Releasing Hormone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration,Chemical Structure;Progestin;Established Pharmacologic Class (EPC);Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
9,2,2,Concomitant Medications,Generic Name,RxNorm,norethindrone,,,,7514.0,7514.0,7514,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Contraceptives, Oral, Sequential;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal","SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Estren derivatives;PROGESTOGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Norethindrone;Norethindrone Acetate;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Polycyclic Compounds;Fused-Ring Compounds,"Embolism;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Liver Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Uterine Diseases;Hemorrhage;Peripheral Vascular Diseases;Thrombosis;Phlebitis;Vasculitis;Pathological Conditions, Signs and Symptoms;Neoplasms by Site;Uterine Hemorrhage;Pregnancy;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Skin and Connective Tissue Diseases;Female Urogenital Diseases and Pregnancy Complications;Pulmonary Embolism;Respiratory Tract Diseases;Female Urogenital Diseases;Reproduction;Digestive System Diseases;Neoplasms;Embolism and Thrombosis","Endometriosis;Skin Diseases;Gonadal Disorders;Endometrial Hyperplasia;Menorrhagia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Hemorrhage;Sebaceous Gland Diseases;Hypogonadism;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Urogenital Diseases;Skin and Connective Tissue Diseases;Acne Vulgaris;Female Urogenital Diseases and Pregnancy Complications;Acneiform Eruptions;Female Urogenital Diseases;Endocrine System Diseases","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Decreased Luteinizing Hormone Secretion;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Pituitary Gland Activity Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Gonadotropin Releasing Hormone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration,Chemical Structure;Progestin;Established Pharmacologic Class (EPC);Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
10,115,33,Concomitant Medications,Generic Name,RxNorm,norethi,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],748977.0,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],,7514.0,7514,True,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Contraceptives, Oral, Sequential;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal","SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Estren derivatives;PROGESTOGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Norethindrone;Norethindrone Acetate;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Polycyclic Compounds;Fused-Ring Compounds,"Embolism;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Liver Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Uterine Diseases;Hemorrhage;Peripheral Vascular Diseases;Thrombosis;Phlebitis;Vasculitis;Pathological Conditions, Signs and Symptoms;Neoplasms by Site;Uterine Hemorrhage;Pregnancy;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Skin and Connective Tissue Diseases;Female Urogenital Diseases and Pregnancy Complications;Pulmonary Embolism;Respiratory Tract Diseases;Female Urogenital Diseases;Reproduction;Digestive System Diseases;Neoplasms;Embolism and Thrombosis","Endometriosis;Skin Diseases;Gonadal Disorders;Endometrial Hyperplasia;Menorrhagia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Hemorrhage;Sebaceous Gland Diseases;Hypogonadism;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Urogenital Diseases;Skin and Connective Tissue Diseases;Acne Vulgaris;Female Urogenital Diseases and Pregnancy Complications;Acneiform Eruptions;Female Urogenital Diseases;Endocrine System Diseases","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Decreased Luteinizing Hormone Secretion;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Pituitary Gland Activity Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Gonadotropin Releasing Hormone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration,Chemical Structure;Progestin;Established Pharmacologic Class (EPC);Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
11,115,33,Concomitant Medications,Generic Name,RxNorm,norethi,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],748977.0,{28 (Norethindrone 0.35 MG Oral Tablet) } Pack [Nora-BE 28 Day],,7514.0,7514,True,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Contraceptives, Oral, Sequential;Physiological Effects of Drugs;Contraceptives, Oral;Contraceptive Agents, Hormonal","SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;Progestogens;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;Estren derivatives;PROGESTOGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,Norpregnanes;Norpregnenes;Norethindrone;Norethindrone Acetate;Substances;Steroids;Substances and Cells (CHEM);Norsteroids;Polycyclic Compounds;Fused-Ring Compounds,"Embolism;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Lung Diseases;Skin Diseases;Thromboembolism;Life Phases, Behavior Mechanisms and Physiologic States;Drug Hypersensitivity;Liver Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Breast Diseases;Uterine Diseases;Hemorrhage;Peripheral Vascular Diseases;Thrombosis;Phlebitis;Vasculitis;Pathological Conditions, Signs and Symptoms;Neoplasms by Site;Uterine Hemorrhage;Pregnancy;Thrombophlebitis;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Vascular Diseases;Skin and Connective Tissue Diseases;Female Urogenital Diseases and Pregnancy Complications;Pulmonary Embolism;Respiratory Tract Diseases;Female Urogenital Diseases;Reproduction;Digestive System Diseases;Neoplasms;Embolism and Thrombosis","Endometriosis;Skin Diseases;Gonadal Disorders;Endometrial Hyperplasia;Menorrhagia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Hemorrhage;Sebaceous Gland Diseases;Hypogonadism;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Urogenital Diseases;Skin and Connective Tissue Diseases;Acne Vulgaris;Female Urogenital Diseases and Pregnancy Complications;Acneiform Eruptions;Female Urogenital Diseases;Endocrine System Diseases","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Organ System Specific Effects;Female Reproductive System Activity Alteration;Decreased Luteinizing Hormone Secretion;Inhibit Ovulation;Decreased Embryonic Implantation;Endocrine Activity Alteration;Ovarian Function Alteration;Embryonic Implantation Alteration;Pituitary Gland Activity Alteration;Embryonic & Fetal Alteration;Ovulation Alteration;Gonadotropin Releasing Hormone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration,Chemical Structure;Progestin;Established Pharmacologic Class (EPC);Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES","CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS,OTHER;PROGESTINS;ANTINEOPLASTICS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES;ANTINEOPLASTIC HORMONES",,,Medicinal product categorized by therapeutic role;Contraceptive agent,,,,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
12,3,3,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
13,3,3,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
14,6,5,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
15,6,5,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
16,19,8,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
17,19,8,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
18,70,24,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
19,70,24,Concomitant Medications,Generic Name,RxNorm,metformin,,,,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
20,90,28,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
21,90,28,Concomitant Medications,Generic Name,RxNorm,Metformin,Metformin,6809.0,Metformin,6809.0,6809.0,6809,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Metformin;Organic Chemicals,"Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Physiologic Effect (PE),Chemical Structure;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Biguanide,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
22,4,3,Concomitant Medications,Generic Name,RxNorm,Epesin,,,,,,,True,,,,,,,,,,,,,,,,,,,,,,,,
23,5,4,Concomitant Medications,Generic Name,RxNorm,tylenol,,,,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
24,5,4,Concomitant Medications,Generic Name,RxNorm,tylenol,,,,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
25,27,10,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
26,27,10,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
27,44,17,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
28,44,17,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
29,47,18,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
30,47,18,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
31,52,20,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
32,52,20,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
33,59,21,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
34,59,21,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
35,60,22,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
36,60,22,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
37,84,26,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
38,84,26,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
39,94,28,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
40,94,28,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
41,136,41,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
42,136,41,Concomitant Medications,Generic Name,RxNorm,tylenol,Tylenol Pill,1187315.0,Tylenol Pill,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
43,142,43,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
44,142,43,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
45,151,45,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
46,151,45,Concomitant Medications,Generic Name,RxNorm,Tylenol,Tylenol,202433.0,Tylenol,202433.0,202433.0,202433,False,"Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antipyretics",Anilides;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,,Phenol structure-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
47,7,5,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
48,7,5,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
49,16,8,Concomitant Medications,Generic Name,RxNorm,lisinopril,,,,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
50,16,8,Concomitant Medications,Generic Name,RxNorm,lisinopril,,,,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
51,23,9,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
52,23,9,Concomitant Medications,Generic Name,RxNorm,Lisinopril,Lisinopril,29046.0,Lisinopril,29046.0,29046.0,29046,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cardiotonic Agents;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Lisinopril;Peptides;Substances;Dipeptides;Substances and Cells (CHEM);Oligopeptides;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Infarction;Necrosis;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Ischemia;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
53,8,5,Concomitant Medications,Generic Name,RxNorm,Atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
54,8,5,Concomitant Medications,Generic Name,RxNorm,Atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
55,17,8,Concomitant Medications,Generic Name,RxNorm,atorvastatin,,,,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
56,17,8,Concomitant Medications,Generic Name,RxNorm,atorvastatin,,,,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
57,73,24,Concomitant Medications,Generic Name,RxNorm,atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
58,73,24,Concomitant Medications,Generic Name,RxNorm,atorvastatin,atorvastatin,83367.0,atorvastatin,83367.0,83367.0,83367,False,Anticholesteremic Agents;Antihypertensive Agents;Calcium Channel Blockers;Enzyme Inhibitors;Therapeutic Uses;Antimetabolites;MeSH Pharmacologic Actions (MESHPA);Lipid Regulating Agents;Physiological Effects of Drugs;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Hydroxymethylglutaryl-CoA Reductase Inhibitors;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"LIPID MODIFYING AGENTS, PLAIN;Combinations of various lipid modifying agents;Lipid modifying agents in combination with other drugs;HMG CoA reductase inhibitors;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;LIPID MODIFYING AGENTS, COMBINATIONS;Anatomical Therapeutic Chemical (ATC1-4)",HMG-CoA reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Lipids;Fatty Acids;Atorvastatin;Heptanoic Acids;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Heterocyclic Compounds, 1-Ring;Azoles","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Postpartum Period;Digestive System Diseases;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Hepatic Insufficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Liver Failure","Heart Diseases;Dyslipidemias;Arteriosclerosis;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Hyperlipoproteinemias;Arterial Occlusive Diseases;Hypercholesterolemia;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Cardiovascular Diseases;Metabolic Diseases;Lipid Metabolism Disorders;Coronary Disease;Nutritional and Metabolic Diseases","Heart Diseases;Coronary Artery Disease;Vascular Diseases;Myocardial Ischemia;Arterial Occlusive Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Arteriosclerosis;Disease;Coronary Disease",,Mechanism of Action (MoA);Enzyme Inhibitors;Enzyme Interactions;Cholesterol Synthesis Inhibitors;Sterol Synthesis Inhibitors;Hydroxymethylglutaryl-CoA Reductase Inhibitors,Cholesterol Synthesis Alteration;Metabolic Activity Alteration;Decreased Cholesterol Synthesis;Lipid Metabolism Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Sterol Metabolism Alteration;Cholesterol Metabolism Alteration,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Cardiovascular Agent;Enzyme Interaction;HMG-CoA Reductase Inhibitor,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,CALCIUM CHANNEL BLOCKERS;ANTILIPEMIC AGENTS;CARDIOVASCULAR MEDICATIONS;VA CLASSES,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,,,,
59,9,5,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
60,9,5,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
61,58,21,Concomitant Medications,Generic Name,RxNorm,Benzonatate,benzonatate,18993.0,benzonatate,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
62,58,21,Concomitant Medications,Generic Name,RxNorm,Benzonatate,benzonatate,18993.0,benzonatate,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
63,137,41,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
64,137,41,Concomitant Medications,Generic Name,RxNorm,benzonatate,benzonatate 100 MG,315473.0,benzonatate 100 MG,18993.0,18993.0,18993,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
65,10,5,Concomitant Medications,Generic Name,RxNorm,beclomethasone dipropionate,Beclomethasone Dipropionate,1348.0,Beclomethasone Dipropionate,1348.0,1348.0,1348,False,"Glucocorticoids;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,"Pregnadienetriols;Substances;Steroids;Beclomethasone;Substances and Cells (CHEM);Polycyclic Compounds;Steroids, Chlorinated;Fused-Ring Compounds;Pregnadienes;Pregnanes","Asthma;Hypersensitivity;Chemically-Induced Disorders;Drug Hypersensitivity;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Hypersensitivity;Infections;Rhinitis;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Inflammation;Hypersensitivity, Immediate;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Pathologic Processes","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Vascular Tone Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Vasoconstriction;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"NASAL AND THROAT AGENTS,TOPICAL;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","NASAL AND THROAT AGENTS,TOPICAL;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Fecal Excretion;Pharmacokinetics (PK);Elimination;Route of Excretion,,,,,,,,
66,10,5,Concomitant Medications,Generic Name,RxNorm,beclomethasone dipropionate,Beclomethasone Dipropionate,1348.0,Beclomethasone Dipropionate,1348.0,1348.0,1348,False,"Glucocorticoids;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,"Pregnadienetriols;Substances;Steroids;Beclomethasone;Substances and Cells (CHEM);Polycyclic Compounds;Steroids, Chlorinated;Fused-Ring Compounds;Pregnadienes;Pregnanes","Asthma;Hypersensitivity;Chemically-Induced Disorders;Drug Hypersensitivity;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Hypersensitivity;Infections;Rhinitis;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Inflammation;Hypersensitivity, Immediate;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Pathologic Processes","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Vascular Tone Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Vasoconstriction;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"NASAL AND THROAT AGENTS,TOPICAL;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","NASAL AND THROAT AGENTS,TOPICAL;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Fecal Excretion;Pharmacokinetics (PK);Elimination;Route of Excretion,,,,,,,,
67,11,6,Concomitant Medications,Generic Name,RxNorm,Augmentin,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],618037.0,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],151392.0,151392.0,151392,False,Anti-Infective Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);beta-Lactamase Inhibitors;Anti-Bacterial Agents;Molecular Mechanisms of Pharmacological Action,"Penicillins with extended spectrum;BETA-LACTAM ANTIBACTERIALS, PENICILLINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Broad spectrum penicillin antibacterial agent;Aminopenicillin antibacterial agent;Medicinal product categorized by disposition,Penicillin-containing product;Nitrogen and/or nitrogen compound-containing product;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent;Aminopenicillin antibacterial agent;Medicinal product categorized by structure;Beta-lactam-containing product,"Penicillin G;Heterocyclic Compounds, 2-Ring;Amides;Inorganic Chemicals;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Amoxicillin;Ampicillin;Organic Chemicals;Substances;Penicillins;Heterocyclic Compounds;Substances and Cells (CHEM);Clavulanic Acid;Clavulanic Acids;Lactams;Heterocyclic Compounds, 1-Ring;beta-Lactams","Biliary Tract Diseases;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cholestasis;Cholestasis, Extrahepatic;Bile Duct Diseases","Otitis;Bites and Stings;Chemically-Induced Disorders;Male Urogenital Diseases;Duodenal Ulcer;Wounds and Injuries;Respiratory Tract Diseases;Nose Diseases;Skin Diseases;Chlamydia Infections;Tick-Borne Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Intestinal Diseases;Respiratory Tract Infections;Sinusitis;Pasteurellaceae Infections;Urologic Diseases;Gram-Positive Bacterial Infections;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Actinomycosis;Sexually Transmitted Diseases;Poisoning;Urinary Tract Infections;Actinomycetales Infections;Borrelia Infections;Vector Borne Diseases;Listeriosis;Otitis Media;Pathological Conditions, Signs and Symptoms;Helicobacter Infections;Lyme Disease;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Soft Tissue Infections;Urogenital Diseases;Staphylococcal Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Duodenal Diseases;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Digestive System Diseases;Gastrointestinal Diseases;Peptic Ulcer;Female Urogenital Diseases and Pregnancy Complications;Bites, Human;Spirochaetales Infections;Female Urogenital Diseases;Chlamydiaceae Infections;Communicable Diseases;Sexually Transmitted Diseases, Bacterial;Stomach Diseases;Haemophilus Infections;Skin Diseases, Bacterial","Heart Diseases;Cardiovascular Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Infections",,beta Lactamase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Transpeptidase Inhibitors,Decreased Cell Wall Synthesis & Repair;Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cell Wall Alteration;Cellular Structure Alteration,,"ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES","ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES",Anti-infective Agent;Antibacterial Agent;Therapeutic Categories,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),Antiinfective agent;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent;Aminopenicillin antibacterial agent;Antibacterial agent;Medicinal product categorized by therapeutic role,"Acids, Acyclic;Carbamates;Penicillins;Electrolytes;Lactams;Thiocarbamates;Acids, Noncarboxylic;Heterocyclic Compounds, 2-Ring;Ditiocarb;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Ions;Organic Chemicals;Heterocyclic Compounds, 1-Ring;beta-Lactams;Disulfiram;Hydrogen Sulfide;Inorganic Chemicals;Sulfur Compounds;Acids;Sulfides;Disulfides;Carboxylic Acids;Anions;Amides;Substances;Substances and Cells (CHEM);Gases",,,,,,
68,11,6,Concomitant Medications,Generic Name,RxNorm,Augmentin,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],618037.0,Amoxicillin 1000 MG / Clavulanate 62.5 MG [Augmentin],151392.0,151392.0,151392,False,Anti-Infective Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);beta-Lactamase Inhibitors;Anti-Bacterial Agents;Molecular Mechanisms of Pharmacological Action,"Penicillins with extended spectrum;BETA-LACTAM ANTIBACTERIALS, PENICILLINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Broad spectrum penicillin antibacterial agent;Aminopenicillin antibacterial agent;Medicinal product categorized by disposition,Penicillin-containing product;Nitrogen and/or nitrogen compound-containing product;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent;Aminopenicillin antibacterial agent;Medicinal product categorized by structure;Beta-lactam-containing product,"Penicillin G;Heterocyclic Compounds, 2-Ring;Amides;Inorganic Chemicals;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Amoxicillin;Ampicillin;Organic Chemicals;Substances;Penicillins;Heterocyclic Compounds;Substances and Cells (CHEM);Clavulanic Acid;Clavulanic Acids;Lactams;Heterocyclic Compounds, 1-Ring;beta-Lactams","Biliary Tract Diseases;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cholestasis;Cholestasis, Extrahepatic;Bile Duct Diseases","Otitis;Bites and Stings;Chemically-Induced Disorders;Male Urogenital Diseases;Duodenal Ulcer;Wounds and Injuries;Respiratory Tract Diseases;Nose Diseases;Skin Diseases;Chlamydia Infections;Tick-Borne Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Intestinal Diseases;Respiratory Tract Infections;Sinusitis;Pasteurellaceae Infections;Urologic Diseases;Gram-Positive Bacterial Infections;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Actinomycosis;Sexually Transmitted Diseases;Poisoning;Urinary Tract Infections;Actinomycetales Infections;Borrelia Infections;Vector Borne Diseases;Listeriosis;Otitis Media;Pathological Conditions, Signs and Symptoms;Helicobacter Infections;Lyme Disease;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Soft Tissue Infections;Urogenital Diseases;Staphylococcal Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Duodenal Diseases;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Digestive System Diseases;Gastrointestinal Diseases;Peptic Ulcer;Female Urogenital Diseases and Pregnancy Complications;Bites, Human;Spirochaetales Infections;Female Urogenital Diseases;Chlamydiaceae Infections;Communicable Diseases;Sexually Transmitted Diseases, Bacterial;Stomach Diseases;Haemophilus Infections;Skin Diseases, Bacterial","Heart Diseases;Cardiovascular Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Infections",,beta Lactamase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Transpeptidase Inhibitors,Decreased Cell Wall Synthesis & Repair;Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cell Wall Alteration;Cellular Structure Alteration,,"ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES","ANTIMICROBIALS;PENICILLINS,AMINO DERIVATIVES;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;VA CLASSES",Anti-infective Agent;Antibacterial Agent;Therapeutic Categories,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),Antiinfective agent;Broad spectrum penicillin antibacterial agent;Beta-lactam antibacterial agent;Penicillin antibacterial agent;Aminopenicillin antibacterial agent;Antibacterial agent;Medicinal product categorized by therapeutic role,"Acids, Acyclic;Carbamates;Penicillins;Electrolytes;Lactams;Thiocarbamates;Acids, Noncarboxylic;Heterocyclic Compounds, 2-Ring;Ditiocarb;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Ions;Organic Chemicals;Heterocyclic Compounds, 1-Ring;beta-Lactams;Disulfiram;Hydrogen Sulfide;Inorganic Chemicals;Sulfur Compounds;Acids;Sulfides;Disulfides;Carboxylic Acids;Anions;Amides;Substances;Substances and Cells (CHEM);Gases",,,,,,
69,12,6,Concomitant Medications,Generic Name,RxNorm,Doxycycline,Doxycycline,3640.0,Doxycycline,3640.0,3640.0,3640,False,Anti-Infective Agents;Antiparasitic Agents;Antiprotozoal Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Anti-Bacterial Agents;Antimalarials,ANTIBACTERIALS FOR SYSTEMIC USE;STOMATOLOGICAL PREPARATIONS;Tetracyclines;Antiinfectives and antiseptics for local oral treatment;ANTIINFECTIVES FOR SYSTEMIC USE;TETRACYCLINES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),,Tetracycline structure-containing product;Medicinal product categorized by structure;Tetracycline antibacterial agent,"Hydrocarbons;Hydrocarbons, Cyclic;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic;Doxycycline","Age Groups;Life Phases, Behavior Mechanisms and Physiologic States;Child, Preschool;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Child;Digestive System Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Mycoplasma Infections;Campylobacter Infections;Pleural Diseases;Lung Diseases;Eye Diseases;Conjunctival Diseases;Treponemal Infections;Eye Infections;Chlamydia Infections;Tick-Borne Diseases;Skin Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Spotted Fever Group Rickettsiosis;Anthrax;Respiratory Tract Infections;Conjunctivitis, Bacterial;Pneumonia;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Trachoma;Rickettsia Infections;Psittacosis;Borrelia Infections;Vector Borne Diseases;Pathological Conditions, Signs and Symptoms;Enterobacteriaceae Infections;Rocky Mountain Spotted Fever;Rickettsiaceae Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Mycoplasmatales Infections;Urogenital Diseases;Conjunctivitis;Vibrio Infections;Corneal Diseases;Eye Infections, Bacterial;Skin Diseases, Infectious;Pleural Effusion;Skin and Connective Tissue Diseases;Skin Diseases, Bacterial;Plague;Relapsing Fever;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bacillaceae Infections;Granuloma Inguinale;Spirochaetales Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Syphilis;Yersinia Infections;Cholera;Chlamydophila Infections;Communicable Diseases","Malaria;Vector Borne Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Parasitic Diseases;Protozoan Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Cell Membrane Alteration;Organ System Specific Effects;Cellular Activity Alteration;Decreased Mitosis;Decreased Protein Synthesis;Striated Muscle Anabolism Alteration;Generalized Systemic Effects;Translation Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Cellular Division Phase Alteration;Mitosis Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Cellular Structure Alteration,Established Pharmacologic Class (EPC);Chemical Structure;Tetracycline-class Drug,ANTIMICROBIALS;VA CLASSES;TETRACYCLINES,ANTIMICROBIALS;VA CLASSES;TETRACYCLINES,,,Antiprotozoal agent;Antiinfective agent;Antiparasitic-containing product;Antimalarial agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Tetracycline antibacterial agent,"Hydrocarbons;Hydrocarbons, Cyclic;Tetracycline;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic",,,"Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sclerosis;Pathologic Processes","Hydrocarbons;Hydrocarbons, Cyclic;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic",,
70,12,6,Concomitant Medications,Generic Name,RxNorm,Doxycycline,Doxycycline,3640.0,Doxycycline,3640.0,3640.0,3640,False,Anti-Infective Agents;Antiparasitic Agents;Antiprotozoal Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Anti-Bacterial Agents;Antimalarials,ANTIBACTERIALS FOR SYSTEMIC USE;STOMATOLOGICAL PREPARATIONS;Tetracyclines;Antiinfectives and antiseptics for local oral treatment;ANTIINFECTIVES FOR SYSTEMIC USE;TETRACYCLINES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),,Tetracycline structure-containing product;Medicinal product categorized by structure;Tetracycline antibacterial agent,"Hydrocarbons;Hydrocarbons, Cyclic;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic;Doxycycline","Age Groups;Life Phases, Behavior Mechanisms and Physiologic States;Child, Preschool;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Child;Digestive System Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Mycoplasma Infections;Campylobacter Infections;Pleural Diseases;Lung Diseases;Eye Diseases;Conjunctival Diseases;Treponemal Infections;Eye Infections;Chlamydia Infections;Tick-Borne Diseases;Skin Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Spotted Fever Group Rickettsiosis;Anthrax;Respiratory Tract Infections;Conjunctivitis, Bacterial;Pneumonia;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Trachoma;Rickettsia Infections;Psittacosis;Borrelia Infections;Vector Borne Diseases;Pathological Conditions, Signs and Symptoms;Enterobacteriaceae Infections;Rocky Mountain Spotted Fever;Rickettsiaceae Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Mycoplasmatales Infections;Urogenital Diseases;Conjunctivitis;Vibrio Infections;Corneal Diseases;Eye Infections, Bacterial;Skin Diseases, Infectious;Pleural Effusion;Skin and Connective Tissue Diseases;Skin Diseases, Bacterial;Plague;Relapsing Fever;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bacillaceae Infections;Granuloma Inguinale;Spirochaetales Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Syphilis;Yersinia Infections;Cholera;Chlamydophila Infections;Communicable Diseases","Malaria;Vector Borne Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Parasitic Diseases;Protozoan Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Cell Membrane Alteration;Organ System Specific Effects;Cellular Activity Alteration;Decreased Mitosis;Decreased Protein Synthesis;Striated Muscle Anabolism Alteration;Generalized Systemic Effects;Translation Alteration;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Cellular Division Phase Alteration;Mitosis Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Cellular Structure Alteration,Established Pharmacologic Class (EPC);Chemical Structure;Tetracycline-class Drug,ANTIMICROBIALS;VA CLASSES;TETRACYCLINES,ANTIMICROBIALS;VA CLASSES;TETRACYCLINES,,,Antiprotozoal agent;Antiinfective agent;Antiparasitic-containing product;Antimalarial agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Tetracycline antibacterial agent,"Hydrocarbons;Hydrocarbons, Cyclic;Tetracycline;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic",,,"Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sclerosis;Pathologic Processes","Hydrocarbons;Hydrocarbons, Cyclic;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Substances;Substances and Cells (CHEM);Tetracyclines;Organic Chemicals;Naphthacenes;Hydrocarbons, Aromatic",,
71,13,6,Concomitant Medications,Generic Name,RxNorm,Advair,,,,301543.0,301543.0,301543,False,"Adrenergic Agonists;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Anti-Asthmatic Agents;Sympathomimetics;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Autonomic Agents;Adrenergic beta-2 Receptor Agonists;Bronchodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Adrenergic Agents;Anti-Allergic Agents;Hormones, Hormone Substitutes, and Hormone Antagonists","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Selective beta-2-adrenoreceptor agonists;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Glucocorticoids;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Steroid-containing product;Phenol structure-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Ethanolamines;Salmeterol Xinafoate;Androstadienes;Albuterol;Amino Alcohols;Steroids;Organic Chemicals;Fused-Ring Compounds;Phenethylamines;Ethanol;Amines;Polycyclic Compounds;Alcohols;Androstenes;Ethylamines;Androstanes;Substances;Substances and Cells (CHEM);Fluticasone,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Signs and Symptoms;Disease Attributes;Pathologic Processes;Infections;Hypersensitivity;Food Hypersensitivity;Skin Diseases, Infectious;Skin and Connective Tissue Diseases;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Milk Hypersensitivity;Acute Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Asthma;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Bronchial Spasm;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Nasal Polyps;Polyps;Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Asthma;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Exercise-Induced Allergies;Hypersensitivity;Bronchial Spasm;Otorhinolaryngologic Diseases;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Steroid Hormone Receptor Agonists;Adrenergic beta-Agonists;Glucocorticoid Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;G-Protein-linked Receptor Interactions;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Endocrine Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Cellular Degradation/Digestion Alteration;Peripheral Nervous System Activity Alteration;Bronchodilation;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Corticosteroid;Established Pharmacologic Class (EPC);beta-Adrenergic Agonist;beta2-Adrenergic Agonist;Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
72,13,6,Concomitant Medications,Generic Name,RxNorm,Advair,,,,301543.0,301543.0,301543,False,"Adrenergic Agonists;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Anti-Asthmatic Agents;Sympathomimetics;Adrenergic beta-Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Autonomic Agents;Adrenergic beta-2 Receptor Agonists;Bronchodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Adrenergic Agents;Anti-Allergic Agents;Hormones, Hormone Substitutes, and Hormone Antagonists","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Selective beta-2-adrenoreceptor agonists;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Glucocorticoids;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Steroid-containing product;Phenol structure-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Ethanolamines;Salmeterol Xinafoate;Androstadienes;Albuterol;Amino Alcohols;Steroids;Organic Chemicals;Fused-Ring Compounds;Phenethylamines;Ethanol;Amines;Polycyclic Compounds;Alcohols;Androstenes;Ethylamines;Androstanes;Substances;Substances and Cells (CHEM);Fluticasone,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Signs and Symptoms;Disease Attributes;Pathologic Processes;Infections;Hypersensitivity;Food Hypersensitivity;Skin Diseases, Infectious;Skin and Connective Tissue Diseases;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Milk Hypersensitivity;Acute Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Asthma;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Bronchial Spasm;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Nasal Polyps;Polyps;Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Asthma;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Exercise-Induced Allergies;Hypersensitivity;Bronchial Spasm;Otorhinolaryngologic Diseases;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Steroid Hormone Receptor Agonists;Adrenergic beta-Agonists;Glucocorticoid Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;G-Protein-linked Receptor Interactions;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Endocrine Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Cellular Degradation/Digestion Alteration;Peripheral Nervous System Activity Alteration;Bronchodilation;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Corticosteroid;Established Pharmacologic Class (EPC);beta-Adrenergic Agonist;beta2-Adrenergic Agonist;Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
73,14,6,Concomitant Medications,Generic Name,RxNorm,Prednisone,Prednisone 10 MG,317663.0,Prednisone 10 MG,8640.0,8640.0,8640,False,"Glucocorticoids;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents;Antineoplastic Agents, Hormonal","CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;Glucocorticoids;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;CORTICOSTEROIDS FOR SYSTEMIC USE;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",Immunomodulator-containing product;Medicinal product categorized by disposition,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,Pregnadienediols;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Pregnadienes;Pregnanes;Prednisone,"Virus Diseases;Bacterial Infections and Mycoses;Chemically-Induced Disorders;DNA Virus Infections;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Chickenpox;Herpesviridae Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Varicella Zoster Virus Infection;Mycoses;Infections","Autoimmune Diseases;Occupational Diseases;Skin Diseases, Eczematous;Thyroid Diseases;Adrenal Gland Diseases;Male Urogenital Diseases;Water-Electrolyte Imbalance;Demyelinating Diseases;Central Nervous System Diseases;Lung Diseases;Eye Diseases;Sarcoidosis;Graft vs Host Disease;Bacterial Infections and Mycoses;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Dermatitis, Seborrheic;Bronchial Diseases;Lymphoproliferative Disorders;Hemorrhage;Arthritis;Rheumatic Diseases;Purpura;Demyelinating Autoimmune Diseases, CNS;Skin and Connective Tissue Diseases;Nephrosis;Lymphatic Diseases;Uveitis;Inflammatory Bowel Diseases;Iris Diseases;Dermatitis;Musculoskeletal Diseases;Conjunctivitis, Allergic;Skin Diseases, Genetic;Tuberculosis;Anemia;Wounds and Injuries;Collagen Diseases;Bacterial Infections;Blood Coagulation Disorders;Lupus Erythematosus, Systemic;Skin Manifestations;Immunoproliferative Disorders;Gram-Positive Bacterial Infections;Tuberculosis, Pulmonary;Thyroiditis;Genetic Diseases, Inborn;Anemia, Hemolytic;Inflammation;Erythema Multiforme;Arthritis, Psoriatic;Conjunctivitis;Urogenital Diseases;Spondylitis;Pemphigus;Neoplasms;Respiratory Tract Diseases;Ankylosis;Metabolic Diseases;Hemic and Lymphatic Diseases;Serum Sickness;Spondylarthritis;Uveitis, Anterior;Synovitis;Thrombotic Microangiopathies;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hypersensitivity, Immediate;Neoplasms by Histologic Type;Nose Diseases;Lung Diseases, Obstructive;Mycobacterium Infections;Spondylitis, Ankylosing;Psoriasis;Bursitis;Asthma;Dermatitis Herpetiformis;Hematologic Diseases;Intestinal Diseases;Anemia, Hemolytic, Autoimmune;Leukoencephalopathies;Colonic Diseases;Respiratory Hypersensitivity;Connective Tissue Diseases;Iritis;Erythema;Brain Diseases;Actinomycetales Infections;Pathological Conditions, Signs and Symptoms;Pneumoconiosis;Nephrotic Syndrome;Hypersensitivity, Delayed;Spinal Diseases;Calcium Metabolism Disorders;Infections;Panuveitis;Autoimmune Diseases of the Nervous System;Otorhinolaryngologic Diseases;Colitis, Ulcerative;Bone Diseases, Infectious;Immune System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Signs and Symptoms;Colitis;Kidney Diseases;Drug Eruptions;Joint Diseases;Uveal Diseases;Drug-Related Side Effects and Adverse Reactions;Lung Injury;Multiple Sclerosis;Skin Diseases, Papulosquamous;Skin Diseases;Conjunctival Diseases;Leukemia;Spondylarthropathies;Drug Hypersensitivity;Respiratory Tract Infections;Lymphoma;Lung Diseases, Interstitial;Dermatitis, Atopic;Rhinitis, Allergic;Disease;Nutritional and Metabolic Diseases;Adrenal Insufficiency;Sebaceous Gland Diseases;Bone Diseases;Rhinitis;Axial Spondyloarthritis;Hemorrhagic Disorders;Hypercalcemia;Purpura, Thrombocytopenic;Thoracic Injuries;Skin Diseases, Vesiculobullous;Pathologic Processes;Blood Platelet Disorders;Berylliosis;Hypersensitivity;Dermatitis, Contact;Nervous System Diseases;Purpura, Thrombocytopenic, Idiopathic;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Gastroenteritis;Gastrointestinal Diseases;Thrombocytopenia","Arthritis, Rheumatoid;Autoimmune Diseases;Myositis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Skin Diseases;Neuralgia;Crystal Arthropathies;Muscular Diseases;Connective Tissue Diseases;Dermatomyositis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Peripheral Nervous System Diseases;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Polymyositis;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Purine-Pyrimidine Metabolism, Inborn Errors;Rheumatic Diseases;Arthritis, Gouty;Neuromuscular Diseases;Skin and Connective Tissue Diseases;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Enzyme Inhibitors;Enzyme Interactions;Steroid Hormone Receptor Agonists;Lipoxygenase Inhibitors;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Decreased Lipid Derived Immunologically Active Molecule Activity;Metabolic Activity Alteration;Cellular Activity Alteration;Decreased Immunologic Activity;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Decreased Vascular Permeability;Generalized Systemic Effects;Translation Alteration;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Decreased Polymorphonuclear Leukocyte Migration;Immunologic Activity Alteration;Endocrine Activity Alteration;Decreased Eicosanoid Activity;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Decreased Leukotriene Activity;Organ System Specific Effects;Vascular Permeability Alteration;Carbohydrate Metabolism Alteration;Decreased Thromboxane Activity;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Decreased Prostaglandin Activity;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Lipid Metabolism Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,,,,,,,,,,
74,15,7,Concomitant Medications,Generic Name,RxNorm,truvada,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],1744006.0,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],495430.0,495430.0,495430,False,Nucleic Acid Synthesis Inhibitors;Anti-Infective Agents;Anti-Retroviral Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Reverse Transcriptase Inhibitors;Anti-HIV Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;DIRECT ACTING ANTIVIRALS;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by disposition;Reverse transcriptase inhibitor-containing product;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Adenine;Emtricitabine;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Cytidine;Deoxycytidine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Ribonucleosides;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidines;Purines;Organophosphorus Compounds;Pyrimidine Nucleosides;Carbohydrates;Nucleosides;Glycosides;Deoxyribonucleosides;Tenofovir;Substances;Substances and Cells (CHEM);Organophosphonates","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hepadnaviridae Infections;Hepatitis, Viral, Human;Lentivirus Infections;Hepatitis;Hepatitis B, Chronic;Virus Diseases;DNA Virus Infections;Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis, Chronic;Disease;Sexually Transmitted Diseases;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Blood-Borne Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Sexually Transmitted Diseases, Viral;Urogenital Diseases;Immunologic Deficiency Syndromes;Acquired Immunodeficiency Syndrome;Chronic Disease;Digestive System Diseases;HIV Infections;Immune System Diseases;Hepatitis B;Slow Virus Diseases;Retroviridae Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Reverse Transcriptase Inhibitors;Mechanism of Action (MoA),Increased Immunologically Active Molecule Activity;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Cellular Activity Alteration;Decreased Reverse Transcription to DNA;Generalized Systemic Effects;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;Reverse Transcription to DNA Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Enzyme Inhibitor;Nucleic Acid Synthesis Inhibitor;Anti-infective;Established Pharmacologic Class (EPC);Nucleoside Analog Antiviral;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,"Carbohydrates;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Glycosides;Substances;Substances and Cells (CHEM)",,
75,15,7,Concomitant Medications,Generic Name,RxNorm,truvada,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],1744006.0,emtricitabine 133 MG / Tenofovir disoproxil fumarate 200 MG [Truvada],495430.0,495430.0,495430,False,Nucleic Acid Synthesis Inhibitors;Anti-Infective Agents;Anti-Retroviral Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Reverse Transcriptase Inhibitors;Anti-HIV Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;DIRECT ACTING ANTIVIRALS;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by disposition;Reverse transcriptase inhibitor-containing product;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Adenine;Emtricitabine;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Cytidine;Deoxycytidine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Ribonucleosides;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidines;Purines;Organophosphorus Compounds;Pyrimidine Nucleosides;Carbohydrates;Nucleosides;Glycosides;Deoxyribonucleosides;Tenofovir;Substances;Substances and Cells (CHEM);Organophosphonates","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hepadnaviridae Infections;Hepatitis, Viral, Human;Lentivirus Infections;Hepatitis;Hepatitis B, Chronic;Virus Diseases;DNA Virus Infections;Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis, Chronic;Disease;Sexually Transmitted Diseases;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Blood-Borne Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Sexually Transmitted Diseases, Viral;Urogenital Diseases;Immunologic Deficiency Syndromes;Acquired Immunodeficiency Syndrome;Chronic Disease;Digestive System Diseases;HIV Infections;Immune System Diseases;Hepatitis B;Slow Virus Diseases;Retroviridae Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Reverse Transcriptase Inhibitors;Mechanism of Action (MoA),Increased Immunologically Active Molecule Activity;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Cellular Activity Alteration;Decreased Reverse Transcription to DNA;Generalized Systemic Effects;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;Reverse Transcription to DNA Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Enzyme Inhibitor;Nucleic Acid Synthesis Inhibitor;Anti-infective;Established Pharmacologic Class (EPC);Nucleoside Analog Antiviral;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,"Carbohydrates;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Glycosides;Substances;Substances and Cells (CHEM)",,
76,68,23,Concomitant Medications,Generic Name,RxNorm,truvada,Truvada Pill,1185615.0,Truvada Pill,495430.0,495430.0,495430,False,Nucleic Acid Synthesis Inhibitors;Anti-Infective Agents;Anti-Retroviral Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Reverse Transcriptase Inhibitors;Anti-HIV Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;DIRECT ACTING ANTIVIRALS;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by disposition;Reverse transcriptase inhibitor-containing product;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Adenine;Emtricitabine;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Cytidine;Deoxycytidine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Ribonucleosides;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidines;Purines;Organophosphorus Compounds;Pyrimidine Nucleosides;Carbohydrates;Nucleosides;Glycosides;Deoxyribonucleosides;Tenofovir;Substances;Substances and Cells (CHEM);Organophosphonates","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hepadnaviridae Infections;Hepatitis, Viral, Human;Lentivirus Infections;Hepatitis;Hepatitis B, Chronic;Virus Diseases;DNA Virus Infections;Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis, Chronic;Disease;Sexually Transmitted Diseases;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Blood-Borne Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Sexually Transmitted Diseases, Viral;Urogenital Diseases;Immunologic Deficiency Syndromes;Acquired Immunodeficiency Syndrome;Chronic Disease;Digestive System Diseases;HIV Infections;Immune System Diseases;Hepatitis B;Slow Virus Diseases;Retroviridae Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Reverse Transcriptase Inhibitors;Mechanism of Action (MoA),Increased Immunologically Active Molecule Activity;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Cellular Activity Alteration;Decreased Reverse Transcription to DNA;Generalized Systemic Effects;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;Reverse Transcription to DNA Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Enzyme Inhibitor;Nucleic Acid Synthesis Inhibitor;Anti-infective;Established Pharmacologic Class (EPC);Nucleoside Analog Antiviral;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,"Carbohydrates;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Glycosides;Substances;Substances and Cells (CHEM)",,
77,68,23,Concomitant Medications,Generic Name,RxNorm,truvada,Truvada Pill,1185615.0,Truvada Pill,495430.0,495430.0,495430,False,Nucleic Acid Synthesis Inhibitors;Anti-Infective Agents;Anti-Retroviral Agents;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Reverse Transcriptase Inhibitors;Anti-HIV Agents;Antiviral Agents;Molecular Mechanisms of Pharmacological Action,"Nucleoside and nucleotide reverse transcriptase inhibitors;ANTIVIRALS FOR SYSTEMIC USE;Antivirals for treatment of HIV infections, combinations;DIRECT ACTING ANTIVIRALS;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4)",Medicinal product categorized by disposition;Reverse transcriptase inhibitor-containing product;Transferase inhibitor-containing product;Enzyme inhibitor-containing product,Pyrimidine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Adenine;Emtricitabine;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Cytidine;Deoxycytidine;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Ribonucleosides;Nucleic Acids, Nucleotides, and Nucleosides;Pyrimidines;Purines;Organophosphorus Compounds;Pyrimidine Nucleosides;Carbohydrates;Nucleosides;Glycosides;Deoxyribonucleosides;Tenofovir;Substances;Substances and Cells (CHEM);Organophosphonates","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hepadnaviridae Infections;Hepatitis, Viral, Human;Lentivirus Infections;Hepatitis;Hepatitis B, Chronic;Virus Diseases;DNA Virus Infections;Liver Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hepatitis, Chronic;Disease;Sexually Transmitted Diseases;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Blood-Borne Infections;Genital Diseases;Infections;Pathologic Processes;Disease Attributes;Sexually Transmitted Diseases, Viral;Urogenital Diseases;Immunologic Deficiency Syndromes;Acquired Immunodeficiency Syndrome;Chronic Disease;Digestive System Diseases;HIV Infections;Immune System Diseases;Hepatitis B;Slow Virus Diseases;Retroviridae Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;Nucleoside Reverse Transcriptase Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Reverse Transcriptase Inhibitors;Mechanism of Action (MoA),Increased Immunologically Active Molecule Activity;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Cellular Activity Alteration;Decreased Reverse Transcription to DNA;Generalized Systemic Effects;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;Reverse Transcription to DNA Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Enzyme Inhibitor;Nucleic Acid Synthesis Inhibitor;Anti-infective;Established Pharmacologic Class (EPC);Nucleoside Analog Antiviral;Enzyme Interaction;Nucleic Acid Related Agent;Antimicrobial;Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,ANTIMICROBIALS;ANTIVIRALS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antiviral agent;Antiretroviral agent,,,,,"Carbohydrates;Nucleic Acids, Nucleotides, and Nucleosides;Nucleosides;Glycosides;Substances;Substances and Cells (CHEM)",,
78,18,8,Concomitant Medications,Generic Name,RxNorm,glipizide,,,,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
79,18,8,Concomitant Medications,Generic Name,RxNorm,glipizide,,,,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
80,72,24,Concomitant Medications,Generic Name,RxNorm,glipizide,glipiZIDE,4821.0,glipiZIDE,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
81,72,24,Concomitant Medications,Generic Name,RxNorm,glipizide,glipiZIDE,4821.0,glipiZIDE,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
82,89,28,Concomitant Medications,Generic Name,RxNorm,Glipizide,Glipizide 10 MG,317379.0,Glipizide 10 MG,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
83,89,28,Concomitant Medications,Generic Name,RxNorm,Glipizide,Glipizide 10 MG,317379.0,Glipizide 10 MG,4821.0,4821.0,4821,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;DRUGS USED IN DIABETES;Sulfonylureas;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Sulfonylurea-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide-containing product;Urea and/or urea derivative-containing product;Medicinal product categorized by structure,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Glipizide;Organic Chemicals;Urea,"Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Receptor Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Pancreatic Islet Activity Alteration;Cell Glucose Transport Alteration;Decreased Glycolysis;Endocrine Activity Alteration;Generalized Systemic Effects;Increased Glucose Transport into Cells;Physiologic Effect (PE);Increased Insulin Secretion,Chemical Structure;Established Pharmacologic Class (EPC);Sulfonylurea;Blood Glucose Regulator,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,Amides;Inorganic Chemicals;Sulfonylurea Compounds;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals;Urea,,
84,20,8,Concomitant Medications,Generic Name,RxNorm,gabapentin,,,,25480.0,25480.0,25480,False,Anticonvulsants;Antimanic Agents;Excitatory Amino Acid Antagonists;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Central Nervous System Depressants;Tranquilizing Agents;Physiological Effects of Drugs;Anti-Anxiety Agents;Analgesics;Central Nervous System Agents;Psychotropic Drugs;Neurotransmitter Agents;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action,NERVOUS SYSTEM;Gabapentinoids;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Calcium channel blocker-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Amino acid-containing product;Medicinal product categorized by structure,"Acids, Acyclic;Carbamates;Macrocyclic Compounds;Butyrates;Hydrocarbons;Fatty Acids;Fatty Acids, Volatile;Cyclohexanes;Cycloparaffins;Organic Chemicals;Lipids;Aminobutyrates;Amines;gamma-Aminobutyric Acid;Polycyclic Compounds;Amino Acids, Peptides, and Proteins;Amino Acids;Acids, Carbocyclic;Hydrocarbons, Cyclic;Gabapentin;Carboxylic Acids;Cyclohexanecarboxylic Acids;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Central Nervous System Diseases;Neuralgia;Bipolar Disorder;Bipolar and Related Disorders;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Pain;Epilepsies, Partial;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Neuromuscular Diseases;Mental Disorders;Nervous System Diseases;Phobic Disorders;Epilepsy;Neuralgia, Postherpetic;Signs and Symptoms;Mood Disorders",,,Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA),Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Organized Electrical Activity Alteration;Nervous System Activity Alteration;Decreased Disorganized Electrical Activity;Physiologic Effect (PE);Disorganized Electrical Activity Alteration;Electrical Activity Alteration;Decreased Organized Electrical Activity,Nervous System Agent;Established Pharmacologic Class (EPC);Anti-epileptic Agent,"ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",Central Nervous System Agent;Anti-epileptic Agent;Therapeutic Categories,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,,,,,,,
85,20,8,Concomitant Medications,Generic Name,RxNorm,gabapentin,,,,25480.0,25480.0,25480,False,Anticonvulsants;Antimanic Agents;Excitatory Amino Acid Antagonists;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Central Nervous System Depressants;Tranquilizing Agents;Physiological Effects of Drugs;Anti-Anxiety Agents;Analgesics;Central Nervous System Agents;Psychotropic Drugs;Neurotransmitter Agents;Excitatory Amino Acid Agents;Molecular Mechanisms of Pharmacological Action,NERVOUS SYSTEM;Gabapentinoids;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Calcium channel blocker-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Amino acid-containing product;Medicinal product categorized by structure,"Acids, Acyclic;Carbamates;Macrocyclic Compounds;Butyrates;Hydrocarbons;Fatty Acids;Fatty Acids, Volatile;Cyclohexanes;Cycloparaffins;Organic Chemicals;Lipids;Aminobutyrates;Amines;gamma-Aminobutyric Acid;Polycyclic Compounds;Amino Acids, Peptides, and Proteins;Amino Acids;Acids, Carbocyclic;Hydrocarbons, Cyclic;Gabapentin;Carboxylic Acids;Cyclohexanecarboxylic Acids;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Central Nervous System Diseases;Neuralgia;Bipolar Disorder;Bipolar and Related Disorders;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Pain;Epilepsies, Partial;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Neuromuscular Diseases;Mental Disorders;Nervous System Diseases;Phobic Disorders;Epilepsy;Neuralgia, Postherpetic;Signs and Symptoms;Mood Disorders",,,Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA),Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Organized Electrical Activity Alteration;Nervous System Activity Alteration;Decreased Disorganized Electrical Activity;Physiologic Effect (PE);Disorganized Electrical Activity Alteration;Electrical Activity Alteration;Decreased Organized Electrical Activity,Nervous System Agent;Established Pharmacologic Class (EPC);Anti-epileptic Agent,"ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTICONVULSANTS;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",Central Nervous System Agent;Anti-epileptic Agent;Therapeutic Categories,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,,,,,,,
86,21,9,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
87,21,9,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
88,31,13,Concomitant Medications,Generic Name,RxNorm,Advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
89,31,13,Concomitant Medications,Generic Name,RxNorm,Advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
90,107,31,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
91,107,31,Concomitant Medications,Generic Name,RxNorm,advil,Advil,153010.0,Advil,153010.0,153010.0,153010,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;OTHER GYNECOLOGICALS;THROAT PREPARATIONS;Other throat preparations;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;OTHER CARDIAC PREPARATIONS;CARDIOVASCULAR SYSTEM;CARDIAC THERAPY;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Carboxylic Acids;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Organic Chemicals;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES","ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;MUSCULOSKELETAL MEDICATIONS;VA CLASSES",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
92,22,9,Concomitant Medications,Generic Name,RxNorm,Naproxen,Naproxen,7258.0,Naproxen,7258.0,7258.0,7258,False,"Gout Suppressants;Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;OTHER GYNECOLOGICALS;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Naphthaleneacetic Acids;Hydrocarbons;Hydrocarbons, Cyclic;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Drug Hypersensitivity;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Common Cold;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Headache;Virus Diseases;Spondylarthropathies;Respiratory Tract Infections;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Back Pain;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;RNA Virus Infections;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Facial Pain;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Menstruation Disturbances;Infections;Pathologic Processes;Stomatognathic Diseases;Tooth Diseases;Picornaviridae Infections;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Toothache;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Pelvic Pain;Respiratory Tract Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS","ANTIMIGRAINE AGENTS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,,,
93,22,9,Concomitant Medications,Generic Name,RxNorm,Naproxen,Naproxen,7258.0,Naproxen,7258.0,7258.0,7258,False,"Gout Suppressants;Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;OTHER GYNECOLOGICALS;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Naphthaleneacetic Acids;Hydrocarbons;Hydrocarbons, Cyclic;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Drug Hypersensitivity;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Common Cold;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Headache;Virus Diseases;Spondylarthropathies;Respiratory Tract Infections;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Back Pain;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;RNA Virus Infections;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Facial Pain;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Menstruation Disturbances;Infections;Pathologic Processes;Stomatognathic Diseases;Tooth Diseases;Picornaviridae Infections;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Toothache;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Pelvic Pain;Respiratory Tract Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS","ANTIMIGRAINE AGENTS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,,,
94,62,22,Concomitant Medications,Generic Name,RxNorm,Naproxen,Aleve,215101.0,Aleve,7258.0,7258.0,7258,False,"Gout Suppressants;Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;OTHER GYNECOLOGICALS;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Naphthaleneacetic Acids;Hydrocarbons;Hydrocarbons, Cyclic;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Drug Hypersensitivity;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Common Cold;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Headache;Virus Diseases;Spondylarthropathies;Respiratory Tract Infections;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Back Pain;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;RNA Virus Infections;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Facial Pain;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Menstruation Disturbances;Infections;Pathologic Processes;Stomatognathic Diseases;Tooth Diseases;Picornaviridae Infections;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Toothache;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Pelvic Pain;Respiratory Tract Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS","ANTIMIGRAINE AGENTS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,,,
95,62,22,Concomitant Medications,Generic Name,RxNorm,Naproxen,Aleve,215101.0,Aleve,7258.0,7258.0,7258,False,"Gout Suppressants;Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","Propionic acid derivatives;MUSCULO-SKELETAL SYSTEM;OTHER GYNECOLOGICALS;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory preparations, non-steroids for topical use;Antiinflammatory products for vaginal administration;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Naphthalene-containing product;Medicinal product categorized by structure,"Naphthaleneacetic Acids;Hydrocarbons;Hydrocarbons, Cyclic;Naphthalenes;Naproxen;Polycyclic Aromatic Hydrocarbons;Substances;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Drug Hypersensitivity;Reproductive Physiological Phenomena;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Common Cold;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Headache;Virus Diseases;Spondylarthropathies;Respiratory Tract Infections;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Back Pain;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;RNA Virus Infections;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Facial Pain;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Menstruation Disturbances;Infections;Pathologic Processes;Stomatognathic Diseases;Tooth Diseases;Picornaviridae Infections;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Toothache;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Pelvic Pain;Respiratory Tract Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;ANTIMIGRAINE AGENTS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS","ANTIMIGRAINE AGENTS;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;ANALGESICS",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,,,
96,24,9,Concomitant Medications,Generic Name,RxNorm,Dayquil,DayQuil Cough,1114038.0,DayQuil Cough,,1114038.0,1114038,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Dextromethorphan;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons;Hydrocarbons, Cyclic;Opiate Alkaloids;Heterocyclic Compounds, Fused-Ring;Polycyclic Aromatic Hydrocarbons;Substances;Alkaloids;Heterocyclic Compounds;Phenanthrenes;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic;Morphinans;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Medullary Respiratory Center Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Receptor Agonist;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
97,24,9,Concomitant Medications,Generic Name,RxNorm,Dayquil,DayQuil Cough,1114038.0,DayQuil Cough,,1114038.0,1114038,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Dextromethorphan;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons;Hydrocarbons, Cyclic;Opiate Alkaloids;Heterocyclic Compounds, Fused-Ring;Polycyclic Aromatic Hydrocarbons;Substances;Alkaloids;Heterocyclic Compounds;Phenanthrenes;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic;Morphinans;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Medullary Respiratory Center Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Receptor Agonist;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
98,40,16,Concomitant Medications,Generic Name,RxNorm,Dayquil,,,,,1114038.0,1114038,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Dextromethorphan;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons;Hydrocarbons, Cyclic;Opiate Alkaloids;Heterocyclic Compounds, Fused-Ring;Polycyclic Aromatic Hydrocarbons;Substances;Alkaloids;Heterocyclic Compounds;Phenanthrenes;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic;Morphinans;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Medullary Respiratory Center Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Receptor Agonist;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
99,40,16,Concomitant Medications,Generic Name,RxNorm,Dayquil,,,,,1114038.0,1114038,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Dextromethorphan;Heterocyclic Compounds, Bridged-Ring;Hydrocarbons;Hydrocarbons, Cyclic;Opiate Alkaloids;Heterocyclic Compounds, Fused-Ring;Polycyclic Aromatic Hydrocarbons;Substances;Alkaloids;Heterocyclic Compounds;Phenanthrenes;Substances and Cells (CHEM);Organic Chemicals;Polycyclic Compounds;Hydrocarbons, Aromatic;Morphinans;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Medullary Respiratory Center Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Receptor Agonist;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
100,25,9,Concomitant Medications,Generic Name,RxNorm,nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
101,25,9,Concomitant Medications,Generic Name,RxNorm,nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
102,41,16,Concomitant Medications,Generic Name,RxNorm,Nyquil,,,,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
103,41,16,Concomitant Medications,Generic Name,RxNorm,Nyquil,,,,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
104,54,21,Concomitant Medications,Generic Name,RxNorm,Nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
105,54,21,Concomitant Medications,Generic Name,RxNorm,Nyquil,Nyquil Cough,702274.0,Nyquil Cough,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
106,109,32,Concomitant Medications,Generic Name,RxNorm,NyQuil,,,,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
107,109,32,Concomitant Medications,Generic Name,RxNorm,NyQuil,,,,,1234386.0,1234386,True,Autonomic Agents;Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Excitatory Amino Acid Agents;Histamine H1 Antagonists;Physiological Effects of Drugs;Antitussive Agents;Antiemetics;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Aminoalkyl ethers;Opium alkaloids and derivatives;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition;Histamine receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Doxylamine;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Signs and Symptoms, Respiratory;Headache;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Pain;Rhinitis, Allergic, Perennial;Rhinitis;Cough;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Respiration Disorders;Sleep Disorders, Intrinsic;Infections;Hypersensitivity;Mental Disorders;Nervous System Diseases;Otorhinolaryngologic Diseases;Dyssomnias;Respiratory Tract Diseases;Immune System Diseases;Sleep Initiation and Maintenance Disorders;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Decreased Medullary Respiratory Drive;Histamine Activity Alteration;Medullary Respiratory Center Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Antihistamine;Receptor Interaction;Receptor Antagonist,"ANTIHISTAMINE/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
108,26,10,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
109,26,10,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
110,30,12,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
111,30,12,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
112,50,19,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
113,50,19,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
114,53,20,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
115,53,20,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
116,55,21,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
117,55,21,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
118,110,32,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
119,110,32,Concomitant Medications,Generic Name,RxNorm,Ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
120,139,42,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
121,139,42,Concomitant Medications,Generic Name,RxNorm,ibuprofen,Ibuprofen,5640.0,Ibuprofen,5640.0,5640.0,5640,False,"Anti-Inflammatory Agents, Non-Steroidal;Enzyme Inhibitors;Analgesics, Non-Narcotic;Sensory System Agents;Cyclooxygenase Inhibitors;Peripheral Nervous System Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses;Anti-Inflammatory Agents;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents;Antirheumatic Agents;Molecular Mechanisms of Pharmacological Action","NERVOUS SYSTEM;OPIOIDS;Other throat preparations;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS;Antiinflammatory products for vaginal administration;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS;MUSCULO-SKELETAL SYSTEM;RESPIRATORY SYSTEM;TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN;CARDIOVASCULAR SYSTEM;Antiinflammatory preparations, non-steroids for topical use;ANALGESICS;Propionic acid derivatives;THROAT PREPARATIONS;OTHER CARDIAC PREPARATIONS;CARDIAC THERAPY;OTHER GYNECOLOGICALS;Other cardiac preparations",COX-2 inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Propionic acid and/or propionic acid derivative-containing product;Medicinal product categorized by structure;Organic acid and/or organic acid derivative-containing product,"Amino Acids;Amino Acids, Peptides, and Proteins;Amino Acids, Basic;Carboxylic Acids;Amino Acids, Essential;Ibuprofen;Substances;Phenylpropionates;Substances and Cells (CHEM);Lysine;Organic Chemicals;Amino Acids, Diamino;Acids, Carbocyclic","Pregnancy Trimesters;Pregnancy Trimester, Third;Chemically-Induced Disorders;Pregnancy Complications;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Pregnancy, Abdominal;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Pregnancy, Ectopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Rhinitis;Infections;Urogenital Diseases;Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Spondylarthritis;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Arthritis, Juvenile;Spondylitis, Ankylosing;Bursitis;Crystal Arthropathies;Pain, Postoperative;Spondylarthropathies;Menorrhagia;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Uterine Diseases;Pain;Hemorrhage;Nutritional and Metabolic Diseases;Dysmenorrhea;Bone Diseases;Axial Spondyloarthritis;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Arthritis;Fever;Inflammation;Uterine Hemorrhage;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Spinal Diseases;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Infections;Pathologic Processes;Postoperative Complications;Urogenital Diseases;Spondylitis;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Bone Diseases, Infectious;Immune System Diseases;Ankylosis;Premenstrual Syndrome;Pelvic Pain;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Pain",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Immunologically Active Molecule Production Alteration;Decreased Platelet Activating Factor Production;Immunologic Activity Alteration;Decreased Immunologic Activity;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Decreased Eicosanoid Production;Decreased Thromboxane Production,Enzyme Interaction;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Established Pharmacologic Class (EPC),"COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS","COLD REMEDIES,COMBINATIONS;NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,OTHER;ANTIRHEUMATICS;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CNS MEDICATIONS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE II;CSA SCHEDULE
122,28,10,Concomitant Medications,Generic Name,RxNorm,tessalon perles,Tessalon Perles,220224.0,Tessalon Perles,220224.0,220224.0,220224,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
123,28,10,Concomitant Medications,Generic Name,RxNorm,tessalon perles,Tessalon Perles,220224.0,Tessalon Perles,220224.0,220224.0,220224,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
124,29,11,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,Viral Vaccines;Biological Products;Complex Mixtures;Ad26COVS1;Substances;Substances and Cells (CHEM);Vaccines;COVID-19 Vaccines,,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,,
125,29,11,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,Viral Vaccines;Biological Products;Complex Mixtures;Ad26COVS1;Substances;Substances and Cells (CHEM);Vaccines;COVID-19 Vaccines,,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,,
126,56,21,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,Viral Vaccines;Biological Products;Complex Mixtures;Ad26COVS1;Substances;Substances and Cells (CHEM);Vaccines;COVID-19 Vaccines,,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,,
127,56,21,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine,,,,,2479830.0,2479830,True,,,,Recombinant deoxyribonucleic acid-containing product;Medicinal product categorized by structure,Viral Vaccines;Biological Products;Complex Mixtures;Ad26COVS1;Substances;Substances and Cells (CHEM);Vaccines;COVID-19 Vaccines,,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,,
128,32,14,Concomitant Medications,Generic Name,RxNorm,sudafed,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],1052767.0,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
129,32,14,Concomitant Medications,Generic Name,RxNorm,sudafed,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],1052767.0,Phenylephrine Hydrochloride 10 MG Oral Tablet [Sudafed PE],203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
130,39,16,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
131,39,16,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
132,86,26,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
133,86,26,Concomitant Medications,Generic Name,RxNorm,Sudafed,,,,203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
134,125,36,Concomitant Medications,Generic Name,RxNorm,sudafed,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],1049668.0,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
135,125,36,Concomitant Medications,Generic Name,RxNorm,sudafed,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],1049668.0,12 HR Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet [Sudafed],203302.0,203302.0,203302,False,Autonomic Agents;Vasoconstrictor Agents;Bronchodilator Agents;Nasal Decongestants;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Anti-Asthmatic Agents;Cardiovascular Agents,Sympathomimetics;RESPIRATORY SYSTEM;NASAL PREPARATIONS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4),Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,Amino Alcohols;Phenethylamines;Pseudoephedrine;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Alcohols;Propanolamines;Ethylamines,"Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Nose Diseases;Lung Diseases, Obstructive;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;RNA Virus Infections;Infections;Picornaviridae Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Adrenergic Agonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Vascular Alterations;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Bronchial Smooth Muscle Tone Alteration;Vasoconstriction;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);Receptor Interaction;alpha-Adrenergic Agonist,"DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES","DECONGESTANTS,SYSTEMIC;RESPIRATORY TRACT MEDICATIONS;VA CLASSES",,,,,,,,,,
136,33,14,Concomitant Medications,Generic Name,RxNorm,Excedrine Migraine,,,,,209468.0,209468,True,"Central Nervous System Stimulants;Peripheral Nervous System Agents;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Platelet Aggregation Inhibitors;Purinergic Antagonists;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Purinergic Agents;Analgesics;Purinergic P1 Receptor Antagonists;Antirheumatic Agents;Cardiovascular Agents","PSYCHOANALEPTICS;Xanthine derivatives;Anilides;BLOOD AND BLOOD FORMING ORGANS;DERMATOLOGICALS;NERVOUS SYSTEM;ANTITHROMBOTIC AGENTS;OTHER DERMATOLOGICAL PREPARATIONS;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Other dermatologicals;Salicylic acid and derivatives;PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Platelet aggregation inhibitors excl. heparin;OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS",Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition;Phosphodiesterase inhibitor-containing product;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Methyl xanthine-containing product;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Purine and/or purine derivative-containing product;Salicylate-containing product;Alkaloid-containing product;Medicinal product categorized by structure,"Phenols;Benzoates;Heterocyclic Compounds, 2-Ring;Hydrocarbons;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Salicylates;Acetanilides;Aniline Compounds;Heterocyclic Compounds;Purinones;Organic Chemicals;Aspirin;Acetaminophen;Caffeine;Alkaloids;Amines;Hydroxy Acids;Purines;Acids, Carbocyclic;Hydrocarbons, Cyclic;Carboxylic Acids;Anilides;Amides;Xanthines;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic;Hydroxybenzoates","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Glucosephosphate Dehydrogenase Deficiency;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Infant;Nose Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Hematologic Diseases;Blood Coagulation Disorders;Drug Hypersensitivity;DNA Virus Infections;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Hemorrhage;Hemorrhagic Disorders;Anemia, Hemolytic, Congenital;Child;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Anemia, Hemolytic;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Signs and Symptoms, Respiratory;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Apnea;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Respiration Disorders;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Respiratory Tract Diseases;Immune System Diseases;Fatigue;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Body Temperature Changes;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Enzyme Inhibitors;Cyclooxygenase Inhibitors;Enzyme Interactions;Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Central Nervous System Stimulation;Decreased Immunologic Activity;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Coagulation Activity Alteration;Hemostasis Alteration;Hemic/Lymphatic Activity Alteration;Immunologically Active Molecule Production Alteration;Collecting Duct Water Permeability Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Organized Electrical Activity Alteration;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Bronchial Smooth Muscle Tone Alteration;Decreased Coagulation Activity;Peripheral Nervous System Activity Alteration;Increased Organized Electrical Activity;Electrical Activity Alteration;Decreased Thromboxane Production;Bronchodilation;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Collecting Duct Water Permeability;Respiratory Smooth Muscle Tone Alteration;Increased Central Nervous System Organized Electrical Activity;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Eicosanoid Production;Central Nervous System Activity Alteration,Nervous System Agent;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Central Nervous System Stimulant;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction;Methylxanthine;Chemical Structure,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Xanthines;Substances;Alkaloids;Heterocyclic Compounds;Substances and Cells (CHEM);Purinones;Purines",,
137,33,14,Concomitant Medications,Generic Name,RxNorm,Excedrine Migraine,,,,,209468.0,209468,True,"Central Nervous System Stimulants;Peripheral Nervous System Agents;Phosphodiesterase Inhibitors;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Platelet Aggregation Inhibitors;Purinergic Antagonists;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Purinergic Agents;Analgesics;Purinergic P1 Receptor Antagonists;Antirheumatic Agents;Cardiovascular Agents","PSYCHOANALEPTICS;Xanthine derivatives;Anilides;BLOOD AND BLOOD FORMING ORGANS;DERMATOLOGICALS;NERVOUS SYSTEM;ANTITHROMBOTIC AGENTS;OTHER DERMATOLOGICAL PREPARATIONS;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Other dermatologicals;Salicylic acid and derivatives;PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Platelet aggregation inhibitors excl. heparin;OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS",Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition;Phosphodiesterase inhibitor-containing product;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Methyl xanthine-containing product;Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Purine and/or purine derivative-containing product;Salicylate-containing product;Alkaloid-containing product;Medicinal product categorized by structure,"Phenols;Benzoates;Heterocyclic Compounds, 2-Ring;Hydrocarbons;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Salicylates;Acetanilides;Aniline Compounds;Heterocyclic Compounds;Purinones;Organic Chemicals;Aspirin;Acetaminophen;Caffeine;Alkaloids;Amines;Hydroxy Acids;Purines;Acids, Carbocyclic;Hydrocarbons, Cyclic;Carboxylic Acids;Anilides;Amides;Xanthines;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic;Hydroxybenzoates","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Glucosephosphate Dehydrogenase Deficiency;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Infant;Nose Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Hematologic Diseases;Blood Coagulation Disorders;Drug Hypersensitivity;DNA Virus Infections;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Hemorrhage;Hemorrhagic Disorders;Anemia, Hemolytic, Congenital;Child;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Anemia, Hemolytic;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Signs and Symptoms, Respiratory;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Apnea;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Respiration Disorders;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Respiratory Tract Diseases;Immune System Diseases;Fatigue;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Body Temperature Changes;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Enzyme Inhibitors;Cyclooxygenase Inhibitors;Enzyme Interactions;Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Central Nervous System Stimulation;Decreased Immunologic Activity;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Hypothalamic Endocrine Activity Alteration;Coagulation Activity Alteration;Hemostasis Alteration;Hemic/Lymphatic Activity Alteration;Immunologically Active Molecule Production Alteration;Collecting Duct Water Permeability Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Organized Electrical Activity Alteration;Respiratory/Pulmonary Activity Alteration;Autonomic Nervous System Activity Alteration;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Bronchial Smooth Muscle Tone Alteration;Decreased Coagulation Activity;Peripheral Nervous System Activity Alteration;Increased Organized Electrical Activity;Electrical Activity Alteration;Decreased Thromboxane Production;Bronchodilation;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Collecting Duct Water Permeability;Respiratory Smooth Muscle Tone Alteration;Increased Central Nervous System Organized Electrical Activity;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Eicosanoid Production;Central Nervous System Activity Alteration,Nervous System Agent;Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Central Nervous System Stimulant;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction;Methylxanthine;Chemical Structure,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Xanthines;Substances;Alkaloids;Heterocyclic Compounds;Substances and Cells (CHEM);Purinones;Purines",,
138,34,15,Concomitant Medications,Generic Name,RxNorm,Fosinopril,Fosinopril Oral Tablet [Monopril],367691.0,Fosinopril Oral Tablet [Monopril],50166.0,50166.0,50166,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Amino acid derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Amino Acids, Cyclic;Acids, Acyclic;Fosinopril;Phosphorus Acids;Acids, Noncarboxylic;Phosphinic Acids;Imines;Organic Chemicals;Inorganic Chemicals;Acids;Phosphorus Compounds;Amino Acids, Peptides, and Proteins;Amino Acids;Imino Acids;Organophosphorus Compounds;Carboxylic Acids;Substances;Substances and Cells (CHEM);Proline","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Ventricular Dysfunction;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
139,34,15,Concomitant Medications,Generic Name,RxNorm,Fosinopril,Fosinopril Oral Tablet [Monopril],367691.0,Fosinopril Oral Tablet [Monopril],50166.0,50166.0,50166,False,Angiotensin-Converting Enzyme Inhibitors;Antihypertensive Agents;Protease Inhibitors;Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"ACE inhibitors, plain;ACE INHIBITORS, PLAIN;CARDIOVASCULAR SYSTEM;AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Angiotensin-converting enzyme inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Amino acid derivative-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Amino Acids, Cyclic;Acids, Acyclic;Fosinopril;Phosphorus Acids;Acids, Noncarboxylic;Phosphinic Acids;Imines;Organic Chemicals;Inorganic Chemicals;Acids;Phosphorus Compounds;Amino Acids, Peptides, and Proteins;Amino Acids;Imino Acids;Organophosphorus Compounds;Carboxylic Acids;Substances;Substances and Cells (CHEM);Proline","Chemically-Induced Disorders;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Angioedema;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hyperaldosteronism;Drug Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pregnancy;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Immune System Diseases;Reproduction;Endocrine System Diseases;Skin Diseases, Vascular;Hypotension;Urticaria","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Hypertension;Glucose Metabolism Disorders;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Ventricular Dysfunction;Urogenital Diseases;Vascular Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Heart Failure;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases","Kidney Diseases;Diabetic Nephropathies;Male Urogenital Diseases;Glucose Metabolism Disorders;Hypertrophy;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Pathological Conditions, Anatomical;Nutritional and Metabolic Diseases;Heart Diseases;Cardiomegaly;Ventricular Dysfunction;Pathological Conditions, Signs and Symptoms;Hypertrophy, Left Ventricular;Urogenital Diseases;Diabetes Mellitus;Ventricular Dysfunction, Left;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Endocrine System Diseases;Metabolic Diseases",Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Angiotensin-converting Enzyme Inhibitors,Increased Renal Ion Excretion;Decreased Kinin Degradation;Renal Arterial Vasodilation;Decreased Immunologic Activity;Decreased Mineralocorticoid Secretion;Cardiovascular Activity Alteration;Generalized Systemic Effects;Vascular Tone Alteration;Decreased Immunologically Active Molecule Degradation;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Vasodilation;Hemic/Lymphatic Activity Alteration;Immunologic Activity Alteration;Arterial Vasodilation;Renal/Urological Activity Alteration;Endocrine Activity Alteration;Intravascular Volume Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Renal Ion Transport Alteration;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Vascular Alterations;Decreased Bradykinin Degradation;Decreased Renal K+ Excretion;Immunologically Active Molecule Degradation Alteration,Enzyme Inhibitor;Angiotensin Converting Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Cardiovascular Agent;Enzyme Interaction;Antimicrobial;Protease Inhibitor,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,VA CLASSES;CARDIOVASCULAR MEDICATIONS;ACE INHIBITORS,,,,,,,,,,
140,35,15,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,,,,,"Vaccines, Synthetic;Viral Vaccines;Biological Products;BNT162 Vaccine;Complex Mixtures;mRNA Vaccines;Substances;Substances and Cells (CHEM);Antigens;Recombinant Proteins;Vaccines;Proteins;COVID-19 Vaccines;Biological Factors;Nucleic Acid-Based Vaccines;Amino Acids, Peptides, and Proteins",,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,
141,49,18,Concomitant Medications,Generic Name,RxNorm,COVID Vaccine (Pfizer),,,,,2468230.0,2468230,True,,,,,"Vaccines, Synthetic;Viral Vaccines;Biological Products;BNT162 Vaccine;Complex Mixtures;mRNA Vaccines;Substances;Substances and Cells (CHEM);Antigens;Recombinant Proteins;Vaccines;Proteins;COVID-19 Vaccines;Biological Factors;Nucleic Acid-Based Vaccines;Amino Acids, Peptides, and Proteins",,,,,,,,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,IMMUNOLOGICAL AGENTS;VACCINES;VA CLASSES,,,,,,,,,,
142,36,16,Concomitant Medications,Generic Name,RxNorm,Zyrtec,ZyrTEC,58930.0,ZyrTEC,58930.0,58930.0,58930,False,"Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Anti-Allergic Agents;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Piperazine derivatives;RESPIRATORY SYSTEM;SENSORY ORGANS;Other antiallergics;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Piperazines;Cetirizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydroxyzine","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases, Vascular;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Urticaria;Nose Diseases;Rhinitis, Allergic;Skin Diseases;Rhinitis, Allergic, Perennial;Infections",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Histamine-1 Receptor Antagonist,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,,,,,,,,,
143,66,23,Concomitant Medications,Generic Name,RxNorm,zyrtec,Zyrtec,58930.0,Zyrtec,58930.0,58930.0,58930,False,"Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Anti-Allergic Agents;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Piperazine derivatives;RESPIRATORY SYSTEM;SENSORY ORGANS;Other antiallergics;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Piperazines;Cetirizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydroxyzine","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases, Vascular;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Urticaria;Nose Diseases;Rhinitis, Allergic;Skin Diseases;Rhinitis, Allergic, Perennial;Infections",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Histamine-1 Receptor Antagonist,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,,,,,,,,,
144,132,38,Concomitant Medications,Generic Name,RxNorm,Zyrtec,,,,58930.0,58930.0,58930,False,"Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Anti-Allergic Agents;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Piperazine derivatives;RESPIRATORY SYSTEM;SENSORY ORGANS;Other antiallergics;OPHTHALMOLOGICALS;DECONGESTANTS AND ANTIALLERGICS;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Piperazine and/or piperazine derivative-containing product;Medicinal product categorized by structure,"Piperazines;Cetirizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydroxyzine","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases, Vascular;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Urticaria;Nose Diseases;Rhinitis, Allergic;Skin Diseases;Rhinitis, Allergic, Perennial;Infections",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Histamine-1 Receptor Antagonist,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,,,,,,,,,
145,38,16,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
146,38,16,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
147,48,18,Concomitant Medications,Generic Name,RxNorm,multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
148,48,18,Concomitant Medications,Generic Name,RxNorm,multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
149,141,43,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
150,141,43,Concomitant Medications,Generic Name,RxNorm,Multivitamin,,,,,1234482.0,1234482,True,Cariostatic Agents;Vitamin B Complex;Antimetabolites;Vitamins;Physiological Effects of Drugs;Antioxidants;Photosensitizing Agents;Molecular Mechanisms of Pharmacological Action;Hypolipidemic Agents;Calcium-Regulating Hormones and Agents;Protective Agents;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Dermatologic Agents;Lipid Regulating Agents;Bone Density Conservation Agents;Vasodilator Agents;Cardiovascular Agents,"MINERAL SUPPLEMENTS;DERMATOLOGICALS;Other nasal preparations;Other ophthalmologicals;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;Other plain vitamin preparations;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;Ascorbic acid (vitamin C), plain;LIPID MODIFYING AGENTS, PLAIN;RESPIRATORY SYSTEM;Vitamin D and analogues;PERIPHERAL VASODILATORS;Vitamin B12 (cyanocobalamin and analogues);Vitamin B1, plain;Nicotinic acid and derivatives;CARDIOVASCULAR SYSTEM;LIPID MODIFYING AGENTS;NASAL PREPARATIONS;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;Retinoids for topical use in acne;VITAMIN B12 AND FOLIC ACID;Organic acids;VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO;BLOOD AND BLOOD FORMING ORGANS;VITAMINS;ANTI-ACNE PREPARATIONS;OTHER MINERAL SUPPLEMENTS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Fluoride;VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;Vitamin A, plain;Caries prophylactic agents;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS;ANTIANEMIC PREPARATIONS",Hormone-containing product;Calcium regulating hormone-containing product;Medicinal product categorized by disposition,Azole-containing product;Retinoid-containing product;Steroid-containing product;Nitrogen and/or nitrogen compound-containing product;Thiazole-containing product;Terpene-containing product;Fluorine and/or fluorine compound-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product;Carbohydrate-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Vitamin A and/or vitamin A derivative-containing product;Sodium and/or sodium compound-containing product;Sulfur and/or sulfur compound-containing product;Vitamin D and/or vitamin D derivative-containing product;Medicinal product categorized by structure;Alcohol-containing product;Metal and/or metallic compound-containing product,"Thiamine;Sodium Compounds;Membrane Lipids;Polyenes;Biomedical and Dental Materials;Heterocyclic Compounds, 2-Ring;Steroids;Vitamin D;Ions;Fluorine Compounds;Pigments, Biological;Azoles;Acids, Heterocyclic;Vitamin B 6;Heterocyclic Compounds, 4 or More Rings;Tetrapyrroles;Retinoids;Riboflavin;Corrinoids;Vitamin A;Fluorides;Chemical Actions and Uses;Acids, Acyclic;Macrocyclic Compounds;Electrolytes;Acids, Noncarboxylic;Cycloparaffins;Vitamin E;Heterocyclic Compounds;Organic Chemicals;Niacin;Hydrocarbons, Acyclic;Pyrimidines;Hydroxy Acids;Sodium Fluoride;Pyrans;Carbohydrates;Picolines;Carboxylic Acids;Anions;Cholecalciferol;Pteridines;Benzopyrans;Carotenoids;Vitamin B 12;Diterpenes;Cholestanes;Nicotinic Acids;Pyrroles;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Coenzymes;Acids;Enzymes and Coenzymes;Sterols;Alkenes;Hydrocarbons, Cyclic;Specialty Uses of Chemicals;Substances;Substances and Cells (CHEM);Hydrocarbons, Alicyclic;Cariostatic Agents;Ascorbic Acid;Terpenes;Cyclohexenes;Hydrocarbons;Cyclohexanes;Heterocyclic Compounds, Fused-Ring;Thiazoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Sugar Acids;Cholestenes;Secosteroids;Polycyclic Compounds;Hydrofluoric Acid;Biological Factors;Protective Agents;Flavins;Pyridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Dyslipidemias;Autoimmune Diseases;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Male Urogenital Diseases;Dyskinesia, Drug-Induced;Demyelinating Diseases;Central Nervous System Diseases;Night Blindness;Eye Diseases;Bone Diseases, Metabolic;Lacrimal Apparatus Diseases;Lung Diseases;Tauopathies;Rickets, Hypophosphatemic;Neurodegenerative Diseases;Brain Diseases, Metabolic, Inborn;Pellagra;Kidney Failure, Chronic;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Hypophosphatemia;Anemia, Megaloblastic;Phosphorus Metabolism Disorders;Neoplasms by Site;Vitamin A Deficiency;Dyskinesias;Hypertriglyceridemia;Demyelinating Autoimmune Diseases, CNS;Neurotoxicity Syndromes;Vascular Diseases;Chronic Disease;Skin and Connective Tissue Diseases;Mental Disorders;Vitamin E Deficiency;Inflammatory Bowel Diseases;Dermatitis;Musculoskeletal Diseases;Dementia;Anemia;Alcohol-Related Disorders;Wounds and Injuries;Renal Tubular Transport, Inborn Errors;Hypophosphatemia, Familial;Diabetic Neuropathies;Glucose Metabolism Disorders;Xerophthalmia;Scurvy;Ascorbic Acid Deficiency;Poisoning;RNA Virus Infections;Alcoholic Neuropathy;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Anemia, Hemolytic;Vision Disorders;Hyperlipidemias;Disease Attributes;Picornaviridae Infections;Renal Insufficiency;Urogenital Diseases;Anemia, Macrocytic;Diabetes Mellitus;Photosensitivity Disorders;Anemia, Pernicious;Diabetes Complications;Respiratory Tract Diseases;Neoplasms;Metabolic Diseases;Lipid Metabolism Disorders;Respiratory Tract Neoplasms;Crohn Disease;Hemic and Lymphatic Diseases;Avitaminosis;Parathyroid Diseases;Chemically-Induced Disorders;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Riboflavin Deficiency;Common Cold;Thiamine Deficiency;Psoriasis;Hematologic Diseases;Intestinal Diseases;Leukoencephalopathies;Hypercholesterolemia;Brain Diseases;Peripheral Nervous System Diseases;Renal Insufficiency, Chronic;Dry Eye Syndromes;Alcohol-Induced Disorders, Nervous System;Rickets;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Vitamin B 12 Deficiency;Infections;Polyneuropathies;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Familial Hypophosphatemic Rickets;Lung Neoplasms;Wounds, Penetrating;Immune System Diseases;Female Urogenital Diseases;Beriberi;Endocrine System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Movement Disorders;Kidney Diseases;Neurocognitive Disorders;Deficiency Diseases;Metal Metabolism, Inborn Errors;Malnutrition;Drug-Related Side Effects and Adverse Reactions;Multiple Sclerosis;Skin Diseases, Papulosquamous;Substance-Related Disorders;Skin Neoplasms;Skin Diseases;Alcohol-Induced Disorders;Conjunctival Diseases;Hypoparathyroidism;Virus Diseases;Methemoglobinemia;Respiratory Tract Infections;Vitamin B 6 Deficiency;Alzheimer Disease;Disease;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Thoracic Neoplasms;Bone Diseases;Vitamin D Deficiency;Hemorrhagic Disorders;Neurologic Manifestations;Osteoporosis;Wernicke Encephalopathy;Vitamin B Deficiency;Pathologic Processes;Sensation Disorders;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Gastroenteritis;Digestive System Diseases;Nutrition Disorders;Gastrointestinal Diseases","Dementia;Hemic and Lymphatic Diseases;Avitaminosis;Dental Deposits;Neurocognitive Disorders;Chemically-Induced Disorders;Deficiency Diseases;Arterial Occlusive Diseases;Dyskinesia, Drug-Induced;Anemia;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Periodontal Diseases;Lung Diseases;Wounds and Injuries;Lung Injury;Dental Caries;Central Nervous System Diseases;Tauopathies;Riboflavin Deficiency;Coronary Artery Disease;Infant, Premature, Diseases;Mouth Diseases;Bronchopulmonary Dysplasia;Hematologic Diseases;Neurodegenerative Diseases;Vitamin B 6 Deficiency;Alzheimer Disease;Tooth Demineralization;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Poisoning;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Drug-Related Side Effects and Adverse Reactions;Tooth Loss;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Thoracic Injuries;Vitamin A Deficiency;Anemia, Hemolytic;Dyskinesias;Vitamin B Deficiency;Dental Plaque;Coronary Disease;Vitamin B 12 Deficiency;Tooth Diseases;Stomatognathic Diseases;Infant, Newborn, Diseases;Vascular Diseases;Neurotoxicity Syndromes;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Vitamin E Deficiency;Arteriosclerosis;Ventilator-Induced Lung Injury;Signs and Symptoms;Movement Disorders",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Metabolic Activity Alteration;Cellular Activity Alteration;Digestive/GI System Activity Alteration;Bone Formation Stimulation;Generalized Systemic Effects;Bone Alteration;Physiologic Effect (PE);Sterol Metabolism Alteration;Glucose Metabolism Alteration;Decreased Vitamin Uptake and Modification;Renal/Urological Activity Alteration;Small Intestine Fluid/Electrolyte Alteration;Decreased Renal Ion Excretion;Organ System Specific Effects;Stimulation Small Intestine Fluid/Electrolyte Absorption;Carbohydrate Metabolism Alteration;Decreased Cholesterol Synthesis;Small Intestine Fluid/Electrolyte Absorption Alteration;Decreased Renal Ca++ Excretion;Renal Ion Transport Alteration;Musculoskeletal Activity Alteration;Cholesterol Metabolism Alteration;Cholesterol Synthesis Alteration;Lipid Metabolism Alteration;Bone Formation Alteration;Vitamin Uptake and Modification Alteration,Vitamin A;Vitamin C;Established Pharmacologic Class (EPC);Vitamin B12;Vitamin D;Chemical Structure;Nicotinic Acid;Vitamin or Mineral;Hormone,,,,,,,,,"Kidney Diseases;Urogenital Diseases;Flushing;Diarrhea;Skin Manifestations;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Flatulence;Pathological Conditions, Signs and Symptoms;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms","Vitamin B 12;Acids, Acyclic;Ascorbic Acid;Terpenes;Diterpenes;Macrocyclic Compounds;Polyenes;Pyrroles;Nicotinic Acids;Cyclohexenes;Hydrocarbons;Cyclohexanes;Cycloparaffins;Heterocyclic Compounds, Fused-Ring;Vitamin D;Steroids;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Fused-Ring Compounds;Heterocyclic Compounds, 1-Ring;Azoles;Heterocyclic Compounds, 4 or More Rings;Acids, Heterocyclic;Tetrapyrroles;Retinoids;Hydrocarbons, Acyclic;Sugar Acids;Alkenes;Secosteroids;Hydroxy Acids;Polycyclic Compounds;Corrinoids;Biological Factors;Carbohydrates;Hydrocarbons, Cyclic;Carboxylic Acids;Vitamin A;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Alicyclic;Carotenoids","Intestinal Diseases;Malabsorption Syndromes;Gastrointestinal Diseases;Digestive System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",
151,42,17,Concomitant Medications,Generic Name,RxNorm,Aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
152,42,17,Concomitant Medications,Generic Name,RxNorm,Aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
153,96,29,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
154,96,29,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
155,106,30,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
156,106,30,Concomitant Medications,Generic Name,RxNorm,aspirin,Aspirin,1191.0,Aspirin,1191.0,1191.0,1191,False,"Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Fibrin Modulating Agents;Anti-Inflammatory Agents;Antipyretics;Fibrinolytic Agents;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Molecular Mechanisms of Pharmacological Action;Hypnotics and Sedatives;Platelet Aggregation Inhibitors;Central Nervous System Agents;Hematologic Agents;Enzyme Inhibitors;Cyclooxygenase Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Antirheumatic Agents;Cardiovascular Agents",BLOOD AND BLOOD FORMING ORGANS;NERVOUS SYSTEM;OPIOIDS;ANTITHROMBOTIC AGENTS;Opioids in combination with non-opioid analgesics;STOMATOLOGICAL PREPARATIONS;Other agents for local oral treatment;Salicylic acid and derivatives;Platelet aggregation inhibitors excl. heparin;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Platelet aggregation inhibitor-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Salicylate-containing product;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Aspirin;Hydrocarbons;Carboxylic Acids;Hydrocarbons, Cyclic;Benzene Derivatives;Hydroxybenzoates;Phenols;Salicylates;Substances;Substances and Cells (CHEM);Benzoates;Organic Chemicals;Hydroxy Acids;Hydrocarbons, Aromatic;Acids, Carbocyclic","Hemic and Lymphatic Diseases;Nasal Polyps;Age Groups;Polyps;Child, Preschool;Pregnancy Trimester, Third;Pregnancy Trimesters;Chemically-Induced Disorders;Hematemesis;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Lung Diseases, Obstructive;Nose Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Virus Diseases;Blood Coagulation Disorders;Hematologic Diseases;Drug Hypersensitivity;DNA Virus Infections;Respiratory Tract Infections;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Chickenpox;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Hemorrhage;Adolescent;Rhinitis;Hemorrhagic Disorders;Child;Pathological Conditions, Signs and Symptoms;Varicella Zoster Virus Infection;Vomiting;Infections;Pathologic Processes;Blood Platelet Disorders;Melena;Gastrointestinal Hemorrhage;Hypersensitivity;Otorhinolaryngologic Diseases;Gastrointestinal Diseases;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Signs and Symptoms, Digestive;Herpesviridae Infections;Signs and Symptoms","Arthritis, Rheumatoid;Autoimmune Diseases;Joint Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Gout;Rheumatic Fever;Crystal Arthropathies;Bacterial Infections and Mycoses;Bacterial Infections;Connective Tissue Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pain;Nutritional and Metabolic Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Fever;Arthritis;Inflammation;Purine-Pyrimidine Metabolism, Inborn Errors;Body Temperature Changes;Rheumatic Diseases;Streptococcal Infections;Infections;Pathologic Processes;Skin and Connective Tissue Diseases;Osteoarthritis;Nervous System Diseases;Immune System Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Musculoskeletal Diseases","Brain Ischemia;Pregnancy Complications;Hypertension;Infarction;Central Nervous System Diseases;Necrosis;Cerebral Infarction;Cerebrovascular Disorders;Stroke;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pre-Eclampsia;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Myocardial Ischemia;Hypertension, Pregnancy-Induced;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Brain Infarction;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Myocardial Infarction;Signs and Symptoms",,Cyclooxygenase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Immunologically Active Molecule Production;Decreased Platelet Activating Factor Production;Decreased Immunologic Activity;Generalized Systemic Effects;Physiologic Effect (PE);Coagulation Activity Alteration;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Hemostasis Alteration;Decreased Platelet Aggregation;Immunologic Activity Alteration;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Decreased Coagulation Activity;Decreased Thromboxane Production;Organ System Specific Effects;Platelet Aggregation Alteration;Hematologic Activity Alteration;Decreased Eicosanoid Production,Nonsteroidal Anti-inflammatory Drug;Enzyme Inhibitor;Platelet Aggregation Inhibitor;Hematology Agent;Established Pharmacologic Class (EPC);Enzyme Interaction,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;SKELETAL MUSCLE RELAXANTS;RESPIRATORY TRACT MEDICATIONS;BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS;ANTACIDS;NON-OPIOID ANALGESICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SODIUM BICARBONATE CONTAINING ANTACIDS;MUSCULOSKELETAL MEDICATIONS;VA CLASSES;PLATELET AGGREGATION INHIBITORS;OPIOID ANALGESICS;ANALGESICS;GASTROINTESTINAL MEDICATIONS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE IV;SCHEDULE II;SCHEDULE III;CSA SCHEDULE
157,43,17,Concomitant Medications,Generic Name,RxNorm,Levothyroxin,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
158,43,17,Concomitant Medications,Generic Name,RxNorm,Levothyroxin,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
159,95,29,Concomitant Medications,Generic Name,RxNorm,levothyroxine,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
160,95,29,Concomitant Medications,Generic Name,RxNorm,levothyroxine,levothyroxine,10582.0,levothyroxine,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
161,150,44,Concomitant Medications,Generic Name,RxNorm,Levothyroxine,,,,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
162,150,44,Concomitant Medications,Generic Name,RxNorm,Levothyroxine,,,,10582.0,10582.0,10582,False,,"THYROID THERAPY;Thyroid hormones;Anatomical Therapeutic Chemical (ATC1-4);THYROID PREPARATIONS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Thyroid Diseases;Adrenal Gland Diseases;Chemically-Induced Disorders;Infarction;Drug-Related Side Effects and Adverse Reactions;Necrosis;Thyrotoxicosis;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Adrenal Insufficiency;Heart Diseases;Hyperthyroidism;Myocardial Ischemia;Ischemia;Pathological Conditions, Signs and Symptoms;Pathologic Processes;Vascular Diseases;Myocardial Infarction;Endocrine System Diseases","Endocrine Gland Neoplasms;Autoimmune Diseases;Myxedema;Thyroid Diseases;Goiter;Thyrotoxicosis;Connective Tissue Diseases;Thyroiditis, Autoimmune;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Disease;Hyperthyroidism;Thyroiditis;Neoplasms by Site;Head and Neck Neoplasms;Hypothyroidism;Mucinoses;Skin and Connective Tissue Diseases;Immune System Diseases;Neoplasms;Endocrine System Diseases","Thyroid Diseases;Hypothyroidism;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,Hormone Receptor Interactions;Thyroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Increased Gluconeogenesis;Cellular Activity Alteration;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Increased Metabolic Rate;Metabolic Rate Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Hormone;l-Thyroxine,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;THYROID SUPPLEMENTS;VA CLASSES,,,,,,,,"Amino Acids;Amino Acids, Cyclic;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Thyroid Hormones;Thyroxine;Amino Acids, Aromatic;Amino Acids, Peptides, and Proteins","Disease;Thyroid Diseases;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States",
163,45,17,Concomitant Medications,Generic Name,RxNorm,Calcium,Calcium,1895.0,Calcium,1895.0,1895.0,1895,False,Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA);Calcium-Regulating Hormones and Agents,,,Medicinal product categorized by chemical element;Calcium and/or calcium compound-containing product;Mineral-containing product;Medicinal product categorized by structure;Metal and/or metallic compound-containing product,"Metals, Alkaline Earth;Inorganic Chemicals;Blood Coagulation Factors;Substances;Substances and Cells (CHEM);Blood Proteins;Metals;Proteins;Calcium;Biological Factors;Elements;Amino Acids, Peptides, and Proteins",,,,,Chelating Activity;Physiochemical Activity;Binding Activity;Mechanism of Action (MoA);Phosphate Chelating Activity,,Phosphate Binder;Physical or Chemical Agent;Established Pharmacologic Class (EPC);Chemical Structure;Vitamin or Mineral;Calcium,,,,,,,,,,"Metals, Alkaline Earth;Inorganic Chemicals;Blood Coagulation Factors;Substances;Substances and Cells (CHEM);Blood Proteins;Metals;Proteins;Calcium;Biological Factors;Elements;Amino Acids, Peptides, and Proteins",,
164,45,17,Concomitant Medications,Generic Name,RxNorm,Calcium,Calcium,1895.0,Calcium,1895.0,1895.0,1895,False,Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA);Calcium-Regulating Hormones and Agents,,,Medicinal product categorized by chemical element;Calcium and/or calcium compound-containing product;Mineral-containing product;Medicinal product categorized by structure;Metal and/or metallic compound-containing product,"Metals, Alkaline Earth;Inorganic Chemicals;Blood Coagulation Factors;Substances;Substances and Cells (CHEM);Blood Proteins;Metals;Proteins;Calcium;Biological Factors;Elements;Amino Acids, Peptides, and Proteins",,,,,Chelating Activity;Physiochemical Activity;Binding Activity;Mechanism of Action (MoA);Phosphate Chelating Activity,,Phosphate Binder;Physical or Chemical Agent;Established Pharmacologic Class (EPC);Chemical Structure;Vitamin or Mineral;Calcium,,,,,,,,,,"Metals, Alkaline Earth;Inorganic Chemicals;Blood Coagulation Factors;Substances;Substances and Cells (CHEM);Blood Proteins;Metals;Proteins;Calcium;Biological Factors;Elements;Amino Acids, Peptides, and Proteins",,
165,46,18,Concomitant Medications,Generic Name,RxNorm,tegretol,Tegretol Oral Product,1180855.0,Tegretol Oral Product,203029.0,203029.0,203029,False,"Sodium Channel Blockers;Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Psychotropic Drugs;Analgesics, Non-Narcotic;Sensory System Agents;Tranquilizing Agents;Molecular Mechanisms of Pharmacological Action;Anticonvulsants;Antimanic Agents;Cytochrome P-450 Enzyme Inducers;Cytochrome P-450 CYP3A Inducers;Central Nervous System Agents;Metabolic Side Effects of Drugs and Substances;Membrane Transport Modulators;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Cardiovascular Agents",ANTIEPILEPTICS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;Carboxamide derivatives,,,"Carbamazepine;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Dibenzazepines;Heterocyclic Compounds, 3-Ring","Hemic and Lymphatic Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Chemically-Induced Disorders;Drug Hypersensitivity;Bone Marrow Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Schizophrenia Spectrum and Other Psychotic Disorders;Stress Disorders, Post-Traumatic;Chemically-Induced Disorders;Central Nervous System Diseases;Substance-Related Disorders;Epilepsy, Complex Partial;Bipolar Disorder;Trauma and Stressor Related Disorders;Mouth Diseases;Cranial Nerve Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Schizophrenia;Epilepsies, Partial;Restless Legs Syndrome;Psychotic Disorders;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Facial Neuralgia;Epilepsy, Generalized;Facial Nerve Diseases;Parasomnias;Sleep Disorders, Intrinsic;Stomatognathic Diseases;Substance Withdrawal Syndrome;Mental Disorders;Nervous System Diseases;Dyssomnias;Epilepsy;Epilepsy, Tonic-Clonic;Trigeminal Neuralgia;Bipolar and Related Disorders;Stress Disorders, Traumatic;Mood Disorders;Trigeminal Nerve Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Enzyme Inducers;Cytochrome P450 1A2 Inducers;Cytochrome P450 2C19 Inducers;Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA);Cytochrome P450 2C9 Inducers;Cytochrome P450 2B6 Inducers;Enzyme Interactions;Cytochrome P450 3A4 Inducers;Ion Channel Interactions;Cytochrome P450 1A Inducers;Cytochrome P450 3A Inducers;Cytochrome P450 Inducers;Transcription Factor Activity;Sodium Channel Interactions;Receptor Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Organized Electrical Activity Alteration;Nervous System Activity Alteration;Decreased Disorganized Electrical Activity;Physiologic Effect (PE);Disorganized Electrical Activity Alteration;Electrical Activity Alteration;Decreased Organized Electrical Activity,Mood Stabilizer;Established Pharmacologic Class (EPC);Nervous System Agent,ANTICONVULSANTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,,Central Nervous System Agent;Antidepressive Agent;Therapeutic Categories;Antimanic Agent,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,"Azoles;Piperazines;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Triazoles;Heterocyclic Compounds, 1-Ring",,,,,,
166,46,18,Concomitant Medications,Generic Name,RxNorm,tegretol,Tegretol Oral Product,1180855.0,Tegretol Oral Product,203029.0,203029.0,203029,False,"Sodium Channel Blockers;Peripheral Nervous System Agents;Central Nervous System Depressants;Physiological Effects of Drugs;Psychotropic Drugs;Analgesics, Non-Narcotic;Sensory System Agents;Tranquilizing Agents;Molecular Mechanisms of Pharmacological Action;Anticonvulsants;Antimanic Agents;Cytochrome P-450 Enzyme Inducers;Cytochrome P-450 CYP3A Inducers;Central Nervous System Agents;Metabolic Side Effects of Drugs and Substances;Membrane Transport Modulators;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Analgesics;Cardiovascular Agents",ANTIEPILEPTICS;Anatomical Therapeutic Chemical (ATC1-4);NERVOUS SYSTEM;Carboxamide derivatives,,,"Carbamazepine;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Dibenzazepines;Heterocyclic Compounds, 3-Ring","Hemic and Lymphatic Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Hematologic Diseases;Chemically-Induced Disorders;Drug Hypersensitivity;Bone Marrow Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Schizophrenia Spectrum and Other Psychotic Disorders;Stress Disorders, Post-Traumatic;Chemically-Induced Disorders;Central Nervous System Diseases;Substance-Related Disorders;Epilepsy, Complex Partial;Bipolar Disorder;Trauma and Stressor Related Disorders;Mouth Diseases;Cranial Nerve Diseases;Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Schizophrenia;Epilepsies, Partial;Restless Legs Syndrome;Psychotic Disorders;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Sleep Wake Disorders;Facial Neuralgia;Epilepsy, Generalized;Facial Nerve Diseases;Parasomnias;Sleep Disorders, Intrinsic;Stomatognathic Diseases;Substance Withdrawal Syndrome;Mental Disorders;Nervous System Diseases;Dyssomnias;Epilepsy;Epilepsy, Tonic-Clonic;Trigeminal Neuralgia;Bipolar and Related Disorders;Stress Disorders, Traumatic;Mood Disorders;Trigeminal Nerve Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Enzyme Inducers;Cytochrome P450 1A2 Inducers;Cytochrome P450 2C19 Inducers;Unknown Cellular or Molecular Interaction;Mechanism of Action (MoA);Cytochrome P450 2C9 Inducers;Cytochrome P450 2B6 Inducers;Enzyme Interactions;Cytochrome P450 3A4 Inducers;Ion Channel Interactions;Cytochrome P450 1A Inducers;Cytochrome P450 3A Inducers;Cytochrome P450 Inducers;Transcription Factor Activity;Sodium Channel Interactions;Receptor Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Decreased Central Nervous System Disorganized Electrical Activity;Organized Electrical Activity Alteration;Nervous System Activity Alteration;Decreased Disorganized Electrical Activity;Physiologic Effect (PE);Disorganized Electrical Activity Alteration;Electrical Activity Alteration;Decreased Organized Electrical Activity,Mood Stabilizer;Established Pharmacologic Class (EPC);Nervous System Agent,ANTICONVULSANTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,,Central Nervous System Agent;Antidepressive Agent;Therapeutic Categories;Antimanic Agent,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,"Azoles;Piperazines;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Triazoles;Heterocyclic Compounds, 1-Ring",,,,,,
167,51,20,Concomitant Medications,Generic Name,RxNorm,albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
168,51,20,Concomitant Medications,Generic Name,RxNorm,albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
169,78,25,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol 0.09 MG/ACTUAT,329498.0,Albuterol 0.09 MG/ACTUAT,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
170,78,25,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol 0.09 MG/ACTUAT,329498.0,Albuterol 0.09 MG/ACTUAT,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
171,112,33,Concomitant Medications,Generic Name,RxNorm,albuteral,Albuterol Sulfate,142153.0,Albuterol Sulfate,,435.0,435,True,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
172,112,33,Concomitant Medications,Generic Name,RxNorm,albuteral,Albuterol Sulfate,142153.0,Albuterol Sulfate,,435.0,435,True,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
173,121,34,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
174,121,34,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
175,133,38,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
176,133,38,Concomitant Medications,Generic Name,RxNorm,Albuterol,,,,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
177,143,43,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
178,143,43,Concomitant Medications,Generic Name,RxNorm,Albuterol,Albuterol,435.0,Albuterol,435.0,435.0,435,False,Autonomic Agents;Reproductive Control Agents;Adrenergic Agonists;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Tocolytic Agents;Adrenergic beta-Agonists;Adrenergic Agents;Physiological Effects of Drugs;Anti-Asthmatic Agents;Adrenergic beta-2 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"ADRENERGICS FOR SYSTEMIC USE;RESPIRATORY SYSTEM;Selective beta-2-adrenoreceptor agonists;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRENERGICS, INHALANTS;Anatomical Therapeutic Chemical (ATC1-4)",Selective beta-2 agonist-containing product;Adrenergic receptor agonist-containing product;Beta adrenergic receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Ethanolamine and/or ethanolamine derivative-containing product;Medicinal product categorized by structure,Albuterol;Amino Alcohols;Ethanolamines;Phenethylamines;Organic Chemicals;Substances;Substances and Cells (CHEM);Ethanol;Amines;Alcohols;Ethylamines,"Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Immune System Diseases;Disease;Hypersensitivity","Asthma;Hypersensitivity;Bronchial Spasm;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Asthma;Lung Diseases, Obstructive;Hypersensitivity;Bronchial Spasm;Asthma, Exercise-Induced;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Exercise-Induced Allergies",,Adrenergic Agonists;Adrenergic beta2-Agonists;Adrenergic Receptor Interactions;Adrenergic beta-Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Smooth Muscle Tone Alteration;Organ System Specific Effects;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Respiratory Smooth Muscle Tone Alteration;Nervous System Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Bronchodilation;Musculoskeletal Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Established Pharmacologic Class (EPC);beta2-Adrenergic Agonist;beta-Adrenergic Agonist;Receptor Interaction,"ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;BRONCHODILATORS,SYMPATHOMIMETIC,INHALATION;BRONCHODILATORS,SYMPATHOMIMETIC,ORAL;RESPIRATORY TRACT MEDICATIONS;VA CLASSES;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,
179,57,21,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
180,74,24,Concomitant Medications,Generic Name,RxNorm,vitamin c,,,,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
181,81,25,Concomitant Medications,Generic Name,RxNorm,Vitamin C,Vitamin C TR,220879.0,Vitamin C TR,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
182,105,30,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
183,129,37,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
184,152,45,Concomitant Medications,Generic Name,RxNorm,Vitamin C,,,,1151.0,1151.0,1151,False,Protective Agents;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Antioxidants;Molecular Mechanisms of Pharmacological Action,"Organic acids;Ascorbic acid (vitamin C), plain;VITAMINS;SENSORY ORGANS;ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS;Other ophthalmologicals;GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;OTHER OPHTHALMOLOGICALS;ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",,Carbohydrate-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Tyrosinemias;Hemostatic Disorders;Amino Acid Metabolism, Inborn Errors;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Wounds and Injuries;Common Cold;Virus Diseases;Methemoglobinemia;Brain Diseases, Metabolic, Inborn;Hematologic Diseases;Scurvy;Respiratory Tract Infections;Ascorbic Acid Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Nutritional and Metabolic Diseases;Hemorrhagic Disorders;RNA Virus Infections;Brain Diseases, Metabolic;Genetic Diseases, Inborn;Infections;Picornaviridae Infections;Vascular Diseases;Nervous System Diseases;Nutrition Disorders;Respiratory Tract Diseases;Wounds, Penetrating;Metabolism, Inborn Errors;Metabolic Diseases",,,Oxidation-Reduction Activity;Free Radical Scavenging Activity;Enzyme Interactions;Physiochemical Activity;Mechanism of Action (MoA);Reduction Activity,Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Vitamin C;Established Pharmacologic Class (EPC);Vitamin or Mineral,"IRON;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;ELECTROLYTES/MINERALS;LAXATIVES;VITAMIN C;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS","VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN C;LAXATIVES;VITAMIN COMBINATIONS,OTHER;VA CLASSES;HYPEROSMOTIC LAXATIVES;VITAMINS,COMBINATIONS;GASTROINTESTINAL MEDICATIONS",,,,,,,"Kidney Diseases;Urogenital Diseases;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Hyperoxaluria;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Carbohydrates;Carboxylic Acids;Acids, Acyclic;Ascorbic Acid;Sugar Acids;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydroxy Acids",,
185,61,22,Concomitant Medications,Generic Name,RxNorm,citalopram,Citalopram,2556.0,Citalopram,2556.0,2556.0,2556,False,"Selective Serotonin Reuptake Inhibitors;Serotonin Agents;Psychotropic Drugs;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antidepressive Agents, Second-Generation;Membrane Transport Modulators;Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Central Nervous System Agents;Antidepressive Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Propylamine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Citalopram;Substances and Cells (CHEM);Benzofurans;Amines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Dementia;Neurocognitive Disorders;Chemically-Induced Disorders;Obsessive-Compulsive Disorder;Central Nervous System Diseases;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Glucose Metabolism Disorders;Tobacco Use Disorder;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Nutritional and Metabolic Diseases;Depressive Disorder;Neuromuscular Diseases;Diabetes Mellitus;Mental Disorders;Nervous System Diseases;Diabetes Complications;Alcoholism;Endocrine System Diseases;Metabolic Diseases;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Acetates;Acids, Acyclic;Oxazolidinones;Oxazoles;Linezolid;Pimozide;Heterocyclic Compounds, 2-Ring;Fatty Acids;Fatty Acids, Volatile;Phenothiazines;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Acetamides;Heterocyclic Compounds, 1-Ring;Azoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Benzimidazoles;Methylene Blue;Carboxylic Acids;Amides;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 3-Ring",,,,,,
186,61,22,Concomitant Medications,Generic Name,RxNorm,citalopram,Citalopram,2556.0,Citalopram,2556.0,2556.0,2556,False,"Selective Serotonin Reuptake Inhibitors;Serotonin Agents;Psychotropic Drugs;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antidepressive Agents, Second-Generation;Membrane Transport Modulators;Neurotransmitter Uptake Inhibitors;Physiological Effects of Drugs;Central Nervous System Agents;Antidepressive Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",ANTIDEPRESSANTS;PSYCHOANALEPTICS;NERVOUS SYSTEM;Anatomical Therapeutic Chemical (ATC1-4);Selective serotonin reuptake inhibitors,Selective serotonin re-uptake inhibitor-containing product;Medicinal product categorized by disposition,Propylamine-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Nitriles;Propylamines;Heterocyclic Compounds, Fused-Ring;Organic Chemicals;Substances;Heterocyclic Compounds;Citalopram;Substances and Cells (CHEM);Benzofurans;Amines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Dementia;Neurocognitive Disorders;Chemically-Induced Disorders;Obsessive-Compulsive Disorder;Central Nervous System Diseases;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Glucose Metabolism Disorders;Tobacco Use Disorder;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Nutritional and Metabolic Diseases;Depressive Disorder;Neuromuscular Diseases;Diabetes Mellitus;Mental Disorders;Nervous System Diseases;Diabetes Complications;Alcoholism;Endocrine System Diseases;Metabolic Diseases;Mood Disorders",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Serotonin Transporter Interactions;Symporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Increased Immunologically Active Molecule Activity;Organ System Specific Effects;Increased Immunologic Activity;Increased Immunologically Active Biogenic Amine Activity;Immunologically Active Molecule Activity Alteration;Immunologic Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Increased Central Nervous System Serotonin Activity;Increased Serotonin Activity;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Serotonin Activity Alteration;Physiologic Effect (PE),Nervous System Agent;Established Pharmacologic Class (EPC);Serotonin Reuptake Inhibitor,"ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES","ANTIDEPRESSANTS;ANTIDEPRESSANTS,OTHER;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES",,,Antidepressant agent;Medicinal product categorized by therapeutic role,"Acetates;Acids, Acyclic;Oxazolidinones;Oxazoles;Linezolid;Pimozide;Heterocyclic Compounds, 2-Ring;Fatty Acids;Fatty Acids, Volatile;Phenothiazines;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Acetamides;Heterocyclic Compounds, 1-Ring;Azoles;Lipids;Inorganic Chemicals;Sulfur Compounds;Benzimidazoles;Methylene Blue;Carboxylic Acids;Amides;Substances;Substances and Cells (CHEM);Heterocyclic Compounds, 3-Ring",,,,,,
187,63,23,Concomitant Medications,Generic Name,RxNorm,chlorthaladone,,,,,2409.0,2409,True,Antihypertensive Agents;Diuretics;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Sodium Chloride Symporter Inhibitors;Physiological Effects of Drugs;Natriuretic Agents;Membrane Transport Modulators;Molecular Mechanisms of Pharmacological Action;Cardiovascular Agents,"Sulfonamides, plain;CARDIOVASCULAR SYSTEM;LOW-CEILING DIURETICS, EXCL. THIAZIDES;Anatomical Therapeutic Chemical (ATC1-4);DIURETICS",,Nitrogen and/or nitrogen compound-containing product;Sulfur and/or sulfur compound-containing product;Sulfonamide diuretic agent;Sulfonamide-containing product;Medicinal product categorized by structure,"Sulfonamides;Sulfones;Benzophenones;Ketones;Phthalimides;Heterocyclic Compounds, 2-Ring;Hydrocarbons;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Inorganic Chemicals;Phthalic Acids;Sulfur Compounds;Imides;Acids, Carbocyclic;Chlorthalidone;Hydrocarbons, Cyclic;Carboxylic Acids;Amides;Substances;Substances and Cells (CHEM);Isoindoles;Hydrocarbons, Aromatic","Urination Disorders;Kidney Diseases;Urogenital Diseases;Renal Insufficiency;Anuria;Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Drug Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Urologic Diseases;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproduction;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Reproductive Physiological Phenomena;Disease","Nephritis;Kidney Diseases;Male Urogenital Diseases;Hypertension;Glomerulonephritis;Edema;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Liver Cirrhosis;Fibrosis;Heart Diseases;Pathological Conditions, Signs and Symptoms;Nephrotic Syndrome;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Renal Insufficiency;Heart Failure;Nephrosis;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Signs and Symptoms",,,Sodium Chloride Symporter Interactions;Receptor Interactions;Sodium Chloride Symporter Inhibitors;Mechanism of Action (MoA);Symporter Interactions;Ion Transporter Interactions;Membrane Transporter Interactions,Increased Renal Ion Excretion;Cardiovascular Activity Alteration;Physiologic Effect (PE);Increased Renal K+ Excretion;Hemic/Lymphatic Activity Alteration;Increased Diuresis;Renal/Urological Activity Alteration;Intravascular Volume Alteration;Increased Distal Tubule Cl- Excretion;Diuresis Alteration;Organ System Specific Effects;Increased Renal Na+ Excretion;Decreased Intravascular Volume;Blood Pressure Alteration;Hematologic Activity Alteration;Increased Distal Tubule H+ Excretion;Renal Ion Transport Alteration;Increased Distal Tubule Na+ Excretion;Increased Renal H+ Excretion;Blood & Lymphatic Fluid Function Alteration;Decreased Blood Pressure;Increased Renal Cl- Excretion;Increased Distal Tubule K+ Excretion,Thiazide-like Diuretic;Established Pharmacologic Class (EPC);Diuretic,THIAZIDES/RELATED DIURETICS;VA CLASSES;ANTIHYPERTENSIVE COMBINATIONS;DIURETICS;CARDIOVASCULAR MEDICATIONS,THIAZIDES/RELATED DIURETICS;VA CLASSES;ANTIHYPERTENSIVE COMBINATIONS;DIURETICS;CARDIOVASCULAR MEDICATIONS,,,Medicinal product categorized by therapeutic role;Sulfonamide diuretic agent;Diuretic agent,Sulfonamides;Amides;Inorganic Chemicals;Sulfur Compounds;Sulfones;Substances;Substances and Cells (CHEM);Organic Chemicals,,,,,,
188,64,23,Concomitant Medications,Generic Name,RxNorm,propanolol,,,,8787.0,8787.0,8787,False,Antihypertensive Agents;Vasodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Adrenergic Antagonists;Adrenergic Agents;Physiological Effects of Drugs;Adrenergic beta-Antagonists;Anti-Arrhythmia Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Cardiovascular Agents,"CARDIOVASCULAR SYSTEM;Beta blocking agents, non-selective;Anatomical Therapeutic Chemical (ATC1-4);BETA BLOCKING AGENTS",Adrenergic receptor antagonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,"Hydrocarbons, Aromatic;Hydrocarbons;Hydrocarbons, Cyclic;Propranolol;Phenoxypropanolamines;Amino Alcohols;Naphthalenes;Polycyclic Aromatic Hydrocarbons;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Polycyclic Compounds;Alcohols;Propanolamines","Chemically-Induced Disorders;Pulmonary Edema;Drug-Related Side Effects and Adverse Reactions;Infarction;Hypersensitivity, Immediate;Lung Diseases;Necrosis;Lung Diseases, Obstructive;Skin Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Cardiac Conduction System Disease;Arrhythmia, Sinus;Respiratory Hypersensitivity;Atrioventricular Block;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Bronchial Diseases;Heart Block;Heart Diseases;Peripheral Vascular Diseases;Myocardial Ischemia;Sick Sinus Syndrome;Thrombosis;Ischemia;Pathological Conditions, Signs and Symptoms;Pregnancy;Raynaud Disease;Livedoid Vasculopathy;Bradycardia;Pathologic Processes;Vascular Diseases;Arrhythmias, Cardiac;Hypersensitivity;Skin and Connective Tissue Diseases;Heart Failure;Shock, Cardiogenic;Respiratory Tract Diseases;Immune System Diseases;Reproduction;Myocardial Infarction;Shock;Skin Diseases, Vascular;Hypotension;Embolism and Thrombosis","Paraganglioma;Hypertension;Ventricular Fibrillation;Infarction;Central Nervous System Diseases;Necrosis;Neoplasms by Histologic Type;Chest Pain;Hypertension, Portal;Angina Pectoris;Pheochromocytoma;Liver Diseases;Cardiac Conduction System Disease;Esophageal and Gastric Varices;Anxiety Disorders;Tachycardia;Esophageal Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Neuroendocrine Tumors;Pain;Heart Diseases;Neuroectodermal Tumors;Myocardial Ischemia;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Neoplasms, Germ Cell and Embryonal;Tachycardia, Supraventricular;Pathologic Processes;Vascular Diseases;Arrhythmias, Cardiac;Mental Disorders;Nervous System Diseases;Essential Tremor;Panic Disorder;Gastrointestinal Diseases;Tachycardia, Ventricular;Digestive System Diseases;Myocardial Infarction;Neoplasms;Neoplasms, Nerve Tissue;Heart Failure;Signs and Symptoms;Movement Disorders","Nervous System Diseases;Central Nervous System Diseases;Migraine Disorders;Headache Disorders, Primary;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Headache Disorders;Brain Diseases",,Adrenergic beta2-Antagonists;Adrenergic beta1-Antagonists;Adrenergic Receptor Interactions;Adrenergic Antagonists;Adrenergic beta-Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Cardiac Rate Alteration;Bronchoconstriction;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Vasodilation;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Negative Chronotropy;Arterial Vasodilation;Bronchial Smooth Muscle Tone Alteration;Peripheral Nervous System Activity Alteration;Negative Inotropy;Organ System Specific Effects;Cardiac Rhythm Alteration;Blood Pressure Alteration;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Blood Pressure;Cardiac Contractility Alteration;Vascular Alterations,Nervous System Agent;Established Pharmacologic Class (EPC);Cardiovascular Agent;beta-Adrenergic Blocker;Receptor Interaction;Receptor Antagonist,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;BETA BLOCKERS/RELATED,VA CLASSES;CARDIOVASCULAR MEDICATIONS;BETA BLOCKERS/RELATED,,,,,,Organ System Specific Effects;Cardiac Rate Alteration;Negative Chronotropy;Cardiovascular Activity Alteration;Physiologic Effect (PE),,,,
189,64,23,Concomitant Medications,Generic Name,RxNorm,propanolol,,,,8787.0,8787.0,8787,False,Antihypertensive Agents;Vasodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Adrenergic Antagonists;Adrenergic Agents;Physiological Effects of Drugs;Adrenergic beta-Antagonists;Anti-Arrhythmia Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Cardiovascular Agents,"CARDIOVASCULAR SYSTEM;Beta blocking agents, non-selective;Anatomical Therapeutic Chemical (ATC1-4);BETA BLOCKING AGENTS",Adrenergic receptor antagonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor antagonist-containing product,Nitrogen and/or nitrogen compound-containing product;Alcohol-containing product;Medicinal product categorized by structure,"Hydrocarbons, Aromatic;Hydrocarbons;Hydrocarbons, Cyclic;Propranolol;Phenoxypropanolamines;Amino Alcohols;Naphthalenes;Polycyclic Aromatic Hydrocarbons;Organic Chemicals;Substances;Substances and Cells (CHEM);Propanols;Amines;Polycyclic Compounds;Alcohols;Propanolamines","Chemically-Induced Disorders;Pulmonary Edema;Drug-Related Side Effects and Adverse Reactions;Infarction;Hypersensitivity, Immediate;Lung Diseases;Necrosis;Lung Diseases, Obstructive;Skin Diseases;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Bronchial Hyperreactivity;Drug Hypersensitivity;Cardiac Conduction System Disease;Arrhythmia, Sinus;Respiratory Hypersensitivity;Atrioventricular Block;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Bronchial Diseases;Heart Block;Heart Diseases;Peripheral Vascular Diseases;Myocardial Ischemia;Sick Sinus Syndrome;Thrombosis;Ischemia;Pathological Conditions, Signs and Symptoms;Pregnancy;Raynaud Disease;Livedoid Vasculopathy;Bradycardia;Pathologic Processes;Vascular Diseases;Arrhythmias, Cardiac;Hypersensitivity;Skin and Connective Tissue Diseases;Heart Failure;Shock, Cardiogenic;Respiratory Tract Diseases;Immune System Diseases;Reproduction;Myocardial Infarction;Shock;Skin Diseases, Vascular;Hypotension;Embolism and Thrombosis","Paraganglioma;Hypertension;Ventricular Fibrillation;Infarction;Central Nervous System Diseases;Necrosis;Neoplasms by Histologic Type;Chest Pain;Hypertension, Portal;Angina Pectoris;Pheochromocytoma;Liver Diseases;Cardiac Conduction System Disease;Esophageal and Gastric Varices;Anxiety Disorders;Tachycardia;Esophageal Diseases;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Neuroendocrine Tumors;Pain;Heart Diseases;Neuroectodermal Tumors;Myocardial Ischemia;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Neoplasms, Germ Cell and Embryonal;Tachycardia, Supraventricular;Pathologic Processes;Vascular Diseases;Arrhythmias, Cardiac;Mental Disorders;Nervous System Diseases;Essential Tremor;Panic Disorder;Gastrointestinal Diseases;Tachycardia, Ventricular;Digestive System Diseases;Myocardial Infarction;Neoplasms;Neoplasms, Nerve Tissue;Heart Failure;Signs and Symptoms;Movement Disorders","Nervous System Diseases;Central Nervous System Diseases;Migraine Disorders;Headache Disorders, Primary;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Headache Disorders;Brain Diseases",,Adrenergic beta2-Antagonists;Adrenergic beta1-Antagonists;Adrenergic Receptor Interactions;Adrenergic Antagonists;Adrenergic beta-Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Cardiac Rate Alteration;Bronchoconstriction;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Vasodilation;Autonomic Nervous System Activity Alteration;Respiratory/Pulmonary Activity Alteration;Negative Chronotropy;Arterial Vasodilation;Bronchial Smooth Muscle Tone Alteration;Peripheral Nervous System Activity Alteration;Negative Inotropy;Organ System Specific Effects;Cardiac Rhythm Alteration;Blood Pressure Alteration;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Decreased Blood Pressure;Cardiac Contractility Alteration;Vascular Alterations,Nervous System Agent;Established Pharmacologic Class (EPC);Cardiovascular Agent;beta-Adrenergic Blocker;Receptor Interaction;Receptor Antagonist,ANTIHYPERTENSIVE COMBINATIONS;VA CLASSES;CARDIOVASCULAR MEDICATIONS;BETA BLOCKERS/RELATED,VA CLASSES;CARDIOVASCULAR MEDICATIONS;BETA BLOCKERS/RELATED,,,,,,Organ System Specific Effects;Cardiac Rate Alteration;Negative Chronotropy;Cardiovascular Activity Alteration;Physiologic Effect (PE),,,,
190,65,23,Concomitant Medications,Generic Name,RxNorm,loratadine,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,1112258.0,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,28889.0,28889.0,28889,False,"Antipruritics;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Dermatologic Agents;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Anti-Allergic Agents;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Anatomical Therapeutic Chemical (ATC1-4);Other antihistamines for systemic use;ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Piperidine derivative-containing product;Medicinal product categorized by structure,"Hydrocarbons;Hydrocarbons, Cyclic;Loratadine;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Benzocycloheptenes;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Organic Chemicals;Cyproheptadine;Hydrocarbons, Aromatic;Dibenzocycloheptenes;Heterocyclic Compounds, 1-Ring;Piperidines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases, Vascular;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Urticaria;Nose Diseases;Rhinitis, Allergic;Skin Diseases;Rhinitis, Allergic, Perennial;Infections",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;VA CLASSES;ANTIHISTAMINES,OTHER","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;VA CLASSES;ANTIHISTAMINES,OTHER",,,,,,,,,,
191,65,23,Concomitant Medications,Generic Name,RxNorm,loratadine,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,1112258.0,24 HR desloratadine 5 MG / Pseudoephedrine sulfate 240 MG Extended Release Oral Tablet,28889.0,28889.0,28889,False,"Antipruritics;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Dermatologic Agents;Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Anti-Allergic Agents;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Anatomical Therapeutic Chemical (ATC1-4);Other antihistamines for systemic use;ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Piperidine derivative-containing product;Medicinal product categorized by structure,"Hydrocarbons;Hydrocarbons, Cyclic;Loratadine;Polycyclic Aromatic Hydrocarbons;Polycyclic Compounds;Benzocycloheptenes;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Organic Chemicals;Cyproheptadine;Hydrocarbons, Aromatic;Dibenzocycloheptenes;Heterocyclic Compounds, 1-Ring;Piperidines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Skin Diseases, Vascular;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Urticaria;Nose Diseases;Rhinitis, Allergic;Skin Diseases;Rhinitis, Allergic, Perennial;Infections",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,,"COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;VA CLASSES;ANTIHISTAMINES,OTHER","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINES;VA CLASSES;ANTIHISTAMINES,OTHER",,,,,,,,,,
192,67,23,Concomitant Medications,Generic Name,RxNorm,xyzol,,,,,398335.0,398335,True,"Histamine Antagonists;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Piperazine derivatives;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,,"Piperazines;Cetirizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydroxyzine","Kidney Diseases;Urogenital Diseases;Renal Insufficiency;Chemically-Induced Disorders;Drug Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Skin Diseases;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis, Allergic, Seasonal;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases;Skin Diseases, Vascular;Urticaria",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Histamine-1 Receptor Antagonist,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,,,,,,,,,
193,67,23,Concomitant Medications,Generic Name,RxNorm,xyzol,,,,,398335.0,398335,True,"Histamine Antagonists;MeSH Pharmacologic Actions (MESHPA);Histamine H1 Antagonists, Non-Sedating;Histamine H1 Antagonists;Physiological Effects of Drugs;Histamine Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents",Piperazine derivatives;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,,"Piperazines;Cetirizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring;Hydroxyzine","Kidney Diseases;Urogenital Diseases;Renal Insufficiency;Chemically-Induced Disorders;Drug Hypersensitivity;Female Urogenital Diseases and Pregnancy Complications;Male Urogenital Diseases;Female Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Nose Diseases;Skin Diseases;Respiratory Tract Infections;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Rhinitis, Allergic, Seasonal;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases;Skin Diseases, Vascular;Urticaria",,,Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Histamine Activity;Decreased Immunologic Activity;Histamine Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity,Established Pharmacologic Class (EPC);Receptor Antagonist;Receptor Interaction;Histamine-1 Receptor Antagonist,"ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES","ANTIHISTAMINES,PIPERAZINE;ANTIHISTAMINES;VA CLASSES",,,,,,,,,,
194,69,23,Concomitant Medications,Generic Name,RxNorm,finesteride,,,,,25025.0,25025,True,"Steroid Synthesis Inhibitors;Enzyme Inhibitors;Hormone Antagonists;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Genitourinary Agents;Urological Agents;5-alpha Reductase Inhibitors;Molecular Mechanisms of Pharmacological Action",DERMATOLOGICALS;OTHER DERMATOLOGICAL PREPARATIONS;UROLOGICALS;Testosterone-5-alpha reductase inhibitors;Other dermatologicals;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,5-alpha reductase inhibitor-containing product;Medicinal product categorized by disposition;Enzyme inhibitor-containing product,Medicinal product categorized by structure;Steroid-containing product,"Androstanes;Azasteroids;Finasteride;Substances;Steroids;Steroids, Heterocyclic;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Androstenes","Age Groups;Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Drug Hypersensitivity;Child;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Male Urogenital Diseases;Genital Neoplasms, Male;Prostatic Neoplasms;Virilism;Hair Diseases;Skin Diseases;Hypotrichosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Hirsutism;Pathological Conditions, Anatomical;Alopecia;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Genital Diseases;Urogenital Diseases;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Genital Diseases, Male;Prostatic Hyperplasia;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Female Urogenital Diseases;Signs and Symptoms",,,Steroid Synthesis Inhibitors;Enzyme Inhibitors;Androgen Synthesis Inhibitors;Enzyme Interactions;Sex Hormone Synthesis Inhibitors;Mechanism of Action (MoA);5-alpha Reductase Inhibitors,Organ System Specific Effects;Testicular Endocrine Activity Alteration;Endocrine Activity Alteration;Decreased Dihydrotestosterone Secretion;Physiologic Effect (PE),Enzyme Interaction;5-alpha Reductase Inhibitor;Established Pharmacologic Class (EPC);Enzyme Inhibitor,"HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","HORMONES/SYNTHETICS/MODIFIERS,OTHER;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,,,
195,71,24,Concomitant Medications,Generic Name,RxNorm,pioglitazone,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,1368403.0,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,33738.0,33738.0,33738,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;DRUGS USED IN DIABETES;Thiazolidinediones;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Peroxisome proliferator-activated receptor agonist-containing product;Thiazolidinedione-containing product;Medicinal product categorized by disposition;Peroxisome proliferator-activated gamma receptor agonist-containing product,Sulfur and/or sulfur compound-containing product;Thiazole-containing product;Thiazolidinedione-containing product;Medicinal product categorized by structure,"Thiazoles;Azoles;Inorganic Chemicals;Pioglitazone;Sulfur Compounds;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Thiazolidinediones;Organic Chemicals;Heterocyclic Compounds, 1-Ring","Heart Diseases;Heart Failure;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Peroxisome Proliferator-activated Receptor alpha Agonists;Transcription Factor Activity;Peroxisome Proliferator-activated Receptor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Increased Glycolysis;Physiologic Effect (PE),Receptor Agonist;Established Pharmacologic Class (EPC);Thiazolidinedione;Blood Glucose Regulator;Peroxisome Proliferator Receptor gamma Agonist;Receptor Interaction;Peroxisome Proliferator Receptor alpha Agonist;Chemical Structure,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,"Thiazoles;Inorganic Chemicals;PPAR gamma;Sulfur Compounds;Receptors, Cytoplasmic and Nuclear;Organic Chemicals;PPAR alpha;Substances;Substances and Cells (CHEM);Heterocyclic Compounds;Thiazolidinediones;Transcription Factors;Proteins;Peroxisome Proliferator-Activated Receptors;Heterocyclic Compounds, 1-Ring;Azoles;Amino Acids, Peptides, and Proteins",,
196,71,24,Concomitant Medications,Generic Name,RxNorm,pioglitazone,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,1368403.0,alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet,33738.0,33738.0,33738,False,Hypoglycemic Agents;Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA),"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;DRUGS USED IN DIABETES;Thiazolidinediones;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Peroxisome proliferator-activated receptor agonist-containing product;Thiazolidinedione-containing product;Medicinal product categorized by disposition;Peroxisome proliferator-activated gamma receptor agonist-containing product,Sulfur and/or sulfur compound-containing product;Thiazole-containing product;Thiazolidinedione-containing product;Medicinal product categorized by structure,"Thiazoles;Azoles;Inorganic Chemicals;Pioglitazone;Sulfur Compounds;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Thiazolidinediones;Organic Chemicals;Heterocyclic Compounds, 1-Ring","Heart Diseases;Heart Failure;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Insulin Receptor Agonists;Insulin Receptor Interactions;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Peroxisome Proliferator-activated Receptor alpha Agonists;Transcription Factor Activity;Peroxisome Proliferator-activated Receptor Activity;Receptor Interactions,Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Cell Glucose Transport Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Increased Glycolysis;Physiologic Effect (PE),Receptor Agonist;Established Pharmacologic Class (EPC);Thiazolidinedione;Blood Glucose Regulator;Peroxisome Proliferator Receptor gamma Agonist;Receptor Interaction;Peroxisome Proliferator Receptor alpha Agonist;Chemical Structure,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,"Thiazoles;Inorganic Chemicals;PPAR gamma;Sulfur Compounds;Receptors, Cytoplasmic and Nuclear;Organic Chemicals;PPAR alpha;Substances;Substances and Cells (CHEM);Heterocyclic Compounds;Thiazolidinediones;Transcription Factors;Proteins;Peroxisome Proliferator-Activated Receptors;Heterocyclic Compounds, 1-Ring;Azoles;Amino Acids, Peptides, and Proteins",,
197,75,24,Concomitant Medications,Generic Name,RxNorm,vitamin d,,,,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
198,75,24,Concomitant Medications,Generic Name,RxNorm,vitamin d,,,,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
199,119,34,Concomitant Medications,Generic Name,RxNorm,Vitamin D,,,,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
200,119,34,Concomitant Medications,Generic Name,RxNorm,Vitamin D,,,,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
201,154,45,Concomitant Medications,Generic Name,RxNorm,Vitamin D,Vitamin D,11253.0,Vitamin D,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
202,154,45,Concomitant Medications,Generic Name,RxNorm,Vitamin D,Vitamin D,11253.0,Vitamin D,11253.0,11253.0,11253,False,MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs;Bone Density Conservation Agents,,,,Substances;Vitamin D;Steroids;Substances and Cells (CHEM);Secosteroids;Polycyclic Compounds;Fused-Ring Compounds,,,,,,,,,,,,,,,,,,,
203,76,25,Concomitant Medications,Generic Name,RxNorm,Codeine cough syrup,,,,,756905.0,756905,True,"Narcotics;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Sensory System Agents;Central Nervous System Depressants;Analgesics, Opioid;Expectorants;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents","RESPIRATORY SYSTEM;NERVOUS SYSTEM;COUGH AND COLD PREPARATIONS;OPIOIDS;Natural opium alkaloids;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS",Opioid receptor agonist-containing product;Morphinan opioid-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Morphinan-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Isoquinoline-containing product;Medicinal product categorized by structure;Naturally occurring alkaloid-containing product,"Heterocyclic Compounds, Bridged-Ring;Phenols;Catechols;Phenyl Ethers;Polycyclic Aromatic Hydrocarbons;Morphinans;Morphine Derivatives;Hydrocarbons;Guaifenesin;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Hydromorphone;Alkaloids;Guaiacol;Polycyclic Compounds;Phenanthrenes;Hydrocarbons, Cyclic;Ethers;Methyl Ethers;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Intracranial Hypertension;Drug Hypersensitivity;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Brain Diseases;Respiration Disorders;Pregnancy;Hypersensitivity;Nervous System Diseases;Respiratory Tract Diseases;Immune System Diseases;Reproduction;Respiratory Insufficiency","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Pain, Postoperative;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Pain;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Neurologic Manifestations;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Pathologic Processes;Postoperative Complications;Hypersensitivity;Nervous System Diseases;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms",,,Opioid Receptor Interactions;Opioid mu-Receptor Agonists;Opioid Agonists;Full Opioid Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Central Nervous System Depression;Analgesia;Organized Electrical Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Respiratory Secretion Viscosity;Nervous System Activity Alteration;Central Nervous System Activity Alteration;Respiratory Secretion Alteration;Peripheral Nervous System Activity Alteration;Sensory System Activity Alteration;Physiologic Effect (PE);Electrical Activity Alteration;Increased Respiratory Secretions;Decreased Organized Electrical Activity,Opioid Agonist;Nervous System Agent;Receptor Agonist;Respiratory Agent;Established Pharmacologic Class (EPC);Receptor Interaction;Expectorant,,,,,Medicinal product categorized by therapeutic role;Expectorant agent,,,Organ System Specific Effects;Organized Electrical Activity Alteration;Physiologic Effect (PE);Nervous System Activity Alteration;Decreased Central Nervous System Organized Electrical Activity;Electrical Activity Alteration;Decreased Organized Electrical Activity,,,,
204,76,25,Concomitant Medications,Generic Name,RxNorm,Codeine cough syrup,,,,,756905.0,756905,True,"Narcotics;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Sensory System Agents;Central Nervous System Depressants;Analgesics, Opioid;Expectorants;Physiological Effects of Drugs;Analgesics;Central Nervous System Agents","RESPIRATORY SYSTEM;NERVOUS SYSTEM;COUGH AND COLD PREPARATIONS;OPIOIDS;Natural opium alkaloids;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS",Opioid receptor agonist-containing product;Morphinan opioid-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Morphinan-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Isoquinoline-containing product;Medicinal product categorized by structure;Naturally occurring alkaloid-containing product,"Heterocyclic Compounds, Bridged-Ring;Phenols;Catechols;Phenyl Ethers;Polycyclic Aromatic Hydrocarbons;Morphinans;Morphine Derivatives;Hydrocarbons;Guaifenesin;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Hydromorphone;Alkaloids;Guaiacol;Polycyclic Compounds;Phenanthrenes;Hydrocarbons, Cyclic;Ethers;Methyl Ethers;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Central Nervous System Diseases;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Intracranial Hypertension;Drug Hypersensitivity;Respiratory Hypersensitivity;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Brain Diseases;Respiration Disorders;Pregnancy;Hypersensitivity;Nervous System Diseases;Respiratory Tract Diseases;Immune System Diseases;Reproduction;Respiratory Insufficiency","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Pain, Postoperative;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Pain;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Neurologic Manifestations;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Pathologic Processes;Postoperative Complications;Hypersensitivity;Nervous System Diseases;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms",,,Opioid Receptor Interactions;Opioid mu-Receptor Agonists;Opioid Agonists;Full Opioid Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Central Nervous System Depression;Analgesia;Organized Electrical Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Respiratory Secretion Viscosity;Nervous System Activity Alteration;Central Nervous System Activity Alteration;Respiratory Secretion Alteration;Peripheral Nervous System Activity Alteration;Sensory System Activity Alteration;Physiologic Effect (PE);Electrical Activity Alteration;Increased Respiratory Secretions;Decreased Organized Electrical Activity,Opioid Agonist;Nervous System Agent;Receptor Agonist;Respiratory Agent;Established Pharmacologic Class (EPC);Receptor Interaction;Expectorant,,,,,Medicinal product categorized by therapeutic role;Expectorant agent,,,Organ System Specific Effects;Organized Electrical Activity Alteration;Physiologic Effect (PE);Nervous System Activity Alteration;Decreased Central Nervous System Organized Electrical Activity;Electrical Activity Alteration;Decreased Organized Electrical Activity,,,,
205,77,25,Concomitant Medications,Generic Name,RxNorm,azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
206,77,25,Concomitant Medications,Generic Name,RxNorm,azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
207,122,34,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
208,122,34,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
209,148,43,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
210,148,43,Concomitant Medications,Generic Name,RxNorm,Azithromycin,Azithromycin,18631.0,Azithromycin,18631.0,18631.0,18631,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;Macrolides;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Antibiotics;Anatomical Therapeutic Chemical (ATC1-4)",,Macrolide-containing product;Macrolide antibacterial agent;Medicinal product categorized by structure,Erythromycin;Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds;Azithromycin,"Hypersensitivity;Liver Diseases;Digestive System Diseases;Immune System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Otitis;Mycoplasma Infections;Urethral Diseases;Male Urogenital Diseases;Mycobacterium Infections, Nontuberculous;Lung Diseases;Pneumonia, Mycoplasma;Pharyngeal Diseases;Mycobacterium Infections;Skin Diseases;Urethritis;Chlamydia Infections;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Pneumonia;Urologic Diseases;Gram-Positive Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Sexually Transmitted Diseases;Actinomycetales Infections;Otitis Media;Pathological Conditions, Signs and Symptoms;Neisseriaceae Infections;Streptococcal Infections;Ear Diseases;Genital Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Urogenital Diseases;Staphylococcal Infections;Mycoplasmatales Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Female Urogenital Diseases and Pregnancy Complications;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases;Gram-Negative Bacterial Infections;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases","Heart Diseases;Cardiovascular Infections;Actinomycetales Infections;Bacterial Infections and Mycoses;Bacterial Infections;Endocarditis;Endocarditis, Bacterial;Mycobacterium Infections, Nontuberculous;Gram-Positive Bacterial Infections;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mycobacterium Infections;Infections",,Protein Synthesis Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Organ System Specific Effects;Cellular Activity Alteration;Decreased Protein Synthesis;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Cellular Synthetic Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Striated Muscle Anabolism Alteration,Anti-infective;Established Pharmacologic Class (EPC);Macrolide Antimicrobial;Chemical Structure;Antimicrobial;Macrolide,"OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC","OPHTHALMIC AGENTS;ANTIMICROBIALS;ANTIBACTERIALS,TOPICAL OPHTHALMIC;VA CLASSES;ERYTHROMYCINS/MACROLIDES;ANTI-INFECTIVE,TOPICAL OPHTHALMIC",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,Elimination;Route of Excretion;Pharmacokinetics (PK);Hepatic Excretion,Medicinal product categorized by therapeutic role;Antiinfective agent;Macrolide antibacterial agent;Antibacterial agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzimidazoles;Pimozide",,,,Polyketides;Lactones;Macrolides;Macrocyclic Compounds;Substances and Cells (CHEM);Substances;Organic Chemicals;Polycyclic Compounds,,
211,79,25,Concomitant Medications,Generic Name,RxNorm,Qvar,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],966537.0,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],226084.0,226084.0,226084,False,"Glucocorticoids;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,"Pregnadienetriols;Substances;Steroids;Beclomethasone;Substances and Cells (CHEM);Polycyclic Compounds;Steroids, Chlorinated;Fused-Ring Compounds;Pregnadienes;Pregnanes","Asthma;Hypersensitivity;Chemically-Induced Disorders;Drug Hypersensitivity;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Hypersensitivity;Infections;Rhinitis;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Inflammation;Hypersensitivity, Immediate;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Pathologic Processes","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Vascular Tone Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Vasoconstriction;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Fecal Excretion;Pharmacokinetics (PK);Elimination;Route of Excretion,,,,,,,,
212,79,25,Concomitant Medications,Generic Name,RxNorm,Qvar,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],966537.0,Beclomethasone Dipropionate 0.04 MG/ACTUAT [Qvar],226084.0,226084.0,226084,False,"Glucocorticoids;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,"Pregnadienetriols;Substances;Steroids;Beclomethasone;Substances and Cells (CHEM);Polycyclic Compounds;Steroids, Chlorinated;Fused-Ring Compounds;Pregnadienes;Pregnanes","Asthma;Hypersensitivity;Chemically-Induced Disorders;Drug Hypersensitivity;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive","Hypersensitivity;Infections;Rhinitis;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Inflammation;Hypersensitivity, Immediate;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Pathologic Processes","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Vascular Tone Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Vasoconstriction;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","VA CLASSES;RESPIRATORY TRACT MEDICATIONS;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,Renal Excretion;Fecal Excretion;Pharmacokinetics (PK);Elimination;Route of Excretion,,,,,,,,
213,80,25,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1303916.0,Cholecalciferol 50000 UNT Oral Tablet [Dialyvite Vitamin D3 Max],1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
214,85,26,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
215,98,29,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
216,102,30,Concomitant Medications,Generic Name,RxNorm,vitamin d3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
217,108,32,Concomitant Medications,Generic Name,RxNorm,Vitamin D3,,,,1244014.0,1244014.0,1244014,False,,,,,,,,,,,,,,,,,,,,,,,,
218,82,25,Concomitant Medications,Generic Name,RxNorm,Acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,"Narcotics;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Central Nervous System Depressants;Analgesics, Opioid;Physiological Effects of Drugs;Anti-Inflammatory Agents;Analgesics;Central Nervous System Agents;Antipyretics;Antirheumatic Agents",Anilides;NERVOUS SYSTEM;OPIOIDS;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Opioid receptor agonist-containing product;Morphinan opioid-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Morphinan-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Isoquinoline-containing product;Medicinal product categorized by structure;Naturally occurring alkaloid-containing product,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,"ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTIHISTAMINE/ANTITUSSIVE;ANTIRHEUMATICS;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;MUSCULOSKELETAL MEDICATIONS;COLD REMEDIES,COMBINATIONS;CNS MEDICATIONS,OTHER","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/ANALGESIC;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/ANTITUSSIVE;COLD REMEDIES,OTHER;NON-OPIOID ANALGESICS;CNS MEDICATIONS,OTHER;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE V;SCHEDULE III;SCHEDULE IV;SCHEDULE II;CSA SCHEDULE
219,134,39,Concomitant Medications,Generic Name,RxNorm,acetaminophen,Acetaminophen,161.0,Acetaminophen,161.0,161.0,161,False,"Narcotics;Anti-Inflammatory Agents, Non-Steroidal;Analgesics, Non-Narcotic;Sensory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Central Nervous System Depressants;Analgesics, Opioid;Physiological Effects of Drugs;Anti-Inflammatory Agents;Analgesics;Central Nervous System Agents;Antipyretics;Antirheumatic Agents",Anilides;NERVOUS SYSTEM;OPIOIDS;Opioids in combination with non-opioid analgesics;Anatomical Therapeutic Chemical (ATC1-4);OTHER ANALGESICS AND ANTIPYRETICS;ANALGESICS,Opioid receptor agonist-containing product;Morphinan opioid-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Phenol structure-containing product;Morphinan-containing product;Alkaloid-containing product;Morphinan opioid-containing product;Isoquinoline-containing product;Medicinal product categorized by structure;Naturally occurring alkaloid-containing product,Anilides;Acetaminophen;Amides;Acetanilides;Organic Chemicals;Aniline Compounds;Substances;Substances and Cells (CHEM);Amines,"Hemic and Lymphatic Diseases;Glucosephosphate Dehydrogenase Deficiency;Chemically-Induced Disorders;Anemia;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hematologic Diseases;Drug Hypersensitivity;Liver Diseases;Carbohydrate Metabolism, Inborn Errors;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Anemia, Hemolytic, Congenital;Genetic Diseases, Inborn;Anemia, Hemolytic;Digestive System Diseases;Metabolism, Inborn Errors;Metabolic Diseases","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain","Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Fever;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Body Temperature Changes;Disease;Signs and Symptoms;Pain",,Prostaglandin Receptor Interactions;Prostaglandin Receptor Antagonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions,Decreased Immunologically Active Molecule Production;Organ System Specific Effects;Immunologically Active Molecule Production Alteration;Immunologic Activity Alteration;Decreased Eicosanoid Production;Decreased Immunologic Activity;Endocrine Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Decreased Lipid Derived Immunologically Active Molecule Production;Decreased Prostaglandin Production;Physiologic Effect (PE);Peripheral Nervous System Activity Alteration;Hypothalamic Endocrine Activity Alteration;Central Nervous System Activity Alteration,,"ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/ANALGESIC;NON-OPIOID ANALGESICS;OPIOID ANALGESICS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;NONSALICYLATE NSAIs,ANTIRHEUMATIC;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;ANALGESICS;DECONGESTANT/ANTITUSSIVE/ANALGESIC;ANTIHISTAMINE/ANTITUSSIVE;ANTIRHEUMATICS;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;MUSCULOSKELETAL MEDICATIONS;COLD REMEDIES,COMBINATIONS;CNS MEDICATIONS,OTHER","COLD REMEDIES,COMBINATIONS;ANTIHISTAMINE/DECONGESTANT/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/ANALGESIC;RESPIRATORY TRACT MEDICATIONS;ANTIHISTAMINE/ANTITUSSIVE;COLD REMEDIES,OTHER;NON-OPIOID ANALGESICS;CNS MEDICATIONS,OTHER;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES;ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC;OPIOID ANALGESICS;ANALGESICS",,Renal Excretion;Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism;Route of Excretion,,,,,,,,SCHEDULE V;SCHEDULE III;SCHEDULE IV;SCHEDULE II;CSA SCHEDULE
220,83,26,Concomitant Medications,Generic Name,RxNorm,Hydrocortisone 2%,,,,,197784.0,197784,True,Anti-Inflammatory Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Corticosteroids for local oral treatment;DERMATOLOGICALS;Glucocorticoids;Corticosteroids acting locally;CORTICOSTEROIDS, OTHER COMBINATIONS;OTOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;Corticosteroids/antiinfectives/mydriatics in combination;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids, weak (group I);CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;OPHTHALMOLOGICALS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;CORTICOSTEROIDS;CORTICOSTEROIDS, PLAIN;CORTICOSTEROIDS FOR SYSTEMIC USE;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;Corticosteroids;Corticosteroids, weak, other combinations;ANTIINFLAMMATORY AGENTS;Corticosteroids, plain;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;VASOPROTECTIVES;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE",Hormone-containing product;Adrenal hormone-containing product;Adrenal cortex hormone-containing product;Medicinal product categorized by disposition,Corticosteroid and/or corticosteroid derivative-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Steroid-containing product,"Hydrocortisone;Hydroxycorticosteroids;11-Hydroxycorticosteroids;Pregnenes;17-Hydroxycorticosteroids;Adrenal Cortex Hormones;Substances;Steroids;Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Pregnenediones;Polycyclic Compounds;Fused-Ring Compounds;Pregnanes","Tuberculosis;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Parasitic Diseases;Mycobacterium Infections;Skin Diseases;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Tuberculosis, Cutaneous;Drug Hypersensitivity;Dermatomycoses;Gram-Positive Bacterial Infections;Mycoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Actinomycetales Infections;Skin Diseases, Parasitic;Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Tuberculosis, Extrapulmonary;Skin Diseases, Viral;Skin Diseases, Bacterial","Facial Dermatoses;Rectal Diseases;Urogenital Abnormalities;Adrenogenital Syndrome;Skin Diseases, Eczematous;Adrenal Gland Diseases;Foot Dermatoses;Male Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hypersensitivity, Immediate;Lung Diseases;Pruritus;Lung Diseases, Obstructive;Steroid Metabolism, Inborn Errors;Skin Diseases;Leg Dermatoses;Hemorrhoids;Asthma;Female Urogenital Diseases and Pregnancy Complications;Gonadal Disorders;Foot Diseases;Scalp Dermatoses;Intestinal Diseases;Skin Manifestations;Colonic Diseases;Respiratory Hypersensitivity;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Bronchial Diseases;Anus Diseases;Nutritional and Metabolic Diseases;Adrenal Insufficiency;Congenital Abnormalities;Disorders of Sex Development;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Inflammation;Adrenal Hyperplasia, Congenital;Rheumatic Diseases;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Pruritus Ani;Dermatitis, Contact;Hand Dermatoses;Gastrointestinal Diseases;Gastroenteritis;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Digestive System Diseases;Colitis, Ulcerative;Inflammatory Bowel Diseases;Shock;Endocrine System Diseases;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Dermatitis;Musculoskeletal Diseases;Colitis",,,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Enzyme Inhibitors;Enzyme Interactions;Steroid Hormone Receptor Agonists;Lipoxygenase Inhibitors;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Decreased Lipid Derived Immunologically Active Molecule Activity;Metabolic Activity Alteration;Cellular Activity Alteration;Decreased Immunologic Activity;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Decreased Vascular Permeability;Generalized Systemic Effects;Translation Alteration;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Decreased Polymorphonuclear Leukocyte Migration;Immunologic Activity Alteration;Endocrine Activity Alteration;Decreased Eicosanoid Activity;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Decreased Leukotriene Activity;Organ System Specific Effects;Vascular Permeability Alteration;Carbohydrate Metabolism Alteration;Decreased Thromboxane Activity;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Decreased Prostaglandin Activity;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Lipid Metabolism Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTI-INFLAMMATORY,TOPICAL;VA CLASSES;DERMATOLOGICAL AGENTS","ANTI-INFLAMMATORY,TOPICAL;VA CLASSES;DERMATOLOGICAL AGENTS",,,,,,,,,,
221,83,26,Concomitant Medications,Generic Name,RxNorm,Hydrocortisone 2%,,,,,197784.0,197784,True,Anti-Inflammatory Agents;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"Corticosteroids for local oral treatment;DERMATOLOGICALS;Glucocorticoids;Corticosteroids acting locally;CORTICOSTEROIDS, OTHER COMBINATIONS;OTOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;Corticosteroids/antiinfectives/mydriatics in combination;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids, weak (group I);CARDIOVASCULAR SYSTEM;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;OPHTHALMOLOGICALS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;CORTICOSTEROIDS;CORTICOSTEROIDS, PLAIN;CORTICOSTEROIDS FOR SYSTEMIC USE;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;Corticosteroids;Corticosteroids, weak, other combinations;ANTIINFLAMMATORY AGENTS;Corticosteroids, plain;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;VASOPROTECTIVES;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE",Hormone-containing product;Adrenal hormone-containing product;Adrenal cortex hormone-containing product;Medicinal product categorized by disposition,Corticosteroid and/or corticosteroid derivative-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Steroid-containing product,"Hydrocortisone;Hydroxycorticosteroids;11-Hydroxycorticosteroids;Pregnenes;17-Hydroxycorticosteroids;Adrenal Cortex Hormones;Substances;Steroids;Hormones;Substances and Cells (CHEM);Hormones, Hormone Substitutes, and Hormone Antagonists;Pregnenediones;Polycyclic Compounds;Fused-Ring Compounds;Pregnanes","Tuberculosis;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Parasitic Diseases;Mycobacterium Infections;Skin Diseases;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Tuberculosis, Cutaneous;Drug Hypersensitivity;Dermatomycoses;Gram-Positive Bacterial Infections;Mycoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Actinomycetales Infections;Skin Diseases, Parasitic;Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Tuberculosis, Extrapulmonary;Skin Diseases, Viral;Skin Diseases, Bacterial","Facial Dermatoses;Rectal Diseases;Urogenital Abnormalities;Adrenogenital Syndrome;Skin Diseases, Eczematous;Adrenal Gland Diseases;Foot Dermatoses;Male Urogenital Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hypersensitivity, Immediate;Lung Diseases;Pruritus;Lung Diseases, Obstructive;Steroid Metabolism, Inborn Errors;Skin Diseases;Leg Dermatoses;Hemorrhoids;Asthma;Female Urogenital Diseases and Pregnancy Complications;Gonadal Disorders;Foot Diseases;Scalp Dermatoses;Intestinal Diseases;Skin Manifestations;Colonic Diseases;Respiratory Hypersensitivity;Connective Tissue Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Bronchial Diseases;Anus Diseases;Nutritional and Metabolic Diseases;Adrenal Insufficiency;Congenital Abnormalities;Disorders of Sex Development;Pathological Conditions, Signs and Symptoms;Genetic Diseases, Inborn;Inflammation;Adrenal Hyperplasia, Congenital;Rheumatic Diseases;Pathologic Processes;Urogenital Diseases;Vascular Diseases;Hypersensitivity;Skin and Connective Tissue Diseases;Pruritus Ani;Dermatitis, Contact;Hand Dermatoses;Gastrointestinal Diseases;Gastroenteritis;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Digestive System Diseases;Colitis, Ulcerative;Inflammatory Bowel Diseases;Shock;Endocrine System Diseases;Female Urogenital Diseases;Metabolism, Inborn Errors;Signs and Symptoms;Metabolic Diseases;Dermatitis;Musculoskeletal Diseases;Colitis",,,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Enzyme Inhibitors;Enzyme Interactions;Steroid Hormone Receptor Agonists;Lipoxygenase Inhibitors;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Decreased Lipid Derived Immunologically Active Molecule Activity;Metabolic Activity Alteration;Cellular Activity Alteration;Decreased Immunologic Activity;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Decreased Vascular Permeability;Generalized Systemic Effects;Translation Alteration;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Decreased Polymorphonuclear Leukocyte Migration;Immunologic Activity Alteration;Endocrine Activity Alteration;Decreased Eicosanoid Activity;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Decreased Leukotriene Activity;Organ System Specific Effects;Vascular Permeability Alteration;Carbohydrate Metabolism Alteration;Decreased Thromboxane Activity;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Decreased Prostaglandin Activity;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Immunologically Active Molecule Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Lipid Metabolism Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTI-INFLAMMATORY,TOPICAL;VA CLASSES;DERMATOLOGICAL AGENTS","ANTI-INFLAMMATORY,TOPICAL;VA CLASSES;DERMATOLOGICAL AGENTS",,,,,,,,,,
222,87,27,Concomitant Medications,Generic Name,RxNorm,Decadron,Decadron Pill,1170298.0,Decadron Pill,227682.0,227682.0,227682,False,"Autonomic Agents;Glucocorticoids;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Antiemetics;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents;Anti-Inflammatory Agents;Central Nervous System Agents;Gastrointestinal Agents;Antineoplastic Agents, Hormonal","Corticosteroids for local oral treatment;Corticosteroids, moderately potent (group II);DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, OTHER COMBINATIONS;OTOLOGICALS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);Corticosteroids, combinations for treatment of acne;CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN;Corticosteroids/antiinfectives/mydriatics in combination;RESPIRATORY SYSTEM;CARDIOVASCULAR SYSTEM;NASAL PREPARATIONS;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;OPHTHALMOLOGICALS;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS;CORTICOSTEROIDS;ANTI-ACNE PREPARATIONS;CORTICOSTEROIDS, PLAIN;CORTICOSTEROIDS FOR SYSTEMIC USE;ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION;Corticosteroids, moderately potent, other combinations;Corticosteroids;ANTIINFLAMMATORY AGENTS;Corticosteroids, plain;STOMATOLOGICAL PREPARATIONS;SENSORY ORGANS;OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS;VASOPROTECTIVES;ANTI-ACNE PREPARATIONS FOR TOPICAL USE;AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE",Immunomodulator-containing product;Medicinal product categorized by disposition,Steroid-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,"Dexamethasone;Pregnadienetriols;Steroids, Fluorinated;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Pregnadienes;Pregnanes","Eye Infections, Fungal;Eye Infections, Bacterial;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Mycoses;Eye Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Eye Infections, Viral;Disease;Eye Infections;Tuberculosis, Ocular;Infections","Autoimmune Diseases;Thyroid Diseases;Adrenal Gland Diseases;Water-Electrolyte Imbalance;Central Nervous System Diseases;Eye Diseases;Lung Diseases;Sarcoidosis;Bacterial Infections and Mycoses;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Addison Disease;Lymphoproliferative Disorders;Hemorrhage;Arthritis;Rheumatic Diseases;Mycosis Fungoides;Purpura;Skin and Connective Tissue Diseases;Lymphatic Diseases;Uveitis;Nausea;Inflammatory Bowel Diseases;Iris Diseases;Brain Edema;Dermatitis;Musculoskeletal Diseases;Tuberculosis;Collagen Diseases;Shock, Septic;Bacterial Infections;Blood Coagulation Disorders;Lupus Erythematosus, Systemic;Skin Manifestations;Immunoproliferative Disorders;Gram-Positive Bacterial Infections;Tuberculosis, Pulmonary;Thyroiditis;Inflammation;Vomiting;Corneal Diseases;Spondylitis;Pemphigus;Neoplasms;Ankylosis;Respiratory Tract Diseases;Sepsis;Metabolic Diseases;Hemic and Lymphatic Diseases;Spondylarthritis;Uveitis, Anterior;Thrombotic Microangiopathies;Hypersensitivity, Immediate;Neoplasms by Histologic Type;Nose Diseases;Mycobacterium Infections;Systemic Inflammatory Response Syndrome;Spondylitis, Ankylosing;Bursitis;Dermatitis Herpetiformis;Lymphoma, T-Cell;Hematologic Diseases;Intestinal Diseases;Colonic Diseases;Respiratory Hypersensitivity;Connective Tissue Diseases;Iritis;Brain Diseases;Actinomycetales Infections;Pathological Conditions, Signs and Symptoms;Calcium Metabolism Disorders;Hypersensitivity, Delayed;Spinal Diseases;Infections;Panuveitis;Otorhinolaryngologic Diseases;Colitis, Ulcerative;Bone Diseases, Infectious;Immune System Diseases;Signs and Symptoms, Digestive;Endocrine System Diseases;Signs and Symptoms;Colitis;Joint Diseases;Uveal Diseases;Skin Diseases;Leukemia;Lymphoma, Non-Hodgkin;Keratitis;Spondylarthropathies;Respiratory Tract Infections;Lymphoma;Rhinitis, Allergic;Disease;Rhinitis, Allergic, Perennial;Nutritional and Metabolic Diseases;Adrenal Insufficiency;Bone Diseases;Rhinitis;Axial Spondyloarthritis;Hemorrhagic Disorders;Hypercalcemia;Purpura, Thrombocytopenic;Skin Diseases, Vesiculobullous;Pathologic Processes;Blood Platelet Disorders;Hypersensitivity;Nervous System Diseases;Purpura, Thrombocytopenic, Idiopathic;Gastroenteritis;Digestive System Diseases;Gastrointestinal Diseases;Shock;Lymphoma, T-Cell, Cutaneous;Thrombocytopenia","Nasal Polyps;Polyps;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Nose Diseases;Asthma;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Anatomical;Pathological Conditions, Signs and Symptoms;Vomiting;Hypersensitivity;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases;Nausea;Signs and Symptoms, Digestive;Signs and Symptoms",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Enzyme Inhibitors;Enzyme Interactions;Steroid Hormone Receptor Agonists;Lipoxygenase Inhibitors;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Decreased Lipid Derived Immunologically Active Molecule Activity;Decreased Immunologically Active Molecule Production;Decreased Myeloid Cell Production;Metabolic Activity Alteration;Cellular Activity Alteration;Decreased Immunologic Activity;Lysosomal Function Alteration;Translation Alteration;Cardiovascular Activity Alteration;Generalized Systemic Effects;Decreased Vascular Permeability;Striated Muscle Metabolic Alteration;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Decreased Complement Production;Decreased Hematopoiesis;Adrenal Cortical Activity Alteration;Decreased Immunologically Active Molecule Activity;Decreased Adhesion Factor Activity;Immunologically Active Molecule Production Alteration;Hemic/Lymphatic Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Decreased Histamine Activity;Hematological Cell Quantity Alteration;Endocrine Activity Alteration;Decreased Eicosanoid Activity;Cellular Degradation/Digestion Alteration;Intravascular Volume Alteration;Striated Muscle Anabolism Alteration;Decreased Leukotriene Activity;Organ System Specific Effects;Vascular Permeability Alteration;Carbohydrate Metabolism Alteration;Decreased Thromboxane Activity;Decreased Intravascular Volume;Decreased Protein Synthesis;Hematopoiesis Alteration;Cellular Synthetic Activity Alteration;Hematologic Activity Alteration;Decreased Prostaglandin Activity;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Blood & Lymphatic Fluid Function Alteration;Immunologically Active Molecule Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Lipid Metabolism Alteration;Decreased Lysosomal Function;Histamine Activity Alteration;Decreased Capillary Permeability;Decreased Cellular Migration;Decreased Kinin Activity,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,GLUCOCORTICOIDS;HORMONES/SYNTHETICS/MODIFIERS;ADRENAL CORTICOSTERIODS;VA CLASSES,,,,,,,,,"Cushing Syndrome;Mental Disorders;Depressive Disorder;Adrenal Gland Diseases;Adrenocortical Hyperfunction;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Mood Disorders",
223,88,27,Concomitant Medications,Generic Name,RxNorm,Tamoxifen,Tamoxifen,10324.0,Tamoxifen,10324.0,10324.0,10324,False,"Hormone Antagonists;Estrogen Receptor Modulators;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Selective Estrogen Receptor Modulators;Estrogen Antagonists;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents;Bone Density Conservation Agents;Antineoplastic Agents, Hormonal",ENDOCRINE THERAPY;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;HORMONE ANTAGONISTS AND RELATED AGENTS;Anti-estrogens;Anatomical Therapeutic Chemical (ATC1-4),Hormone receptor antagonist-containing product;Estrogen receptor antagonist-containing product;Medicinal product categorized by disposition,,"Hydrocarbons;Hydrocarbons, Cyclic;Benzylidene Compounds;Benzene Derivatives;Tamoxifen;Stilbenes;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Vascular Diseases;Embolism;Thrombosis;Chemically-Induced Disorders;Drug Hypersensitivity;Pulmonary Embolism;Respiratory Tract Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Venous Thrombosis;Embolism and Thrombosis","Endocrine Gland Neoplasms;Breast Neoplasms;Gonadal Disorders;Puberty, Precocious;Skin and Connective Tissue Diseases;Gynecomastia;Breast Diseases;Neoplasms by Site;Digestive System Diseases;Neoplasms;Pancreatic Neoplasms;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pancreatic Diseases;Skin Diseases;Digestive System Neoplasms","Breast Neoplasms;Carcinoma, Ductal, Breast;Skin and Connective Tissue Diseases;Carcinoma, Ductal;Carcinoma;Neoplasms by Site;Neoplasms, Ductal, Lobular, and Medullary;Neoplasms;Adenocarcinoma;Neoplasms by Histologic Type;Breast Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases;Disease;Neoplasms, Glandular and Epithelial",,Hormone Receptor Interactions;Steroid Receptor Modulators;Selective Estrogen Receptor Modulators;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions;Hormone Receptor Modulators,Stimulate Ovulation;Organ System Specific Effects;Ovarian Endocrine Activity Alteration;Female Reproductive System Activity Alteration;Nucleic Acid Replication Alteration;Cellular Activity Alteration;DNA Replication Alteration;Decreased Ovarian Estrogen Secretion;Endocrine Activity Alteration;Ovarian Function Alteration;Decreased DNA Replication;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Receptor Agonist;Established Pharmacologic Class (EPC);Estrogen Agonist/Antagonist;Receptor Interaction;Receptor Antagonist,VA CLASSES;ANTINEOPLASTICS;ANTINEOPLASTIC HORMONES,VA CLASSES;ANTINEOPLASTICS;ANTINEOPLASTIC HORMONES,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;4-Hydroxycoumarins;Heterocyclic Compounds;Pyrans;Substances and Cells (CHEM);Benzopyrans;Warfarin;Heterocyclic Compounds, 1-Ring;Coumarins",,,,,,
224,88,27,Concomitant Medications,Generic Name,RxNorm,Tamoxifen,Tamoxifen,10324.0,Tamoxifen,10324.0,10324.0,10324,False,"Hormone Antagonists;Estrogen Receptor Modulators;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Selective Estrogen Receptor Modulators;Estrogen Antagonists;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists;Antineoplastic Agents;Bone Density Conservation Agents;Antineoplastic Agents, Hormonal",ENDOCRINE THERAPY;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;HORMONE ANTAGONISTS AND RELATED AGENTS;Anti-estrogens;Anatomical Therapeutic Chemical (ATC1-4),Hormone receptor antagonist-containing product;Estrogen receptor antagonist-containing product;Medicinal product categorized by disposition,,"Hydrocarbons;Hydrocarbons, Cyclic;Benzylidene Compounds;Benzene Derivatives;Tamoxifen;Stilbenes;Substances;Substances and Cells (CHEM);Organic Chemicals;Hydrocarbons, Aromatic","Life Phases, Behavior Mechanisms and Physiologic States;Vascular Diseases;Embolism;Thrombosis;Chemically-Induced Disorders;Drug Hypersensitivity;Pulmonary Embolism;Respiratory Tract Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Venous Thrombosis;Embolism and Thrombosis","Endocrine Gland Neoplasms;Breast Neoplasms;Gonadal Disorders;Puberty, Precocious;Skin and Connective Tissue Diseases;Gynecomastia;Breast Diseases;Neoplasms by Site;Digestive System Diseases;Neoplasms;Pancreatic Neoplasms;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Pancreatic Diseases;Skin Diseases;Digestive System Neoplasms","Breast Neoplasms;Carcinoma, Ductal, Breast;Skin and Connective Tissue Diseases;Carcinoma, Ductal;Carcinoma;Neoplasms by Site;Neoplasms, Ductal, Lobular, and Medullary;Neoplasms;Adenocarcinoma;Neoplasms by Histologic Type;Breast Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Skin Diseases;Disease;Neoplasms, Glandular and Epithelial",,Hormone Receptor Interactions;Steroid Receptor Modulators;Selective Estrogen Receptor Modulators;Mechanism of Action (MoA);Transcription Factor Activity;Receptor Interactions;Hormone Receptor Modulators,Stimulate Ovulation;Organ System Specific Effects;Ovarian Endocrine Activity Alteration;Female Reproductive System Activity Alteration;Nucleic Acid Replication Alteration;Cellular Activity Alteration;DNA Replication Alteration;Decreased Ovarian Estrogen Secretion;Endocrine Activity Alteration;Ovarian Function Alteration;Decreased DNA Replication;Generalized Systemic Effects;Cellular Synthetic Activity Alteration;Ovulation Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Cellular Cycle Alteration,Receptor Agonist;Established Pharmacologic Class (EPC);Estrogen Agonist/Antagonist;Receptor Interaction;Receptor Antagonist,VA CLASSES;ANTINEOPLASTICS;ANTINEOPLASTIC HORMONES,VA CLASSES;ANTINEOPLASTICS;ANTINEOPLASTIC HORMONES,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;4-Hydroxycoumarins;Heterocyclic Compounds;Pyrans;Substances and Cells (CHEM);Benzopyrans;Warfarin;Heterocyclic Compounds, 1-Ring;Coumarins",,,,,,
225,91,28,Concomitant Medications,Generic Name,RxNorm,Januvia,Januvia Pill,1167815.0,Januvia Pill,638596.0,638596.0,638596,False,"Protease Inhibitors;Enzyme Inhibitors;MeSH Pharmacologic Actions (MESHPA);Hypoglycemic Agents;Physiological Effects of Drugs;Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Dipeptidyl-Peptidase IV Inhibitors;Incretins;Molecular Mechanisms of Pharmacological Action","BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Dipeptidyl peptidase 4 (DPP-4) inhibitors;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Proteinase inhibitor-containing product;Medicinal product categorized by disposition;Serine proteinase inhibitor-containing product;Hydrolase inhibitor-containing product;Dipeptidyl peptidase IV inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Azoles;Pyrazines;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Triazoles;Heterocyclic Compounds, 1-Ring;Sitagliptin Phosphate","Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Dipeptidyl Peptidase 4 Inhibitors,Organ System Specific Effects;Decreased Glucagon Secretion;Pancreatic Islet Activity Alteration;Endocrine Activity Alteration;Physiologic Effect (PE);Increased Insulin Secretion,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Blood Glucose Regulator;Enzyme Interaction;Antimicrobial;Dipeptidyl Peptidase 4 Inhibitor;Protease Inhibitor,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,,,
226,91,28,Concomitant Medications,Generic Name,RxNorm,Januvia,Januvia Pill,1167815.0,Januvia Pill,638596.0,638596.0,638596,False,"Protease Inhibitors;Enzyme Inhibitors;MeSH Pharmacologic Actions (MESHPA);Hypoglycemic Agents;Physiological Effects of Drugs;Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Dipeptidyl-Peptidase IV Inhibitors;Incretins;Molecular Mechanisms of Pharmacological Action","BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Dipeptidyl peptidase 4 (DPP-4) inhibitors;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Peptide hydrolase inhibitor-containing product;Proteinase inhibitor-containing product;Medicinal product categorized by disposition;Serine proteinase inhibitor-containing product;Hydrolase inhibitor-containing product;Dipeptidyl peptidase IV inhibitor-containing product;Enzyme inhibitor-containing product,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Azoles;Pyrazines;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Triazoles;Heterocyclic Compounds, 1-Ring;Sitagliptin Phosphate","Diabetes Mellitus, Type 1;Ketosis;Autoimmune Diseases;Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Complications;Chemically-Induced Disorders;Drug Hypersensitivity;Immune System Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Endocrine System Diseases;Disease;Diabetic Ketoacidosis;Metabolic Diseases;Acid-Base Imbalance;Nutritional and Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Protease Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Dipeptidyl Peptidase 4 Inhibitors,Organ System Specific Effects;Decreased Glucagon Secretion;Pancreatic Islet Activity Alteration;Endocrine Activity Alteration;Physiologic Effect (PE);Increased Insulin Secretion,Enzyme Inhibitor;Established Pharmacologic Class (EPC);Anti-infective;Blood Glucose Regulator;Enzyme Interaction;Antimicrobial;Dipeptidyl Peptidase 4 Inhibitor;Protease Inhibitor,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,,,,,,,,
227,92,28,Concomitant Medications,Generic Name,RxNorm,robitussin dm,Robitussin DM,827249.0,Robitussin DM,,1790650.0,1790650,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Expectorants;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Phenols;Catechols;Phenyl Ethers;Polycyclic Aromatic Hydrocarbons;Morphinans;Guaifenesin;Hydrocarbons;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Guaiacol;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Ethers;Methyl Ethers;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Hypersensitivity;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Respiratory Secretion Viscosity;Medullary Respiratory Center Activity Alteration;Respiratory Secretion Alteration;Physiologic Effect (PE);Increased Respiratory Secretions,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Expectorant;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,,Medicinal product categorized by therapeutic role;Antitussive agent;Expectorant agent,,,,,,,
228,92,28,Concomitant Medications,Generic Name,RxNorm,robitussin dm,Robitussin DM,827249.0,Robitussin DM,,1790650.0,1790650,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Excitatory Amino Acid Agents;Physiological Effects of Drugs;Antitussive Agents;Expectorants;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Medicinal product categorized by disposition,Ether structure-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, Bridged-Ring;Phenols;Catechols;Phenyl Ethers;Polycyclic Aromatic Hydrocarbons;Morphinans;Guaifenesin;Hydrocarbons;Benzene Derivatives;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Organic Chemicals;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Alkaloids;Guaiacol;Polycyclic Compounds;Phenanthrenes;Dextromethorphan;Hydrocarbons, Cyclic;Ethers;Methyl Ethers;Substances;Substances and Cells (CHEM);Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Hypersensitivity;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Neurotransmitter Transporter Interactions;Serotonin Uptake Inhibitors;Sigma-1 Receptor Agonists;Serotonin Transporter Interactions;Symporter Interactions;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Ion Channel Interactions;Uncompetitive NMDA Receptor Antagonists;Ionotropic Glutamate Receptor Antagonists;Receptor Interactions;Membrane Transporter Interactions;NMDA Receptor Antagonists,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Medullary Respiratory Drive;Decreased Respiratory Secretion Viscosity;Medullary Respiratory Center Activity Alteration;Respiratory Secretion Alteration;Physiologic Effect (PE);Increased Respiratory Secretions,Nervous System Agent;Receptor Agonist;Respiratory Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Receptor Interaction;Expectorant;Receptor Antagonist,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,,,,Medicinal product categorized by therapeutic role;Antitussive agent;Expectorant agent,,,,,,,
229,93,28,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
230,114,33,Concomitant Medications,Generic Name,RxNorm,tessalon,Tessalon Perles,220224.0,Tessalon Perles,227783.0,227783.0,227783,False,Respiratory System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Antitussive Agents;Central Nervous System Agents,"Other cough suppressants;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;Anatomical Therapeutic Chemical (ATC1-4)",,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Carboxylic acid and/or carboxylic acid derivative-containing product;Organic acid and/or organic acid derivative-containing product,"Hydrocarbons;Butanes;Alkanes;Hydrocarbons, Acyclic;Organic Chemicals;Substances;Substances and Cells (CHEM);Amines;Butylamines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Signs and Symptoms, Digestive;Hiccup;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",,Receptor Interactions;Antiporter Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Membrane Transporter Interactions;Sodium-Potassium Exchanging ATPase Interactions,Organ System Specific Effects;Tracheobronchial Stretch Receptor Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Tracheobronchial Stretch Receptor Activity;Physiologic Effect (PE),Non-narcotic Antitussive;Respiratory Agent;Established Pharmacologic Class (EPC),ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,ANTITUSSIVES/EXPECTORANTS;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES,Respiratory System Agent;Antitussive Agent;Therapeutic Categories,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
231,97,29,Concomitant Medications,Generic Name,RxNorm,clonazepam,clonazePAM,2598.0,clonazePAM,2598.0,2598.0,2598,False,GABA Modulators;Anticonvulsants;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;GABA Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIEPILEPTICS;Anatomical Therapeutic Chemical (ATC1-4);Benzodiazepine derivatives;NERVOUS SYSTEM,,Medicinal product categorized by structure;Benzazepine-containing product;Benzodiazepine-containing product,"Clonazepam;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM);Benzodiazepinones","Glaucoma, Angle-Closure;Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Eye Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ocular Hypertension;Disease;Glaucoma","Language Disorders;Schizophrenia Spectrum and Other Psychotic Disorders;Seizures;Mood Disorders;Epilepsy, Absence;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neuralgia;Bipolar Disorder;Life Phases, Behavior Mechanisms and Physiologic States;Speech Disorders;Bipolar and Related Disorders;Neurodevelopmental Disorders;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Neurobehavioral Manifestations;Peripheral Nervous System Diseases;Brain Diseases;Pain;Restless Legs Syndrome;Articulation Disorders;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Epilepsies, Myoclonic;Genetic Diseases, Inborn;Epileptic Syndromes;Sleep Wake Disorders;Tic Disorders;Communication Disorders;Behavior and Behavior Mechanisms;Epilepsy, Generalized;Parasomnias;Sleep Disorders, Intrinsic;Neuromuscular Diseases;Mental Disorders;Lennox Gastaut Syndrome;Nervous System Diseases;Panic Disorder;Dyssomnias;Epilepsy;Dysarthria;Schizophrenia;Signs and Symptoms;Movement Disorders",,,GABA A Modulators;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Channel Interactions;Chloride Channel Interactions;Receptor Interactions;Membrane Transporter Interactions;GABA A Receptor Interactions,Organ System Specific Effects;Gamma Amino Butyric Acid (GABA) Activity Alteration;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Increased GABA Activity;Physiologic Effect (PE),Nervous System Agent;Ion Channel or Pump Agent;Established Pharmacologic Class (EPC);Chemical Structure;Benzodiazepine,VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SEDATIVES/HYPONTICS,VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SEDATIVES/HYPONTICS,,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM)",,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM)",,SCHEDULE IV;CSA SCHEDULE
232,97,29,Concomitant Medications,Generic Name,RxNorm,clonazepam,clonazePAM,2598.0,clonazePAM,2598.0,2598.0,2598,False,GABA Modulators;Anticonvulsants;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Physiological Effects of Drugs;GABA Agents;Central Nervous System Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,ANTIEPILEPTICS;Anatomical Therapeutic Chemical (ATC1-4);Benzodiazepine derivatives;NERVOUS SYSTEM,,Medicinal product categorized by structure;Benzazepine-containing product;Benzodiazepine-containing product,"Clonazepam;Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM);Benzodiazepinones","Glaucoma, Angle-Closure;Life Phases, Behavior Mechanisms and Physiologic States;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Digestive System Diseases;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Eye Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Ocular Hypertension;Disease;Glaucoma","Language Disorders;Schizophrenia Spectrum and Other Psychotic Disorders;Seizures;Mood Disorders;Epilepsy, Absence;Central Nervous System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Neuralgia;Bipolar Disorder;Life Phases, Behavior Mechanisms and Physiologic States;Speech Disorders;Bipolar and Related Disorders;Neurodevelopmental Disorders;Anxiety Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Neurobehavioral Manifestations;Peripheral Nervous System Diseases;Brain Diseases;Pain;Restless Legs Syndrome;Articulation Disorders;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Epilepsies, Myoclonic;Genetic Diseases, Inborn;Epileptic Syndromes;Sleep Wake Disorders;Tic Disorders;Communication Disorders;Behavior and Behavior Mechanisms;Epilepsy, Generalized;Parasomnias;Sleep Disorders, Intrinsic;Neuromuscular Diseases;Mental Disorders;Lennox Gastaut Syndrome;Nervous System Diseases;Panic Disorder;Dyssomnias;Epilepsy;Dysarthria;Schizophrenia;Signs and Symptoms;Movement Disorders",,,GABA A Modulators;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Channel Interactions;Chloride Channel Interactions;Receptor Interactions;Membrane Transporter Interactions;GABA A Receptor Interactions,Organ System Specific Effects;Gamma Amino Butyric Acid (GABA) Activity Alteration;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Increased GABA Activity;Physiologic Effect (PE),Nervous System Agent;Ion Channel or Pump Agent;Established Pharmacologic Class (EPC);Chemical Structure;Benzodiazepine,VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SEDATIVES/HYPONTICS,VA CLASSES;BENZODIAZEPINE DERIVATIVE SEDATIVES/HYPNOTICS;CENTRAL NERVOUS SYSTEM MEDICATIONS;SEDATIVES/HYPONTICS,,,Anticonvulsant agent;Medicinal product categorized by therapeutic role,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM)",,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Benzazepines;Heterocyclic Compounds;Benzodiazepines;Substances and Cells (CHEM)",,SCHEDULE IV;CSA SCHEDULE
233,99,29,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,BLOOD AND BLOOD FORMING ORGANS;Vitamin B12 (cyanocobalamin and analogues);Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS,,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Medicinal product categorized by structure,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Autoimmune Diseases;Chemically-Induced Disorders;Deficiency Diseases;Anemia;Demyelinating Diseases;Central Nervous System Diseases;Malnutrition;Multiple Sclerosis;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Alcohol-Induced Disorders;Hematologic Diseases;Glucose Metabolism Disorders;Leukoencephalopathies;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Poisoning;Nutritional and Metabolic Diseases;Anemia, Megaloblastic;Alcohol-Induced Disorders, Nervous System;Alcoholic Neuropathy;Vitamin B Deficiency;Demyelinating Autoimmune Diseases, CNS;Vitamin B 12 Deficiency;Polyneuropathies;Neurotoxicity Syndromes;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Diabetes Mellitus;Anemia, Macrocytic;Mental Disorders;Nervous System Diseases;Diabetes Complications;Anemia, Pernicious;Nutrition Disorders;Immune System Diseases;Endocrine System Diseases;Metabolic Diseases","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Malnutrition;Vitamin B 12 Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Nutritional and Metabolic Diseases",,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Vitamin B12;Vitamin or Mineral,"CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS","CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings",,
234,99,29,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,BLOOD AND BLOOD FORMING ORGANS;Vitamin B12 (cyanocobalamin and analogues);Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS,,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Medicinal product categorized by structure,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Autoimmune Diseases;Chemically-Induced Disorders;Deficiency Diseases;Anemia;Demyelinating Diseases;Central Nervous System Diseases;Malnutrition;Multiple Sclerosis;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Alcohol-Induced Disorders;Hematologic Diseases;Glucose Metabolism Disorders;Leukoencephalopathies;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Poisoning;Nutritional and Metabolic Diseases;Anemia, Megaloblastic;Alcohol-Induced Disorders, Nervous System;Alcoholic Neuropathy;Vitamin B Deficiency;Demyelinating Autoimmune Diseases, CNS;Vitamin B 12 Deficiency;Polyneuropathies;Neurotoxicity Syndromes;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Diabetes Mellitus;Anemia, Macrocytic;Mental Disorders;Nervous System Diseases;Diabetes Complications;Anemia, Pernicious;Nutrition Disorders;Immune System Diseases;Endocrine System Diseases;Metabolic Diseases","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Malnutrition;Vitamin B 12 Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Nutritional and Metabolic Diseases",,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Vitamin B12;Vitamin or Mineral,"CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS","CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings",,
235,111,32,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,BLOOD AND BLOOD FORMING ORGANS;Vitamin B12 (cyanocobalamin and analogues);Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS,,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Medicinal product categorized by structure,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Autoimmune Diseases;Chemically-Induced Disorders;Deficiency Diseases;Anemia;Demyelinating Diseases;Central Nervous System Diseases;Malnutrition;Multiple Sclerosis;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Alcohol-Induced Disorders;Hematologic Diseases;Glucose Metabolism Disorders;Leukoencephalopathies;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Poisoning;Nutritional and Metabolic Diseases;Anemia, Megaloblastic;Alcohol-Induced Disorders, Nervous System;Alcoholic Neuropathy;Vitamin B Deficiency;Demyelinating Autoimmune Diseases, CNS;Vitamin B 12 Deficiency;Polyneuropathies;Neurotoxicity Syndromes;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Diabetes Mellitus;Anemia, Macrocytic;Mental Disorders;Nervous System Diseases;Diabetes Complications;Anemia, Pernicious;Nutrition Disorders;Immune System Diseases;Endocrine System Diseases;Metabolic Diseases","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Malnutrition;Vitamin B 12 Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Nutritional and Metabolic Diseases",,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Vitamin B12;Vitamin or Mineral,"CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS","CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings",,
236,111,32,Concomitant Medications,Generic Name,RxNorm,Vitamin B12,,,,11248.0,11248.0,11248,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,BLOOD AND BLOOD FORMING ORGANS;Vitamin B12 (cyanocobalamin and analogues);Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B12 AND FOLIC ACID;ANTIANEMIC PREPARATIONS,,Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Vitamin B12 and/or vitamin B12 derivative-containing product;Medicinal product categorized by structure,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hemic and Lymphatic Diseases;Avitaminosis;Autoimmune Diseases;Chemically-Induced Disorders;Deficiency Diseases;Anemia;Demyelinating Diseases;Central Nervous System Diseases;Malnutrition;Multiple Sclerosis;Alcohol-Related Disorders;Substance-Related Disorders;Diabetic Neuropathies;Alcohol-Induced Disorders;Hematologic Diseases;Glucose Metabolism Disorders;Leukoencephalopathies;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Peripheral Nervous System Diseases;Poisoning;Nutritional and Metabolic Diseases;Anemia, Megaloblastic;Alcohol-Induced Disorders, Nervous System;Alcoholic Neuropathy;Vitamin B Deficiency;Demyelinating Autoimmune Diseases, CNS;Vitamin B 12 Deficiency;Polyneuropathies;Neurotoxicity Syndromes;Autoimmune Diseases of the Nervous System;Neuromuscular Diseases;Diabetes Mellitus;Anemia, Macrocytic;Mental Disorders;Nervous System Diseases;Diabetes Complications;Anemia, Pernicious;Nutrition Disorders;Immune System Diseases;Endocrine System Diseases;Metabolic Diseases","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Malnutrition;Vitamin B 12 Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Nutritional and Metabolic Diseases",,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Vitamin B12;Vitamin or Mineral,"CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS","CYANOCOBALAMIN;VITAMIN B;VITAMINS;MULTIVITAMINS WITH MINERALS;MULTIVITAMINS;VITAMIN COMBINATIONS,OTHER;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,"Vitamin B 12;Tetrapyrroles;Azoles;Heterocyclic Compounds, Fused-Ring;Substances;Macrocyclic Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Pyrroles;Polycyclic Compounds;Corrinoids;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings",,
237,100,30,Concomitant Medications,Generic Name,RxNorm,Sumatriptan,SUMAtriptan,37418.0,SUMAtriptan,37418.0,37418.0,37418,False,Serotonin Agents;Vasoconstrictor Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Serotonin Receptor Agonists;Physiological Effects of Drugs;Serotonin 5-HT1 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Cardiovascular Agents,Selective serotonin (5HT1) agonists;NERVOUS SYSTEM;ANTIMIGRAINE PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS,Serotonin 5-HT1 receptor agonist-containing product;Serotonin receptor agonist-containing product;Medicinal product categorized by disposition,Sulfonamide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Sulfur and/or sulfur compound-containing product,"Biogenic Amines;Heterocyclic Compounds, 2-Ring;Indoles;Sulfonamides;Amides;Inorganic Chemicals;Biogenic Monoamines;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Tryptamines;Organic Chemicals;Sulfones;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Amines;Sumatriptan","Angina Pectoris, Variant;Chemically-Induced Disorders;Brain Ischemia;Arterial Occlusive Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Infarction;Necrosis;Central Nervous System Diseases;Chest Pain;Migraine with Aura;Angina Pectoris;Coronary Artery Disease;Drug Hypersensitivity;Liver Diseases;Cerebrovascular Disorders;Hypertension, Malignant;Stroke;Migraine Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Peripheral Vascular Diseases;Myocardial Ischemia;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Headache Disorders;Angina, Unstable;Pathologic Processes;Coronary Disease;Vascular Diseases;Arrhythmias, Cardiac;Nervous System Diseases;Digestive System Diseases;Myocardial Infarction;Headache Disorders, Primary;Arteriosclerosis;Signs and Symptoms","Cluster Headache;Nervous System Diseases;Central Nervous System Diseases;Trigeminal Autonomic Cephalalgias;Headache Disorders, Primary;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Headache Disorders;Migraine Disorders;Brain Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Serotonin Agonists;Serotonin 1d Receptor Agonists;Serotonin 1b Receptor Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions;Serotonin Receptor Interactions,Increased Immunologically Active Molecule Activity;Increased Immunologically Active Biogenic Amine Activity;Cardiovascular Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Immunologic Activity Alteration;Arterial Vasoconstriction;Vasoconstriction;Organ System Specific Effects;Increased Central Nervous System Serotonin Activity;Serotonin Activity Alteration;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Vascular Alterations;Cerebral Arterial Vasoconstriction;Increased Serotonin Activity,Nervous System Agent;Receptor Agonist;Serotonin-1b and Serotonin-1d Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Interaction,ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antimigraine agent,,,,,,,
238,100,30,Concomitant Medications,Generic Name,RxNorm,Sumatriptan,SUMAtriptan,37418.0,SUMAtriptan,37418.0,37418.0,37418,False,Serotonin Agents;Vasoconstrictor Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Serotonin Receptor Agonists;Physiological Effects of Drugs;Serotonin 5-HT1 Receptor Agonists;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents;Cardiovascular Agents,Selective serotonin (5HT1) agonists;NERVOUS SYSTEM;ANTIMIGRAINE PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);ANALGESICS,Serotonin 5-HT1 receptor agonist-containing product;Serotonin receptor agonist-containing product;Medicinal product categorized by disposition,Sulfonamide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Sulfur and/or sulfur compound-containing product,"Biogenic Amines;Heterocyclic Compounds, 2-Ring;Indoles;Sulfonamides;Amides;Inorganic Chemicals;Biogenic Monoamines;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Tryptamines;Organic Chemicals;Sulfones;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Amines;Sumatriptan","Angina Pectoris, Variant;Chemically-Induced Disorders;Brain Ischemia;Arterial Occlusive Diseases;Hypertension;Drug-Related Side Effects and Adverse Reactions;Infarction;Necrosis;Central Nervous System Diseases;Chest Pain;Migraine with Aura;Angina Pectoris;Coronary Artery Disease;Drug Hypersensitivity;Liver Diseases;Cerebrovascular Disorders;Hypertension, Malignant;Stroke;Migraine Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Ischemic Attack, Transient;Brain Diseases;Pain;Heart Diseases;Peripheral Vascular Diseases;Myocardial Ischemia;Ischemia;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Headache Disorders;Angina, Unstable;Pathologic Processes;Coronary Disease;Vascular Diseases;Arrhythmias, Cardiac;Nervous System Diseases;Digestive System Diseases;Myocardial Infarction;Headache Disorders, Primary;Arteriosclerosis;Signs and Symptoms","Cluster Headache;Nervous System Diseases;Central Nervous System Diseases;Trigeminal Autonomic Cephalalgias;Headache Disorders, Primary;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Headache Disorders;Migraine Disorders;Brain Diseases",,Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Serotonin Agonists;Serotonin 1d Receptor Agonists;Serotonin 1b Receptor Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions;Serotonin Receptor Interactions,Increased Immunologically Active Molecule Activity;Increased Immunologically Active Biogenic Amine Activity;Cardiovascular Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Immunologic Activity Alteration;Arterial Vasoconstriction;Vasoconstriction;Organ System Specific Effects;Increased Central Nervous System Serotonin Activity;Serotonin Activity Alteration;Increased Immunologic Activity;Immunologically Active Molecule Activity Alteration;Vascular Alterations;Cerebral Arterial Vasoconstriction;Increased Serotonin Activity,Nervous System Agent;Receptor Agonist;Serotonin-1b and Serotonin-1d Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Interaction,ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,ANTIMIGRAINE AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;ANALGESICS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antimigraine agent,,,,,,,
239,103,30,Concomitant Medications,Generic Name,RxNorm,B complex,,,,,801177.0,801177,True,Vitamin B Complex;Radiation-Sensitizing Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Dermatologic Agents;Physiological Effects of Drugs;Photosensitizing Agents,"CICATRIZANTS;PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS;DERMATOLOGICALS;VITAMINS;Vitamin B1, plain;SENSORY ORGANS;Other plain vitamin preparations;Other ophthalmologicals;OTHER PLAIN VITAMIN PREPARATIONS;OPHTHALMOLOGICALS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12;OTHER OPHTHALMOLOGICALS;Other cicatrizants",,Nitrogen and/or nitrogen compound-containing product;Sulfur and/or sulfur compound-containing product;Thiazole-containing product;Vitamin B2 and/or vitamin B2 derivative-containing product;Medicinal product categorized by structure,"Thiamine;beta-Alanine;Nicotinic Acids;Heterocyclic Compounds, 2-Ring;Niacinamide;Heterocyclic Compounds, Fused-Ring;Heterocyclic Compounds;Pigments, Biological;Organic Chemicals;Azoles;Acids, Heterocyclic;Heterocyclic Compounds, 1-Ring;Thiazoles;Vitamin B 6;Inorganic Chemicals;Coenzymes;Sulfur Compounds;Enzymes and Coenzymes;Pantothenic Acid;Pyrimidines;Riboflavin;Imides;Alanine;Biological Factors;Amino Acids, Peptides, and Proteins;Amino Acids;Picolines;Substances;Flavins;Substances and Cells (CHEM);Pyridines;Pteridines;Heterocyclic Compounds, 3-Ring","Vascular Diseases;Pathologic Processes;Chemically-Induced Disorders;Drug Hypersensitivity;Liver Diseases;Pathological Conditions, Signs and Symptoms;Digestive System Diseases;Duodenal Diseases;Gastrointestinal Diseases;Drug-Related Side Effects and Adverse Reactions;Intestinal Diseases;Peptic Ulcer;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Stomach Diseases;Hypotension;Hemorrhage","Avitaminosis;Dyslipidemias;Chemically-Induced Disorders;Deficiency Diseases;Malnutrition;Central Nervous System Diseases;Alcohol-Related Disorders;Substance-Related Disorders;Riboflavin Deficiency;Alcohol-Induced Disorders;Thiamine Deficiency;Pellagra;Vitamin B 6 Deficiency;Hypercholesterolemia;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Brain Diseases;Peripheral Nervous System Diseases;Poisoning;Nutritional and Metabolic Diseases;Peripheral Vascular Diseases;Alcohol-Induced Disorders, Nervous System;Alcoholic Neuropathy;Brain Diseases, Metabolic;Hyperlipidemias;Hypertriglyceridemia;Wernicke Encephalopathy;Vitamin B Deficiency;Polyneuropathies;Neurotoxicity Syndromes;Vascular Diseases;Neuromuscular Diseases;Mental Disorders;Nervous System Diseases;Nutrition Disorders;Beriberi;Metabolic Diseases;Lipid Metabolism Disorders","Avitaminosis;Deficiency Diseases;Arterial Occlusive Diseases;Malnutrition;Riboflavin Deficiency;Skin Diseases;Coronary Artery Disease;Pellagra;Vitamin B 6 Deficiency;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Myocardial Ischemia;Vitamin B Deficiency;Coronary Disease;Vascular Diseases;Skin and Connective Tissue Diseases;Nutrition Disorders;Arteriosclerosis",,Enzyme Activators;Enzyme Interactions;Mechanism of Action (MoA),Cholesterol Synthesis Alteration;Glucose Metabolism Alteration;Decreased Lipogenesis;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Lipid Metabolism Alteration;Cellular Activity Alteration;Decreased Cholesterol Synthesis;Generalized Systemic Effects;Increased Glycogenolysis;Polysaccharide Metabolism Alteration;Increased Metabolic Rate;Physiologic Effect (PE);Metabolic Rate Alteration;Sterol Metabolism Alteration;Cholesterol Metabolism Alteration;Triglyceride Metabolism Alteration,,"MULTIVITAMINS;VITAMINS;VITAMINS,COMBINATIONS;VA CLASSES",,,,,,,,"Flushing;Diarrhea;Skin Manifestations;Flatulence;Pathological Conditions, Signs and Symptoms;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms",,,
240,104,30,Concomitant Medications,Generic Name,RxNorm,"zinc, chelated",,,,253210.0,253210.0,253210,False,,,,,,,,,,,,,,,,,,,,,,,,
241,113,33,Concomitant Medications,Generic Name,RxNorm,budesonide,Budesonide 0.5 MG/ML Inhalant Solution,252559.0,Budesonide 0.5 MG/ML Inhalant Solution,19831.0,19831.0,19831,False,"Autonomic Agents;Bronchodilator Agents;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,Pregnenes;Substances;Budesonide;Steroids;Substances and Cells (CHEM);Pregnenediones;Polycyclic Compounds;Fused-Ring Compounds;Pregnanes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Signs and Symptoms;Disease Attributes;Pathologic Processes;Hypersensitivity;Bronchial Spasm;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Acute Disease","Hypersensitivity, Immediate;Nose Diseases;Intestinal Diseases;Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Gastroenteritis;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Gastrointestinal Diseases;Inflammatory Bowel Diseases","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL;ADRENAL CORTICOSTERIODS;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;HORMONES/SYNTHETICS/MODIFIERS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL;ADRENAL CORTICOSTERIODS;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;HORMONES/SYNTHETICS/MODIFIERS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
242,113,33,Concomitant Medications,Generic Name,RxNorm,budesonide,Budesonide 0.5 MG/ML Inhalant Solution,252559.0,Budesonide 0.5 MG/ML Inhalant Solution,19831.0,19831.0,19831,False,"Autonomic Agents;Bronchodilator Agents;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;INTESTINAL ANTIINFLAMMATORY AGENTS;Corticosteroids acting locally;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Glucocorticoid-containing product;Medicinal product categorized by structure;Corticosteroid and/or corticosteroid derivative-containing product;Pregnane-containing product,Pregnenes;Substances;Budesonide;Steroids;Substances and Cells (CHEM);Pregnenediones;Polycyclic Compounds;Fused-Ring Compounds;Pregnanes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Pathological Conditions, Signs and Symptoms;Disease Attributes;Pathologic Processes;Hypersensitivity;Bronchial Spasm;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Acute Disease","Hypersensitivity, Immediate;Nose Diseases;Intestinal Diseases;Respiratory Tract Infections;Respiratory Hypersensitivity;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Rhinitis, Allergic, Perennial;Rhinitis;Infections;Hypersensitivity;Otorhinolaryngologic Diseases;Gastroenteritis;Digestive System Diseases;Respiratory Tract Diseases;Immune System Diseases;Gastrointestinal Diseases;Inflammatory Bowel Diseases","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Lysosomal Function Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL;ADRENAL CORTICOSTERIODS;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;HORMONES/SYNTHETICS/MODIFIERS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;NASAL AND THROAT AGENTS,TOPICAL;ADRENAL CORTICOSTERIODS;GLUCOCORTICOIDS;RESPIRATORY TRACT MEDICATIONS;HORMONES/SYNTHETICS/MODIFIERS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
243,116,33,Concomitant Medications,Generic Name,RxNorm,Prilosec,PriLOSEC,203345.0,PriLOSEC,203345.0,203345.0,203345,False,Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Anti-Ulcer Agents;Proton Pump Inhibitors;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action,Proton pump inhibitors;DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD);DRUGS FOR ACID RELATED DISORDERS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),Cytochrome P450 inhibitor-containing product;Proton pump inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Benzimidazole-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Omeprazole;Inorganic Chemicals;Sulfoxides;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Substances;Heterocyclic Compounds;Pyridines;Substances and Cells (CHEM);Benzimidazoles;Organic Chemicals;2-Pyridinylmethylsulfinylbenzimidazoles;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Endocrine Gland Neoplasms;Paraneoplastic Endocrine Syndromes;Duodenal Ulcer;Esophagitis;Pharyngeal Diseases;Deglutition Disorders;Bacterial Infections and Mycoses;Bacterial Infections;Intestinal Diseases;Esophageal Diseases;Esophageal Motility Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Paraneoplastic Syndromes;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Helicobacter Infections;Gastrointestinal Neoplasms;Heartburn;Infections;Digestive System Neoplasms;Stomatognathic Diseases;Stomach Ulcer;Duodenal Diseases;Gastrointestinal Diseases;Otorhinolaryngologic Diseases;Digestive System Diseases;Gastroenteritis;Peptic Ulcer;Gram-Negative Bacterial Infections;Neoplasms;Zollinger-Ellison Syndrome;Endocrine System Diseases;Signs and Symptoms, Digestive;Stomach Diseases;Signs and Symptoms;Gastroesophageal Reflux",,,Proton Pump Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Receptor Interactions;Proton Pump Interactions;Cation Transporter Interactions;Cytochrome P450 2C19 Inhibitors;Mechanism of Action (MoA);Cytochrome P450 Inhibitors;Ion Transporter Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Digestive/GI System Activity Alteration;Gastric Acid Alteration;Inhibition Gastric Acid Secretion;Physiologic Effect (PE),Proton Pump Inhibitor;Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Gastrointestinal Agent,"GASTRIC MEDICATIONS,OTHER;VA CLASSES;GASTROINTESTINAL MEDICATIONS","ANTIULCER AGENTS;GASTROINTESTINAL MEDICATIONS;VA CLASSES;H. PYLORI AGENTS;GASTRIC MEDICATIONS,OTHER",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,
244,116,33,Concomitant Medications,Generic Name,RxNorm,Prilosec,PriLOSEC,203345.0,PriLOSEC,203345.0,203345.0,203345,False,Enzyme Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Anti-Ulcer Agents;Proton Pump Inhibitors;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action,Proton pump inhibitors;DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD);DRUGS FOR ACID RELATED DISORDERS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),Cytochrome P450 inhibitor-containing product;Proton pump inhibitor-containing product;Medicinal product categorized by disposition;Hydrolase inhibitor-containing product;Enzyme inhibitor-containing product,Benzimidazole-containing product;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Omeprazole;Inorganic Chemicals;Sulfoxides;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Substances;Heterocyclic Compounds;Pyridines;Substances and Cells (CHEM);Benzimidazoles;Organic Chemicals;2-Pyridinylmethylsulfinylbenzimidazoles;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Endocrine Gland Neoplasms;Paraneoplastic Endocrine Syndromes;Duodenal Ulcer;Esophagitis;Pharyngeal Diseases;Deglutition Disorders;Bacterial Infections and Mycoses;Bacterial Infections;Intestinal Diseases;Esophageal Diseases;Esophageal Motility Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Paraneoplastic Syndromes;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Helicobacter Infections;Gastrointestinal Neoplasms;Heartburn;Infections;Digestive System Neoplasms;Stomatognathic Diseases;Stomach Ulcer;Duodenal Diseases;Gastrointestinal Diseases;Otorhinolaryngologic Diseases;Digestive System Diseases;Gastroenteritis;Peptic Ulcer;Gram-Negative Bacterial Infections;Neoplasms;Zollinger-Ellison Syndrome;Endocrine System Diseases;Signs and Symptoms, Digestive;Stomach Diseases;Signs and Symptoms;Gastroesophageal Reflux",,,Proton Pump Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Receptor Interactions;Proton Pump Interactions;Cation Transporter Interactions;Cytochrome P450 2C19 Inhibitors;Mechanism of Action (MoA);Cytochrome P450 Inhibitors;Ion Transporter Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Digestive/GI System Activity Alteration;Gastric Acid Alteration;Inhibition Gastric Acid Secretion;Physiologic Effect (PE),Proton Pump Inhibitor;Established Pharmacologic Class (EPC);Ion Channel or Pump Agent;Gastrointestinal Agent,"GASTRIC MEDICATIONS,OTHER;VA CLASSES;GASTROINTESTINAL MEDICATIONS","ANTIULCER AGENTS;GASTROINTESTINAL MEDICATIONS;VA CLASSES;H. PYLORI AGENTS;GASTRIC MEDICATIONS,OTHER",,,,,Hepatic Metabolism;Metabolism;Pharmacokinetics (PK);Elimination;Site of Metabolism,,,,,
245,117,34,Concomitant Medications,Generic Name,RxNorm,Rybelsus,,,,2200645.0,2200645.0,2200645,False,,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Glucagon-like peptide-1 (GLP-1) analogues;DRUGS USED IN DIABETES;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Glucagon-like peptide 1 receptor agonist-containing product;Medicinal product categorized by disposition,Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure;Peptide-containing product,"Pancreatic Hormones;Protein Precursors;Peptides;Peptide Hormones;Gastrointestinal Hormones;Glucagon-Like Peptides;Substances and Cells (CHEM);Hormones;Proglucagon;Substances;Hormones, Hormone Substitutes, and Hormone Antagonists;Proteins;Amino Acids, Peptides, and Proteins","Endocrine Gland Neoplasms;Thyroid Diseases;Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Adenocarcinoma;Neoplasms by Histologic Type;Carcinoma, Neuroendocrine;Neoplastic Syndromes, Hereditary;Drug Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Thyroid Neoplasms;Neuroendocrine Tumors;Disease;Multiple Endocrine Neoplasia Type 2a;Neuroectodermal Tumors;Neoplasms, Multiple Primary;Multiple Endocrine Neoplasia Type 2b;Carcinoma;Neoplasms by Site;Head and Neck Neoplasms;Genetic Diseases, Inborn;Neoplasms, Germ Cell and Embryonal;Neoplasms, Nerve Tissue;Neoplasms;Endocrine System Diseases;Neoplasms, Glandular and Epithelial;Multiple Endocrine Neoplasia",,,,Glucagon-like Peptide-1 (GLP-1) Receptor Interactions;Receptor Interactions;Mechanism of Action (MoA);Glucagon-like Peptide-1 (GLP-1) Agonists;G-Protein-linked Receptor Interactions;Glucagon Receptor Interactions,Organ System Specific Effects;Decreased GI Motility;Decreased Glucagon Secretion;Pancreatic Islet Activity Alteration;Decreased Gastric Motility;Digestive/GI System Activity Alteration;Endocrine Activity Alteration;Physiologic Effect (PE);GI Motility Alteration;Increased Insulin Secretion,Receptor Agonist;Established Pharmacologic Class (EPC);Blood Glucose Regulator;Receptor Interaction;GLP-1 Receptor Agonist,"BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;HYPOGLYCEMIC AGENTS,OTHER;VA CLASSES","BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;HYPOGLYCEMIC AGENTS,OTHER;VA CLASSES",,,,,,,,"Pancreatic Hormones;Protein Precursors;Peptides;Glucagon-Like Peptide 1;Peptide Hormones;Gastrointestinal Hormones;Glucagon-Like Peptides;Substances and Cells (CHEM);Hormones;Proglucagon;Substances;Hormones, Hormone Substitutes, and Hormone Antagonists;Proteins;Amino Acids, Peptides, and Proteins",,
246,118,34,Concomitant Medications,Generic Name,RxNorm,Synjardy,,,,1664316.0,1664316.0,1664316,False,MeSH Pharmacologic Actions (MESHPA);Hypoglycemic Agents;Physiological Effects of Drugs;Sodium-Glucose Transporter 2 Inhibitors;Molecular Mechanisms of Pharmacological Action,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;Sodium-glucose co-transporter 2 (SGLT2) inhibitors;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Sodium glucose cotransporter subtype 2 inhibitor-containing product;Medicinal product categorized by disposition,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Carbohydrates;Hydrocarbons;Hydrocarbons, Cyclic;Guanidines;Benzene Derivatives;Biguanides;Glycosides;Amidines;Substances;Substances and Cells (CHEM);Glucosides;Metformin;Benzhydryl Compounds;Organic Chemicals;Hydrocarbons, Aromatic","Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cardiovascular Diseases",,Insulin Receptor Agonists;Insulin Receptor Interactions;Sodium-Glucose Transporter Interactions;Symporter Interactions;Monosaccharide Transporter Interactions;Sodium-Glucose Transporter Inhibitors;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Sodium-Glucose Transporter 2 Inhibitors;Receptor Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Renal Organic Ion Excretion;Renal/Urological Activity Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Renal Organic Ion Transport Alteration;Physiologic Effect (PE);Renal Ion Transport Alteration,Sodium-Glucose Cotransporter 2 Inhibitor;Established Pharmacologic Class (EPC);Biguanide;Blood Glucose Regulator;Chemical Structure,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
247,118,34,Concomitant Medications,Generic Name,RxNorm,Synjardy,,,,1664316.0,1664316.0,1664316,False,MeSH Pharmacologic Actions (MESHPA);Hypoglycemic Agents;Physiological Effects of Drugs;Sodium-Glucose Transporter 2 Inhibitors;Molecular Mechanisms of Pharmacological Action,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS;Combinations of oral blood glucose lowering drugs;Biguanides;DRUGS USED IN DIABETES;Sodium-glucose co-transporter 2 (SGLT2) inhibitors;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4)",Sodium glucose cotransporter subtype 2 inhibitor-containing product;Medicinal product categorized by disposition,Biguanide-containing product;Nitrogen and/or nitrogen compound-containing product;Medicinal product categorized by structure,"Carbohydrates;Hydrocarbons;Hydrocarbons, Cyclic;Guanidines;Benzene Derivatives;Biguanides;Glycosides;Amidines;Substances;Substances and Cells (CHEM);Glucosides;Metformin;Benzhydryl Compounds;Organic Chemicals;Hydrocarbons, Aromatic","Kidney Diseases;Ketosis;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Acidosis;Acid-Base Imbalance;Glucose Metabolism Disorders;Drug Hypersensitivity;Liver Diseases;Urologic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nutritional and Metabolic Diseases;Urogenital Diseases;Renal Insufficiency;Diabetes Mellitus;Diabetes Complications;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Female Urogenital Diseases;Endocrine System Diseases;Diabetic Ketoacidosis;Metabolic Diseases","Diabetes Mellitus;Glucose Metabolism Disorders;Diabetes Mellitus, Type 2;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Nutritional and Metabolic Diseases","Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Cardiovascular Diseases",,Insulin Receptor Agonists;Insulin Receptor Interactions;Sodium-Glucose Transporter Interactions;Symporter Interactions;Monosaccharide Transporter Interactions;Sodium-Glucose Transporter Inhibitors;Receptor Protein Kinase Interactions;Mechanism of Action (MoA);Ion Transporter Interactions;Sodium-Glucose Transporter 2 Inhibitors;Receptor Interactions;Membrane Transporter Interactions,Organ System Specific Effects;Glucose Metabolism Alteration;Carbohydrate Metabolism Alteration;Metabolic Activity Alteration;Glycogen Metabolism Alteration;Cell Glucose Transport Alteration;Increased Renal Organic Ion Excretion;Renal/Urological Activity Alteration;Increased Glucose Transport into Cells;Generalized Systemic Effects;Decreased Glycogenesis;Polysaccharide Metabolism Alteration;Decreased Gluconeogenesis;Renal Organic Ion Transport Alteration;Physiologic Effect (PE);Renal Ion Transport Alteration,Sodium-Glucose Cotransporter 2 Inhibitor;Established Pharmacologic Class (EPC);Biguanide;Blood Glucose Regulator;Chemical Structure,"ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES","ORAL HYPOGLYCEMIC AGENTS,ORAL;BLOOD GLUCOSE REGULATION AGENTS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,Renal Excretion;Elimination;Route of Excretion;Pharmacokinetics (PK),,,,,,Guanidines;Biguanides;Amidines;Substances;Substances and Cells (CHEM);Organic Chemicals,,
248,120,34,Concomitant Medications,Generic Name,RxNorm,Omega 3,,,,4301.0,4301.0,4301,False,,,,,"Lipids;Dietary Fats;Fatty Acids;Dietary Fats, Unsaturated;Fatty Acids, Omega-3;Fatty Acids, Unsaturated;Fats;Substances;Substances and Cells (CHEM);Fish Oils;Oils",,"Dyslipidemias;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Metabolic Diseases;Lipid Metabolism Disorders;Nutritional and Metabolic Diseases","Heart Diseases;Vascular Diseases;Arrhythmias, Cardiac;Myocardial Ischemia;Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Coronary Disease;Pathologic Processes",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Physiochemical Activity;Oxidation Activity;Mechanism of Action (MoA),Cell Membrane Alteration;Decreased Lipogenesis;Increased Lipolysis;Metabolic Activity Alteration;Cellular Activity Alteration;Lipid Metabolism Alteration;Generalized Systemic Effects;Cellular Communication Alteration;Physiologic Effect (PE);Cellular Structure Alteration;Triglyceride Metabolism Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Omega-3 Fatty Acid,,,,,,,,,,"Lipids;Dietary Fats;Fatty Acids;Dietary Fats, Unsaturated;Fatty Acids, Omega-3;Fatty Acids, Unsaturated;Fats;Substances;Substances and Cells (CHEM);Fish Oils;Oils",,
249,120,34,Concomitant Medications,Generic Name,RxNorm,Omega 3,,,,4301.0,4301.0,4301,False,,,,,"Lipids;Dietary Fats;Fatty Acids;Dietary Fats, Unsaturated;Fatty Acids, Omega-3;Fatty Acids, Unsaturated;Fats;Substances;Substances and Cells (CHEM);Fish Oils;Oils",,"Dyslipidemias;Hyperlipidemias;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Hypertriglyceridemia;Disease;Metabolic Diseases;Lipid Metabolism Disorders;Nutritional and Metabolic Diseases","Heart Diseases;Vascular Diseases;Arrhythmias, Cardiac;Myocardial Ischemia;Pathological Conditions, Signs and Symptoms;Cardiovascular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Coronary Disease;Pathologic Processes",,Unknown Cellular or Molecular Interaction;Oxidation-Reduction Activity;Physiochemical Activity;Oxidation Activity;Mechanism of Action (MoA),Cell Membrane Alteration;Decreased Lipogenesis;Increased Lipolysis;Metabolic Activity Alteration;Cellular Activity Alteration;Lipid Metabolism Alteration;Generalized Systemic Effects;Cellular Communication Alteration;Physiologic Effect (PE);Cellular Structure Alteration;Triglyceride Metabolism Alteration,Chemical Structure;Established Pharmacologic Class (EPC);Omega-3 Fatty Acid,,,,,,,,,,"Lipids;Dietary Fats;Fatty Acids;Dietary Fats, Unsaturated;Fatty Acids, Omega-3;Fatty Acids, Unsaturated;Fats;Substances;Substances and Cells (CHEM);Fish Oils;Oils",,
250,123,34,Concomitant Medications,Generic Name,RxNorm,Cefpodoxime,cefpodoxime 200 MG Oral Tablet,309078.0,cefpodoxime 200 MG Oral Tablet,20489.0,20489.0,20489,False,Anti-Bacterial Agents;Anti-Infective Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA),OTHER BETA-LACTAM ANTIBACTERIALS;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);Third-generation cephalosporins,Cephalosporin antibacterial agent;Medicinal product categorized by disposition;Third generation cephalosporin antibacterial agent,Nitrogen and/or nitrogen compound-containing product;Beta-lactam antibacterial agent;Cephalosporin antibacterial agent;Medicinal product categorized by structure;Beta-lactam-containing product;Third generation cephalosporin antibacterial agent,"Heterocyclic Compounds, 2-Ring;Amides;Cephalosporins;Inorganic Chemicals;Ceftizoxime;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Organic Chemicals;Substances;Thiazines;Heterocyclic Compounds;Substances and Cells (CHEM);Cefotaxime;Lactams;Cephacetrile;Heterocyclic Compounds, 1-Ring;beta-Lactams","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Pneumonia, Bacterial;Gonorrhea;Otitis;Maxillary Sinusitis;Male Urogenital Diseases;Cystitis;Proteus Infections;Lung Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Nose Diseases;Skin Diseases;Community-Acquired Infections;Bacterial Infections and Mycoses;Bacterial Infections;Escherichia coli Infections;Respiratory Tract Infections;Pasteurellaceae Infections;Sinusitis;Pneumonia;Gram-Positive Bacterial Infections;Urologic Diseases;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Urinary Bladder Diseases;Disease;Moraxellaceae Infections;Bronchial Diseases;Sexually Transmitted Diseases;Urinary Tract Infections;Otitis Media;Enterobacteriaceae Infections;Pathological Conditions, Signs and Symptoms;Klebsiella Infections;Neisseriaceae Infections;Bronchitis;Streptococcal Infections;Genital Diseases;Ear Diseases;Infections;Pathologic Processes;Stomatognathic Diseases;Disease Attributes;Staphylococcal Infections;Urogenital Diseases;Soft Tissue Infections;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Tonsillitis;Respiratory Tract Diseases;Female Urogenital Diseases and Pregnancy Complications;Female Urogenital Diseases;Sexually Transmitted Diseases, Bacterial;Staphylococcal Skin Infections;Communicable Diseases;Haemophilus Infections;Skin Diseases, Bacterial","Bacterial Infections and Mycoses;Bacterial Infections;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Infections",,Transpeptidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Decreased Cell Wall Synthesis & Repair;Cellular Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Cell Wall Alteration;Cellular Structure Alteration,Anti-infective;Established Pharmacologic Class (EPC);Cephalosporin Antibacterial;Chemical Structure;Antimicrobial;Antibacterial,ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;CEPHALOSPORIN 3RD GENERATION;VA CLASSES,ANTIMICROBIALS;PENICILLINS AND BETA-LACTAM ANTIMICROBIALS;CEPHALOSPORIN 3RD GENERATION;VA CLASSES,,,Antiinfective agent;Beta-lactam antibacterial agent;Cephalosporin antibacterial agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Third generation cephalosporin antibacterial agent,,,,,"Heterocyclic Compounds, 2-Ring;Amides;Cephalosporins;Inorganic Chemicals;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Organic Chemicals;Substances;Thiazines;Heterocyclic Compounds;Substances and Cells (CHEM);Lactams;Heterocyclic Compounds, 1-Ring;beta-Lactams",,
251,124,35,Concomitant Medications,Generic Name,RxNorm,methemazole,,,,,6835.0,6835,True,"Hormone Antagonists;MeSH Pharmacologic Actions (MESHPA);Antithyroid Agents;Physiological Effects of Drugs;Hormones, Hormone Substitutes, and Hormone Antagonists","THYROID THERAPY;Anatomical Therapeutic Chemical (ATC1-4);ANTITHYROID PREPARATIONS;Sulfur-containing imidazole derivatives;SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",,Sulfur and/or sulfur compound-containing product;Nitrogen and/or nitrogen compound-containing product;Thiourea-containing product;Medicinal product categorized by structure,"Azoles;Imidazoles;Inorganic Chemicals;Sulfur Compounds;Substances;Sulfhydryl Compounds;Heterocyclic Compounds;Substances and Cells (CHEM);Methimazole;Organic Chemicals;Heterocyclic Compounds, 1-Ring","Life Phases, Behavior Mechanisms and Physiologic States;Lactation;Chemically-Induced Disorders;Drug Hypersensitivity;Postpartum Period;Reproduction;Drug-Related Side Effects and Adverse Reactions;Pregnancy;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hyperthyroidism;Thyroid Crisis;Thyroid Diseases;Thyrotoxicosis;Goiter;Endocrine System Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease",,,Enzyme Inhibitors;Uncouplers;Thyroid Hormone Synthesis Inhibitors;Enzyme Interactions;Organic Anion Transporter Interactions;Anion Transporter Interactions;Mechanism of Action (MoA);Protein Synthesis Inhibitors;Ion Transporter Interactions;Receptor Interactions;Membrane Transporter Interactions,Cellular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Protein Modification;Physiologic Effect (PE);Decreased Iodine Organification;Endocrine Activity Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Iodine Organification Alteration;Post Translation Protein Modification Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Decreased Thyroid Hormone Iodination;Thyroid Gland Activity Alteration;Thyroid Hormone Iodination Alteration,Thyroid Hormone Synthesis Inhibitor;Enzyme Interaction;Established Pharmacologic Class (EPC);Enzyme Inhibitor,ANTITHYROID AGENTS;THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,ANTITHYROID AGENTS;THYROID MODIFIERS;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antithyroid agent,,,,,,,
252,126,36,Concomitant Medications,Generic Name,RxNorm,mirapex,Mirapex Pill,1180461.0,Mirapex Pill,218402.0,218402.0,218402,False,Protective Agents;Antiparkinson Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dopamine Agents;Physiological Effects of Drugs;Dopamine Agonists;Antioxidants;Central Nervous System Agents;Anti-Dyskinesia Agents;Neurotransmitter Agents;Molecular Mechanisms of Pharmacological Action,NERVOUS SYSTEM;Dopamine agonists;DOPAMINERGIC AGENTS;Anatomical Therapeutic Chemical (ATC1-4);ANTI-PARKINSON DRUGS,Dopamine receptor agonist-containing product;Medicinal product categorized by disposition,,"Thiazoles;Heterocyclic Compounds, 2-Ring;Azoles;Benzothiazoles;Inorganic Chemicals;Heterocyclic Compounds, Fused-Ring;Sulfur Compounds;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Organic Chemicals;Pramipexole;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Parkinson Disease;Basal Ganglia Diseases;Proteostasis Deficiencies;Neurodegenerative Diseases;Parkinsonian Disorders;Mental Disorders;Synucleinopathies;Nervous System Diseases;Depressive Disorder;Mood Disorders;Central Nervous System Diseases;Metabolic Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Brain Diseases;Movement Disorders;Nutritional and Metabolic Diseases",,,Dopamine Agonists;Mechanism of Action (MoA);G-Protein-linked Receptor Interactions;Receptor Interactions;Dopamine Receptor Interactions,Organ System Specific Effects;Increased Central Nervous System Dopamine Activity;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Dopamine Activity Alteration;Physiologic Effect (PE);Increased Dopamine Activity,Nervous System Agent;Receptor Agonist;Nonergot Dopamine Agonist;Established Pharmacologic Class (EPC);Receptor Interaction,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIPARKINSON AGENTS;VA CLASSES,CENTRAL NERVOUS SYSTEM MEDICATIONS;ANTIPARKINSON AGENTS;VA CLASSES,,,Medicinal product categorized by therapeutic role;Antiparkinson agent,,,,,,,
253,127,36,Concomitant Medications,Generic Name,RxNorm,dupixent,,,,1876402.0,1876402.0,1876402,False,,"OTHER DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Agents for dermatitis, excluding corticosteroids;DERMATOLOGICALS",Immunomodulator-containing product;Interleukin receptor antagonist-containing product;Interleukin-4 receptor alpha antagonist-containing product;Medicinal product categorized by disposition,Monoclonal antibody-containing product;Nitrogen and/or nitrogen compound-containing product;Polypeptide-containing product;Protein-containing product;Antibody-containing product;Medicinal product categorized by structure,"Antibodies, Monoclonal;Immunoproteins;Globulins;Serum Globulins;Substances;Immunoglobulins;Substances and Cells (CHEM);Blood Proteins;Proteins;Antibodies, Monoclonal, Humanized;Antibodies;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Skin Diseases, Genetic;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Eczematous;Genetic Diseases, Inborn;Immune System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hypersensitivity, Immediate;Dermatitis, Atopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Skin Diseases;Dermatitis",,,Interleukin 4 Receptor Interactions;Cytokine Receptor Superfamily Interactions;Mechanism of Action (MoA);Interleukin 4 Receptor alpha Antagonists;Receptor Interactions,Physiologic Effect (PE);Decreased Immunologic Activity;Immunologic Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Interleukin Agent;Receptor Interaction;Interleukin-4 Receptor alpha Antagonist;Receptor Antagonist;Immunologic Agent,"VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS","VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS",,,,,,,,"Antibodies, Monoclonal;Immunoproteins;Globulins;Serum Globulins;Substances;Immunoglobulins;Substances and Cells (CHEM);Blood Proteins;Proteins;Antibodies;Amino Acids, Peptides, and Proteins",,
254,127,36,Concomitant Medications,Generic Name,RxNorm,dupixent,,,,1876402.0,1876402.0,1876402,False,,"OTHER DERMATOLOGICAL PREPARATIONS;Anatomical Therapeutic Chemical (ATC1-4);Agents for dermatitis, excluding corticosteroids;DERMATOLOGICALS",Immunomodulator-containing product;Interleukin receptor antagonist-containing product;Interleukin-4 receptor alpha antagonist-containing product;Medicinal product categorized by disposition,Monoclonal antibody-containing product;Nitrogen and/or nitrogen compound-containing product;Polypeptide-containing product;Protein-containing product;Antibody-containing product;Medicinal product categorized by structure,"Antibodies, Monoclonal;Immunoproteins;Globulins;Serum Globulins;Substances;Immunoglobulins;Substances and Cells (CHEM);Blood Proteins;Proteins;Antibodies, Monoclonal, Humanized;Antibodies;Amino Acids, Peptides, and Proteins","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Skin Diseases, Genetic;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Eczematous;Genetic Diseases, Inborn;Immune System Diseases;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Hypersensitivity, Immediate;Dermatitis, Atopic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Skin Diseases;Dermatitis",,,Interleukin 4 Receptor Interactions;Cytokine Receptor Superfamily Interactions;Mechanism of Action (MoA);Interleukin 4 Receptor alpha Antagonists;Receptor Interactions,Physiologic Effect (PE);Decreased Immunologic Activity;Immunologic Activity Alteration;Generalized Systemic Effects,Established Pharmacologic Class (EPC);Interleukin Agent;Receptor Interaction;Interleukin-4 Receptor alpha Antagonist;Receptor Antagonist;Immunologic Agent,"VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS","VA CLASSES;DERMATOLOGICALS,SYSTEMIC,OTHER;DERMATOLOGICAL AGENTS",,,,,,,,"Antibodies, Monoclonal;Immunoproteins;Globulins;Serum Globulins;Substances;Immunoglobulins;Substances and Cells (CHEM);Blood Proteins;Proteins;Antibodies;Amino Acids, Peptides, and Proteins",,
255,128,37,Concomitant Medications,Generic Name,RxNorm,Chinese Medicine,,,,,1368530.0,1368530,True,,,,,,,,,,,,,,,,,,,,,,,,
256,130,37,Concomitant Medications,Generic Name,RxNorm,Vitamin B,,,,11251.0,11251.0,11251,False,,,,,,,,,,,,,,,,,,,,,,,,
257,131,38,Concomitant Medications,Generic Name,RxNorm,Fluticasone,,,,41126.0,41126.0,41126,False,"Autonomic Agents;Sympathomimetics;Bronchodilator Agents;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Allergic Agents;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Androstadienes;Androstanes;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Fluticasone;Androstenes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases","Hypersensitivity;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Infections","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;NASAL AND THROAT AGENTS,TOPICAL;ANTIHISTAMINES,NASAL;RESPIRATORY TRACT MEDICATIONS;DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;NASAL AND THROAT AGENTS,TOPICAL;ANTIHISTAMINES,NASAL;RESPIRATORY TRACT MEDICATIONS;DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
258,131,38,Concomitant Medications,Generic Name,RxNorm,Fluticasone,,,,41126.0,41126.0,41126,False,"Autonomic Agents;Sympathomimetics;Bronchodilator Agents;Glucocorticoids;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Hormones;Physiological Effects of Drugs;Anti-Inflammatory Agents;Hormones, Hormone Substitutes, and Hormone Antagonists;Anti-Allergic Agents;Anti-Asthmatic Agents","RESPIRATORY SYSTEM;DERMATOLOGICALS;Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;ADRENERGICS, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Androstadienes;Androstanes;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Fluticasone;Androstenes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases","Hypersensitivity;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Infections","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;NASAL AND THROAT AGENTS,TOPICAL;ANTIHISTAMINES,NASAL;RESPIRATORY TRACT MEDICATIONS;DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS","ANTIASTHMA,OTHER;ANTI-INFLAMMATORY,TOPICAL;NASAL AND THROAT AGENTS,TOPICAL;ANTIHISTAMINES,NASAL;RESPIRATORY TRACT MEDICATIONS;DERMATOLOGICAL AGENTS;ANTI-INFLAMMATORIES,NASAL;VA CLASSES;ANTI-INFLAMMATORIES,INHALATION;ANTIASTHMA/BRONCHODILATORS",,,,,,,,,,
259,135,40,Concomitant Medications,Generic Name,RxNorm,norgestimate/ethinyl estradiol,,,,214559.0,214559.0,214559,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Estrogens;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Hormones;Physiological Effects of Drugs;Contraceptives, Oral;Hormones, Hormone Substitutes, and Hormone Antagonists;Contraceptive Agents, Hormonal","ENDOCRINE THERAPY;Estrogens;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;Natural and semisynthetic estrogens, plain;ESTROGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;HORMONES AND RELATED AGENTS;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Estrogen receptor agonist-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,"Norpregnanes;Norpregnenes;Estrogenic Steroids, Alkylated;Ethinyl Estradiol;Gonadal Hormones;Estradiol Congeners;Substances;Steroids;Substances and Cells (CHEM);Hormones;Norsteroids;Hormones, Hormone Substitutes, and Hormone Antagonists;Norgestrel;Gonadal Steroid Hormones;Polycyclic Compounds;Fused-Ring Compounds;Norpregnatrienes","Embolism;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Intracranial Arterial Diseases;Central Nervous System Diseases;Liver Neoplasms;Lung Diseases;Tobacco Use Disorder;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Uterine Diseases;Hemorrhage;Myocardial Ischemia;Neoplasms by Site;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Breast Neoplasms;Vascular Diseases;Skin and Connective Tissue Diseases;Mental Disorders;Endometrial Neoplasms;Coronary Artery Disease;Glucose Metabolism Disorders;Uterine Neoplasms;Phlebitis;Urogenital Diseases;Diabetes Mellitus;Tobacco Use;Respiratory Tract Diseases;Neoplasms;Headache Disorders;Metabolic Diseases;Embolism and Thrombosis;Hemic and Lymphatic Diseases;Chemically-Induced Disorders;Thromboembolism;Cerebral Arterial Diseases;Hematologic Diseases;Cerebrovascular Disorders;Breast Diseases;Brain Diseases;Pathological Conditions, Signs and Symptoms;Pregnancy;Behavior and Behavior Mechanisms;Urogenital Neoplasms;Female Urogenital Diseases;Endocrine System Diseases;Arteriosclerosis;Behavior;Arterial Occlusive Diseases;Drug-Related Side Effects and Adverse Reactions;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Peripheral Vascular Diseases;Thrombosis;Vasculitis;Neoplasms, Hormone-Dependent;Uterine Hemorrhage;Thrombophlebitis;Pathologic Processes;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Pulmonary Embolism;Reproduction;Thrombophilia","Sexual Development;Primary Ovarian Insufficiency;Male Urogenital Diseases;Genital Neoplasms, Male;Prostatic Neoplasms;Skin Diseases;Hot Flashes;Gonadal Disorders;Life Phases, Behavior Mechanisms and Physiologic States;Menorrhagia;Menopause, Premature;Menopause;Adnexal Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Infertility;Breast Diseases;Uterine Diseases;Hemorrhage;Hypogonadism;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Climacteric;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Infertility, Female;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Genital Diseases, Male;Ovarian Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Female Urogenital Diseases;Endocrine System Diseases;Amenorrhea;Signs and Symptoms","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Osteoporosis, Postmenopausal;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Estrogen Receptor Agonists;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Inhibit Ovarian Follicular Phase;Decreased Embryonic Implantation;Bone Formation Stimulation;Nervous System Activity Alteration;Ovarian Follicular Phase Alteration;Bone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Female Reproductive System Activity Alteration;Autonomic Nervous System Activity Alteration;Inhibit Ovulation;Peripheral Nervous System Activity Alteration;Organ System Specific Effects;Ovarian Function Alteration;Ovulation Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Vaginal Function Alteration;Uterine Function Alteration;Bone Formation Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Uterine Smooth Muscle Contraction or Tone;Decreased Uterine Smooth Muscle Contraction or Tone,Progestin;Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Interaction;Estrogen;Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Renal Excretion;Hepatic Metabolism;Metabolism;Aromatic hydroxylation;Fecal Excretion;Pharmacokinetics (PK);Elimination;Site of Metabolism;Enzymatic Pathway of Metabolism;Route of Excretion,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Hemostasis Alteration;Hemic/Lymphatic Activity Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Increased Coagulation Activity;Blood Pressure Alteration;Hematologic Activity Alteration;Physiologic Effect (PE);Coagulation Activity Alteration,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
260,135,40,Concomitant Medications,Generic Name,RxNorm,norgestimate/ethinyl estradiol,,,,214559.0,214559.0,214559,False,"Contraceptives, Oral, Synthetic;Reproductive Control Agents;Estrogens;Contraceptives, Oral, Combined;Contraceptive Agents, Female;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Contraceptives, Oral, Hormonal;Contraceptive Agents;Hormones;Physiological Effects of Drugs;Contraceptives, Oral;Hormones, Hormone Substitutes, and Hormone Antagonists;Contraceptive Agents, Hormonal","ENDOCRINE THERAPY;Estrogens;SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;Natural and semisynthetic estrogens, plain;ESTROGENS;Anatomical Therapeutic Chemical (ATC1-4);GENITO URINARY SYSTEM AND SEX HORMONES;HORMONES AND RELATED AGENTS;Progestogens and estrogens, fixed combinations;Progestogens and estrogens, sequential preparations",Hormone-containing product;Estrogen receptor agonist-containing product;Progesterone receptor agonist-containing product;Medicinal product categorized by disposition,Medicinal product categorized by structure;Steroid-containing product,"Norpregnanes;Norpregnenes;Estrogenic Steroids, Alkylated;Ethinyl Estradiol;Gonadal Hormones;Estradiol Congeners;Substances;Steroids;Substances and Cells (CHEM);Hormones;Norsteroids;Hormones, Hormone Substitutes, and Hormone Antagonists;Norgestrel;Gonadal Steroid Hormones;Polycyclic Compounds;Fused-Ring Compounds;Norpregnatrienes","Embolism;Genital Neoplasms, Female;Male Urogenital Diseases;Hypertension;Intracranial Arterial Diseases;Central Nervous System Diseases;Liver Neoplasms;Lung Diseases;Tobacco Use Disorder;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Cardiovascular Diseases;Uterine Diseases;Hemorrhage;Myocardial Ischemia;Neoplasms by Site;Genital Diseases, Female;Venous Thrombosis;Genital Diseases;Digestive System Neoplasms;Coronary Disease;Breast Neoplasms;Vascular Diseases;Skin and Connective Tissue Diseases;Mental Disorders;Endometrial Neoplasms;Coronary Artery Disease;Glucose Metabolism Disorders;Uterine Neoplasms;Phlebitis;Urogenital Diseases;Diabetes Mellitus;Tobacco Use;Respiratory Tract Diseases;Neoplasms;Headache Disorders;Metabolic Diseases;Embolism and Thrombosis;Hemic and Lymphatic Diseases;Chemically-Induced Disorders;Thromboembolism;Cerebral Arterial Diseases;Hematologic Diseases;Cerebrovascular Disorders;Breast Diseases;Brain Diseases;Pathological Conditions, Signs and Symptoms;Pregnancy;Behavior and Behavior Mechanisms;Urogenital Neoplasms;Female Urogenital Diseases;Endocrine System Diseases;Arteriosclerosis;Behavior;Arterial Occlusive Diseases;Drug-Related Side Effects and Adverse Reactions;Heart Valve Diseases;Substance-Related Disorders;Skin Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Liver Diseases;Drug Hypersensitivity;Disease;Nutritional and Metabolic Diseases;Heart Diseases;Peripheral Vascular Diseases;Thrombosis;Vasculitis;Neoplasms, Hormone-Dependent;Uterine Hemorrhage;Thrombophlebitis;Pathologic Processes;Nervous System Diseases;Female Urogenital Diseases and Pregnancy Complications;Digestive System Diseases;Pulmonary Embolism;Reproduction;Thrombophilia","Sexual Development;Primary Ovarian Insufficiency;Male Urogenital Diseases;Genital Neoplasms, Male;Prostatic Neoplasms;Skin Diseases;Hot Flashes;Gonadal Disorders;Life Phases, Behavior Mechanisms and Physiologic States;Menorrhagia;Menopause, Premature;Menopause;Adnexal Diseases;Reproductive Physiological Phenomena;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Infertility;Breast Diseases;Uterine Diseases;Hemorrhage;Hypogonadism;Neoplasms by Site;Pathological Conditions, Signs and Symptoms;Uterine Hemorrhage;Climacteric;Genital Diseases, Female;Menstruation Disturbances;Genital Diseases;Pathologic Processes;Breast Neoplasms;Urogenital Diseases;Infertility, Female;Urogenital Neoplasms;Skin and Connective Tissue Diseases;Genital Diseases, Male;Ovarian Diseases;Female Urogenital Diseases and Pregnancy Complications;Neoplasms;Female Urogenital Diseases;Endocrine System Diseases;Amenorrhea;Signs and Symptoms","Bone Diseases;Life Phases, Behavior Mechanisms and Physiologic States;Reproduction;Pregnancy;Osteoporosis;Reproductive Physiological Phenomena;Bone Diseases, Metabolic;Osteoporosis, Postmenopausal;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Metabolic Diseases;Musculoskeletal Diseases;Nutritional and Metabolic Diseases",,Progestational Hormone Receptor Agonists;Hormone Receptor Interactions;Estrogen Receptor Agonists;Mechanism of Action (MoA);Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Sex Hormone Receptor Agonists;Transcription Factor Activity;Receptor Interactions,Inhibit Ovarian Follicular Phase;Decreased Embryonic Implantation;Bone Formation Stimulation;Nervous System Activity Alteration;Ovarian Follicular Phase Alteration;Bone Alteration;Reproductive System Activity Alteration;Physiologic Effect (PE);Female Reproductive System Activity Alteration;Autonomic Nervous System Activity Alteration;Inhibit Ovulation;Peripheral Nervous System Activity Alteration;Organ System Specific Effects;Ovarian Function Alteration;Ovulation Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Vaginal Function Alteration;Uterine Function Alteration;Bone Formation Alteration;Embryonic Implantation Alteration;Embryonic & Fetal Alteration;Uterine Smooth Muscle Contraction or Tone;Decreased Uterine Smooth Muscle Contraction or Tone,Progestin;Receptor Agonist;Established Pharmacologic Class (EPC);Receptor Interaction;Estrogen;Chemical Structure;Hormone,"CONTRACEPTIVES,SYSTEMIC;HORMONES/SYNTHETICS/MODIFIERS;VA CLASSES",,,Renal Excretion;Hepatic Metabolism;Metabolism;Aromatic hydroxylation;Fecal Excretion;Pharmacokinetics (PK);Elimination;Site of Metabolism;Enzymatic Pathway of Metabolism;Route of Excretion,Medicinal product categorized by therapeutic role;Contraceptive agent,,,Hemostasis Alteration;Hemic/Lymphatic Activity Alteration;Organ System Specific Effects;Cardiovascular Activity Alteration;Increased Blood Pressure;Increased Coagulation Activity;Blood Pressure Alteration;Hematologic Activity Alteration;Physiologic Effect (PE);Coagulation Activity Alteration,,"Gonadal Hormones;Progesterone Congeners;Substances;Substances and Cells (CHEM);Hormones;Hormones, Hormone Substitutes, and Hormone Antagonists;Gonadal Steroid Hormones",,
261,138,42,Concomitant Medications,Generic Name,RxNorm,"""Viro-grip"" cold medicine",Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,1052645.0,Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,,1117392.0,1117392,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Physiological Effects of Drugs;Histamine Agents;Anti-Asthmatic Agents;Nasal Decongestants;Histamine Antagonists;Histamine H1 Antagonists;Neurotransmitter Agents;Excitatory Amino Acid Agents;Autonomic Agents;Molecular Mechanisms of Pharmacological Action;Vasoconstrictor Agents;Central Nervous System Agents;Antipruritics;Bronchodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Anti-Allergic Agents;Antitussive Agents;Cardiovascular Agents,"Sympathomimetics;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;NASAL PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;Substituted alkylamines",Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Propylamine derivative histamine receptor antagonist product,Propylamine-containing product;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Alcohol-containing product;Medicinal product categorized by structure;Propylamine derivative histamine receptor antagonist product,"Heterocyclic Compounds, Bridged-Ring;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Amino Alcohols;Heterocyclic Compounds, Fused-Ring;Chlorpheniramine;Heterocyclic Compounds;Organic Chemicals;Propanols;Propanolamines;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Pheniramine;Phenethylamines;Pseudoephedrine;Alkaloids;Amines;Polycyclic Compounds;Alcohols;Phenanthrenes;Ethylamines;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Age Groups;Urethral Diseases;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Eye Diseases;Glaucoma, Angle-Closure;Lung Diseases, Obstructive;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Intestinal Diseases;Drug Hypersensitivity;Respiratory Hypersensitivity;Urethral Obstruction;Urologic Diseases;Urinary Bladder Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Bronchial Diseases;Glaucoma;Duodenal Obstruction;Intestinal Obstruction;Infant, Premature;Genital Diseases;Urogenital Diseases;Infant, Newborn;Hypersensitivity;Genital Diseases, Male;Duodenal Diseases;Gastrointestinal Diseases;Female Urogenital Diseases and Pregnancy Complications;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Digestive System Diseases;Female Urogenital Diseases;Prostatic Hyperplasia;Urinary Bladder Neck Obstruction;Ocular Hypertension;Peptic Ulcer;Stomach Diseases","Hypersensitivity, Immediate;Lung Diseases;Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Skin Diseases;Nose Diseases;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Infections;Picornaviridae Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases;Skin Diseases, Vascular;Urticaria;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Adrenergic Agonists;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Adrenergic beta-Agonists;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Decreased Immunologic Activity;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Immunologically Active Biogenic Amine Activity;Autonomic Nervous System Activity Alteration;Immunologic Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Medullary Respiratory Center Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Peripheral Nervous System Activity Alteration;Vasoconstriction;Bronchodilation;Organ System Specific Effects;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Immunologically Active Molecule Activity Alteration;Vascular Alterations;Decreased Medullary Respiratory Drive;Histamine Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Histamine-1 Receptor Antagonist;Receptor Interaction;alpha-Adrenergic Agonist;Receptor Antagonist,"ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
262,138,42,Concomitant Medications,Generic Name,RxNorm,"""Viro-grip"" cold medicine",Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,1052645.0,Tylenol Cold Relief (APAP 500 MG / diphenhydrAMINE hydrochloride 12.5 MG) Oral Tablet,,1117392.0,1117392,True,Excitatory Amino Acid Antagonists;Respiratory System Agents;Peripheral Nervous System Agents;Physiological Effects of Drugs;Histamine Agents;Anti-Asthmatic Agents;Nasal Decongestants;Histamine Antagonists;Histamine H1 Antagonists;Neurotransmitter Agents;Excitatory Amino Acid Agents;Autonomic Agents;Molecular Mechanisms of Pharmacological Action;Vasoconstrictor Agents;Central Nervous System Agents;Antipruritics;Bronchodilator Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Anti-Allergic Agents;Antitussive Agents;Cardiovascular Agents,"Sympathomimetics;RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;Opium alkaloids and derivatives;NASAL PREPARATIONS;COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS;NASAL DECONGESTANTS FOR SYSTEMIC USE;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;Substituted alkylamines",Adrenergic receptor agonist-containing product;Alpha-adrenergic and beta-adrenergic agonist-containing product;Alpha adrenergic receptor agonist-containing product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition;Beta adrenergic receptor agonist-containing product;NMDA receptor antagonist-containing product;Sigma-1 receptor agonist-containing product;Propylamine derivative histamine receptor antagonist product,Propylamine-containing product;Nitrogen and/or nitrogen compound-containing product;Ether structure-containing product;Alcohol-containing product;Medicinal product categorized by structure;Propylamine derivative histamine receptor antagonist product,"Heterocyclic Compounds, Bridged-Ring;Polycyclic Aromatic Hydrocarbons;Morphinans;Hydrocarbons;Amino Alcohols;Heterocyclic Compounds, Fused-Ring;Chlorpheniramine;Heterocyclic Compounds;Organic Chemicals;Propanols;Propanolamines;Heterocyclic Compounds, 1-Ring;Heterocyclic Compounds, 4 or More Rings;Opiate Alkaloids;Pheniramine;Phenethylamines;Pseudoephedrine;Alkaloids;Amines;Polycyclic Compounds;Alcohols;Phenanthrenes;Ethylamines;Dextromethorphan;Hydrocarbons, Cyclic;Substances;Substances and Cells (CHEM);Pyridines;Hydrocarbons, Aromatic","Age Groups;Urethral Diseases;Chemically-Induced Disorders;Male Urogenital Diseases;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Infant;Eye Diseases;Glaucoma, Angle-Closure;Lung Diseases, Obstructive;Asthma;Life Phases, Behavior Mechanisms and Physiologic States;Intestinal Diseases;Drug Hypersensitivity;Respiratory Hypersensitivity;Urethral Obstruction;Urologic Diseases;Urinary Bladder Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Bronchial Diseases;Glaucoma;Duodenal Obstruction;Intestinal Obstruction;Infant, Premature;Genital Diseases;Urogenital Diseases;Infant, Newborn;Hypersensitivity;Genital Diseases, Male;Duodenal Diseases;Gastrointestinal Diseases;Female Urogenital Diseases and Pregnancy Complications;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases;Digestive System Diseases;Female Urogenital Diseases;Prostatic Hyperplasia;Urinary Bladder Neck Obstruction;Ocular Hypertension;Peptic Ulcer;Stomach Diseases","Hypersensitivity, Immediate;Lung Diseases;Signs and Symptoms, Respiratory;Lung Diseases, Obstructive;Skin Diseases;Nose Diseases;Common Cold;Asthma;Virus Diseases;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Infections;Picornaviridae Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Otorhinolaryngologic Diseases;Respiratory Tract Diseases;Immune System Diseases;Skin Diseases, Vascular;Urticaria;Signs and Symptoms","Cough;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Respiration Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms, Respiratory;Signs and Symptoms",Monoamine Oxidase Inhibitors;Enzyme Interactions;Mechanism of Action (MoA);Enzyme Inhibitors,Sigma Receptor Interactions;Adrenergic Agonists;Neurotransmitter Transporter Interactions;Ion Channel Interactions;Serotonin Uptake Inhibitors;Adrenergic beta-Agonists;Ionotropic Glutamate Receptor Interactions;Sigma-1 Receptor Agonists;Sigma-1 Receptor Interactions;Receptor Interactions;Histamine H1 Receptor Antagonists;Histamine Receptor Antagonists;Symporter Interactions;G-Protein-linked Receptor Interactions;Ionotropic Glutamate Receptor Antagonists;Membrane Transporter Interactions;NMDA Receptor Antagonists;Adrenergic alpha-Agonists;Adrenergic Receptor Interactions;Serotonin Transporter Interactions;Histamine Receptor Interactions;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Uncompetitive NMDA Receptor Antagonists;Ion Transporter Interactions,Decreased Immunologic Activity;Cardiovascular Activity Alteration;Nervous System Activity Alteration;Generalized Systemic Effects;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Vascular Tone Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Immunologically Active Biogenic Amine Activity;Autonomic Nervous System Activity Alteration;Immunologic Activity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Histamine Activity;Medullary Respiratory Center Activity Alteration;Bronchial Smooth Muscle Tone Alteration;Peripheral Nervous System Activity Alteration;Vasoconstriction;Bronchodilation;Organ System Specific Effects;Respiratory Smooth Muscle Tone Alteration;Musculoskeletal Activity Alteration;Smooth Muscle Tone Alteration;Immunologically Active Molecule Activity Alteration;Vascular Alterations;Decreased Medullary Respiratory Drive;Histamine Activity Alteration,Nervous System Agent;Receptor Agonist;Adrenergic Receptor Agonist;Sympathomimetic Agent;Ion Channel or Pump Agent;Sigma-1 Agonist;Uncompetitive N-methyl-D-aspartate Receptor Antagonist;Established Pharmacologic Class (EPC);Histamine-1 Receptor Antagonist;Receptor Interaction;alpha-Adrenergic Agonist;Receptor Antagonist,"ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE;RESPIRATORY TRACT MEDICATIONS;COLD REMEDIES,COMBINATIONS;VA CLASSES",,,,Medicinal product categorized by therapeutic role;Antitussive agent,,,,,,,
263,140,42,Concomitant Medications,Generic Name,RxNorm,biotin,Biotin Pill,1154424.0,Biotin Pill,1588.0,1588.0,1588,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,VITAMINS;Other plain vitamin preparations;OTHER PLAIN VITAMIN PREPARATIONS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),,Imidazole-containing product;Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Azoles;Imidazoles;Coenzymes;Enzymes and Coenzymes;Substances;Heterocyclic Compounds;Biotin;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Genetic Diseases, Inborn;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Metabolism, Inborn Errors;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,,"VITAMIN B;VITAMINS;MULTIVITAMINS;VITAMIN B,OTHER;VA CLASSES;HERBS/ALTERNATIVE THERAPIES;VITAMINS,COMBINATIONS","VITAMIN B;VITAMINS;MULTIVITAMINS;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,,,
264,140,42,Concomitant Medications,Generic Name,RxNorm,biotin,Biotin Pill,1154424.0,Biotin Pill,1588.0,1588.0,1588,False,Vitamin B Complex;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Vitamins;Physiological Effects of Drugs,VITAMINS;Other plain vitamin preparations;OTHER PLAIN VITAMIN PREPARATIONS;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4),,Imidazole-containing product;Nitrogen and/or nitrogen compound-containing product;Azole-containing product;Medicinal product categorized by structure,"Azoles;Imidazoles;Coenzymes;Enzymes and Coenzymes;Substances;Heterocyclic Compounds;Biotin;Substances and Cells (CHEM);Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Avitaminosis;Deficiency Diseases;Nutrition Disorders;Genetic Diseases, Inborn;Malnutrition;Congenital, Hereditary, and Neonatal Diseases and Abnormalities;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Vitamin B Deficiency;Metabolism, Inborn Errors;Metabolic Diseases;Nutritional and Metabolic Diseases",,,Enzyme Interactions;Mechanism of Action (MoA),Physiologic Effect (PE);Cellular Activity Alteration;Generalized Systemic Effects,,"VITAMIN B;VITAMINS;MULTIVITAMINS;VITAMIN B,OTHER;VA CLASSES;HERBS/ALTERNATIVE THERAPIES;VITAMINS,COMBINATIONS","VITAMIN B;VITAMINS;MULTIVITAMINS;VITAMIN B,OTHER;VA CLASSES;VITAMINS,COMBINATIONS",,,,,,,,,,
265,144,43,Concomitant Medications,Generic Name,RxNorm,Antivert,Meclizine Oral Tablet [Antivert],368885.0,Meclizine Oral Tablet [Antivert],91818.0,91818.0,91818,False,Autonomic Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Cholinergic Antagonists;Cholinergic Agents;Anti-Allergic Agents;Antiemetics;Physiological Effects of Drugs;Histamine H1 Antagonists;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,Piperazine derivatives;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Piperazine derivative histamine receptor antagonist product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Piperazine derivative-containing product;Piperazine and/or piperazine derivative-containing product;Piperazine derivative histamine receptor antagonist product;Medicinal product categorized by structure,"Hydrocarbons;Hydrocarbons, Cyclic;Benzene Derivatives;Piperazines;Meclizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzhydryl Compounds;Organic Chemicals;Hydrocarbons, Aromatic;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Motion Sickness;Labyrinth Diseases;Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Otorhinolaryngologic Diseases;Vertigo;Vestibular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Ear Diseases","Motion Sickness;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms",,Cholinergic Muscarinic Receptor Interactions;Cholinergic Muscarinic Antagonists;Cholinergic Antagonists;Cholinergic Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Central Nervous System Depression;Decreased Immunologic Activity;Digestive/GI System Activity Alteration;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Acetylcholine Activity;Decreased Immunologically Active Biogenic Amine Activity;Acetylcholine Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Emesis Suppression;Organ System Specific Effects;Decreased GI Motility;Immunologically Active Molecule Activity Alteration;Histamine Activity Alteration;GI Motility Alteration;Central Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antiemetic;Gastrointestinal Agent,ANTIVERTIGO AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANTIVERTIGO AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Gastrointestinal Agent;Central Nervous System Agent;Anti-emetic Agent;Therapeutic Categories,,,,,,,,,
266,144,43,Concomitant Medications,Generic Name,RxNorm,Antivert,Meclizine Oral Tablet [Antivert],368885.0,Meclizine Oral Tablet [Antivert],91818.0,91818.0,91818,False,Autonomic Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Histamine Antagonists;Cholinergic Antagonists;Cholinergic Agents;Anti-Allergic Agents;Antiemetics;Physiological Effects of Drugs;Histamine H1 Antagonists;Histamine Agents;Central Nervous System Agents;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,Piperazine derivatives;Anatomical Therapeutic Chemical (ATC1-4);ANTIHISTAMINES FOR SYSTEMIC USE;RESPIRATORY SYSTEM,Histamine H1 receptor antagonist-containing product;Piperazine derivative histamine receptor antagonist product;Histamine receptor antagonist-containing product;Medicinal product categorized by disposition,Piperazine derivative-containing product;Piperazine and/or piperazine derivative-containing product;Piperazine derivative histamine receptor antagonist product;Medicinal product categorized by structure,"Hydrocarbons;Hydrocarbons, Cyclic;Benzene Derivatives;Piperazines;Meclizine;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Benzhydryl Compounds;Organic Chemicals;Hydrocarbons, Aromatic;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Motion Sickness;Labyrinth Diseases;Nervous System Diseases;Neurologic Manifestations;Pathological Conditions, Signs and Symptoms;Otorhinolaryngologic Diseases;Vertigo;Vestibular Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Ear Diseases","Motion Sickness;Pathological Conditions, Signs and Symptoms;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms",,Cholinergic Muscarinic Receptor Interactions;Cholinergic Muscarinic Antagonists;Cholinergic Antagonists;Cholinergic Interactions;Histamine Receptor Interactions;Histamine H1 Receptor Antagonists;Mechanism of Action (MoA);Histamine Receptor Antagonists;G-Protein-linked Receptor Interactions;Receptor Interactions,Central Nervous System Depression;Decreased Immunologic Activity;Digestive/GI System Activity Alteration;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Generalized Systemic Effects;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Acetylcholine Activity;Decreased Immunologically Active Biogenic Amine Activity;Acetylcholine Activity Alteration;Immunologic Activity Alteration;Decreased Histamine Activity;Emesis Suppression;Organ System Specific Effects;Decreased GI Motility;Immunologically Active Molecule Activity Alteration;Histamine Activity Alteration;GI Motility Alteration;Central Nervous System Activity Alteration,Established Pharmacologic Class (EPC);Antiemetic;Gastrointestinal Agent,ANTIVERTIGO AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,ANTIVERTIGO AGENTS;CENTRAL NERVOUS SYSTEM MEDICATIONS;VA CLASSES,Gastrointestinal Agent;Central Nervous System Agent;Anti-emetic Agent;Therapeutic Categories,,,,,,,,,
267,145,43,Concomitant Medications,Generic Name,RxNorm,Guaifenesin,Guaifenesin Pill,1159705.0,Guaifenesin Pill,5032.0,5032.0,5032,False,Respiratory System Agents;Expectorants;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;Anatomical Therapeutic Chemical (ATC1-4)",,Ether structure-containing product;Medicinal product categorized by structure,"Guaifenesin;Hydrocarbons;Hydrocarbons, Cyclic;Benzene Derivatives;Ethers;Phenols;Methyl Ethers;Organic Chemicals;Substances;Substances and Cells (CHEM);Catechols;Phenyl Ethers;Guaiacol;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Hypersensitivity;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms",,,,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Respiratory Secretion Viscosity;Respiratory Secretion Alteration;Physiologic Effect (PE);Increased Respiratory Secretions,Established Pharmacologic Class (EPC);Respiratory Agent;Expectorant,"COLD REMEDIES,COMBINATIONS;DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES","COLD REMEDIES,COMBINATIONS;DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Expectorant agent,,,,,,,SCHEDULE II;SCHEDULE V;SCHEDULE III;CSA SCHEDULE
268,145,43,Concomitant Medications,Generic Name,RxNorm,Guaifenesin,Guaifenesin Pill,1159705.0,Guaifenesin Pill,5032.0,5032.0,5032,False,Respiratory System Agents;Expectorants;MeSH Pharmacologic Actions (MESHPA);Therapeutic Uses,"RESPIRATORY SYSTEM;COUGH AND COLD PREPARATIONS;EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS;Expectorants;Anatomical Therapeutic Chemical (ATC1-4)",,Ether structure-containing product;Medicinal product categorized by structure,"Guaifenesin;Hydrocarbons;Hydrocarbons, Cyclic;Benzene Derivatives;Ethers;Phenols;Methyl Ethers;Organic Chemicals;Substances;Substances and Cells (CHEM);Catechols;Phenyl Ethers;Guaiacol;Hydrocarbons, Aromatic","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Hypersensitivity, Immediate;Lung Diseases;Laryngeal Diseases;Pharyngeal Diseases;Lung Diseases, Obstructive;Signs and Symptoms, Respiratory;Nose Diseases;Common Cold;Virus Diseases;Bacterial Infections and Mycoses;Bacterial Infections;Respiratory Tract Infections;Sinusitis;Respiratory Hypersensitivity;Paranasal Sinus Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Rhinitis, Allergic;Disease;Bronchial Diseases;Rhinitis, Allergic, Perennial;Rhinitis;Cough;RNA Virus Infections;Pathological Conditions, Signs and Symptoms;Respiration Disorders;Laryngitis;Bronchitis;Whooping Cough;Infections;Picornaviridae Infections;Stomatognathic Diseases;Hypersensitivity;Pharyngitis;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Respiratory Tract Diseases;Bordetella Infections;Immune System Diseases;Signs and Symptoms",,,,Organ System Specific Effects;Respiratory Secretion Viscosity Alteration;Respiratory/Pulmonary Activity Alteration;Decreased Respiratory Secretion Viscosity;Respiratory Secretion Alteration;Physiologic Effect (PE);Increased Respiratory Secretions,Established Pharmacologic Class (EPC);Respiratory Agent;Expectorant,"COLD REMEDIES,COMBINATIONS;DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES","COLD REMEDIES,COMBINATIONS;DECONGESTANT/EXPECTORANT;RESPIRATORY TRACT MEDICATIONS;NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;COLD REMEDIES,OTHER;ANTITUSSIVES/EXPECTORANTS;DECONGESTANT/ANTITUSSIVE/EXPECTORANT;DECONGESTANT/ANTITUSSIVE/EXPECTORANT/ANALGESIC;OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;VA CLASSES",,,Medicinal product categorized by therapeutic role;Expectorant agent,,,,,,,SCHEDULE II;SCHEDULE V;SCHEDULE III;CSA SCHEDULE
269,146,43,Concomitant Medications,Generic Name,RxNorm,Flonase,Flonase Nasal Product,1801248.0,Flonase Nasal Product,83373.0,83373.0,83373,False,Autonomic Agents;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Anti-Allergic Agents;Physiological Effects of Drugs;Anti-Inflammatory Agents;Anti-Asthmatic Agents,"RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Androstadienes;Androstanes;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Fluticasone;Androstenes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases","Hypersensitivity;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Infections","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES","ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES",,,,,,,,,,
270,146,43,Concomitant Medications,Generic Name,RxNorm,Flonase,Flonase Nasal Product,1801248.0,Flonase Nasal Product,83373.0,83373.0,83373,False,Autonomic Agents;Bronchodilator Agents;Respiratory System Agents;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Anti-Allergic Agents;Physiological Effects of Drugs;Anti-Inflammatory Agents;Anti-Asthmatic Agents,"RESPIRATORY SYSTEM;DERMATOLOGICALS;Glucocorticoids;CORTICOSTEROIDS, PLAIN;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS;Corticosteroids, potent (group III);NASAL PREPARATIONS;DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE;CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS;Corticosteroids;Anatomical Therapeutic Chemical (ATC1-4)",,Steroid-containing product;Fluorinated corticosteroid-containing product;Glucocorticoid-containing product;Corticosteroid and/or corticosteroid derivative-containing product;Androstane-containing product;Medicinal product categorized by structure,Androstadienes;Androstanes;Substances;Steroids;Substances and Cells (CHEM);Polycyclic Compounds;Fused-Ring Compounds;Fluticasone;Androstenes,"Chemically-Induced Disorders;Drug-Related Side Effects and Adverse Reactions;Hypersensitivity, Immediate;Lung Diseases;Lung Diseases, Obstructive;Skin Diseases;Asthma;Drug Hypersensitivity;Respiratory Hypersensitivity;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Infections;Hypersensitivity;Skin and Connective Tissue Diseases;Skin Diseases, Infectious;Status Asthmaticus;Respiratory Tract Diseases;Immune System Diseases","Hypersensitivity;Rhinitis;Otorhinolaryngologic Diseases;Respiratory Tract Infections;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Rhinitis, Allergic;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Nose Diseases;Rhinitis, Allergic, Perennial;Infections","Asthma;Nasal Polyps;Polyps;Hypersensitivity;Nose Diseases;Otorhinolaryngologic Diseases;Pathological Conditions, Signs and Symptoms;Respiratory Tract Diseases;Immune System Diseases;Respiratory Hypersensitivity;Hypersensitivity, Immediate;Lung Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Bronchial Diseases;Lung Diseases, Obstructive;Pathological Conditions, Anatomical",,Hormone Receptor Interactions;Corticosteroid Hormone Receptor Agonists;Steroid Hormone Receptor Agonists;Hormone Receptor Agonists;Mechanism of Action (MoA);Transcription Factor Activity;Glucocorticoid Receptor Agonists;Receptor Interactions,Cellular Activity Alteration;Decreased Vascular Permeability;Lysosomal Function Alteration;Cardiovascular Activity Alteration;Translation Alteration;Generalized Systemic Effects;Striated Muscle Metabolic Alteration;Decreased Glucocorticoid Secretion;Physiologic Effect (PE);Adrenal Cortical Activity Alteration;Decreased Polymorphonuclear Leukocyte Migration;Endocrine Activity Alteration;Cellular Degradation/Digestion Alteration;Striated Muscle Anabolism Alteration;Organ System Specific Effects;Vascular Permeability Alteration;Decreased Protein Synthesis;Cellular Synthetic Activity Alteration;Cellular Cycle Alteration;Musculoskeletal Activity Alteration;Decreased Fibroblast Migration;Vascular Alterations;Cellular Motion Alteration;Decreased Lysosomal Function;Decreased Capillary Permeability;Decreased Cellular Migration,Receptor Agonist;Corticosteroid;Established Pharmacologic Class (EPC);Receptor Interaction;Chemical Structure;Hormone,"ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES","ANTI-INFLAMMATORIES,NASAL;NASAL AND THROAT AGENTS,TOPICAL;VA CLASSES",,,,,,,,,,
271,147,43,Concomitant Medications,Generic Name,RxNorm,Ondansetron,Ondansetron,26225.0,Ondansetron,26225.0,26225.0,26225,False,Autonomic Agents;Serotonin Agents;Antipruritics;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Antiemetics;Physiological Effects of Drugs;Serotonin Antagonists;Central Nervous System Agents;Serotonin 5-HT3 Receptor Antagonists;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,Serotonin (5HT3) antagonists;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);ANTIEMETICS AND ANTINAUSEANTS,5-HT3 receptor antagonist-containing product;Medicinal product categorized by disposition,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, 3-Ring;Azoles;Indoles;Imidazoles;Ondansetron;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Carbazoles;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Chemically-Induced Disorders;Alcoholism;Alcohol-Related Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Substance-Related Disorders","Postoperative Complications;Pathological Conditions, Signs and Symptoms;Postoperative Nausea and Vomiting;Nausea;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Vomiting;Pathologic Processes",,Serotonin Antagonists;Membrane Transporter Interactions;Serotonin 5HT-3 Receptor Interactions;Serotonin 3 Receptor Antagonists;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Serotonin 5HT-3 Antagonists;Serotonin Receptor Interactions,Decreased Peripheral Nervous System Serotonin Activity;Central Nervous System Depression;Decreased Immunologic Activity;Digestive/GI System Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Decreased Central Nervous System Serotonin Activity;Emesis Suppression;Organ System Specific Effects;Serotonin Activity Alteration;Decreased Serotonin Activity;Immunologically Active Molecule Activity Alteration;Decreased GI Motility;GI Motility Alteration;Central Nervous System Activity Alteration,Nervous System Agent;Established Pharmacologic Class (EPC);Receptor Interaction;Serotonin-3 Receptor Antagonist;Receptor Antagonist,VA CLASSES;ANTIEMETICS;GASTROINTESTINAL MEDICATIONS,VA CLASSES;ANTIEMETICS;GASTROINTESTINAL MEDICATIONS,,,Medicinal product categorized by therapeutic role;Antiemetic agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Apomorphine;Aporphines;Isoquinolines;Alkaloids;Heterocyclic Compounds;Substances and Cells (CHEM);Substances;Benzylisoquinolines;Heterocyclic Compounds, 4 or More Rings",,,,,,
272,147,43,Concomitant Medications,Generic Name,RxNorm,Ondansetron,Ondansetron,26225.0,Ondansetron,26225.0,26225.0,26225,False,Autonomic Agents;Serotonin Agents;Antipruritics;Peripheral Nervous System Agents;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Dermatologic Agents;Antiemetics;Physiological Effects of Drugs;Serotonin Antagonists;Central Nervous System Agents;Serotonin 5-HT3 Receptor Antagonists;Gastrointestinal Agents;Molecular Mechanisms of Pharmacological Action;Neurotransmitter Agents,Serotonin (5HT3) antagonists;ALIMENTARY TRACT AND METABOLISM;Anatomical Therapeutic Chemical (ATC1-4);ANTIEMETICS AND ANTINAUSEANTS,5-HT3 receptor antagonist-containing product;Medicinal product categorized by disposition,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, 3-Ring;Azoles;Indoles;Imidazoles;Ondansetron;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Carbazoles;Heterocyclic Compounds, 1-Ring","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Mental Disorders;Chemically-Induced Disorders;Alcoholism;Alcohol-Related Disorders;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Substance-Related Disorders","Postoperative Complications;Pathological Conditions, Signs and Symptoms;Postoperative Nausea and Vomiting;Nausea;Signs and Symptoms, Digestive;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease;Signs and Symptoms;Vomiting;Pathologic Processes",,Serotonin Antagonists;Membrane Transporter Interactions;Serotonin 5HT-3 Receptor Interactions;Serotonin 3 Receptor Antagonists;Ligand-Gated Ion Channel Interactions;Mechanism of Action (MoA);Ion Channel Interactions;G-Protein-linked Receptor Interactions;Receptor Interactions;Serotonin 5HT-3 Antagonists;Serotonin Receptor Interactions,Decreased Peripheral Nervous System Serotonin Activity;Central Nervous System Depression;Decreased Immunologic Activity;Digestive/GI System Activity Alteration;Generalized Systemic Effects;Nervous System Activity Alteration;Neurotransmitter & Neuromuscular Transmitter Activity Alteration;Physiologic Effect (PE);Decreased Immunologically Active Molecule Activity;Decreased Immunologically Active Biogenic Amine Activity;Immunologic Activity Alteration;Decreased Central Nervous System Serotonin Activity;Emesis Suppression;Organ System Specific Effects;Serotonin Activity Alteration;Decreased Serotonin Activity;Immunologically Active Molecule Activity Alteration;Decreased GI Motility;GI Motility Alteration;Central Nervous System Activity Alteration,Nervous System Agent;Established Pharmacologic Class (EPC);Receptor Interaction;Serotonin-3 Receptor Antagonist;Receptor Antagonist,VA CLASSES;ANTIEMETICS;GASTROINTESTINAL MEDICATIONS,VA CLASSES;ANTIEMETICS;GASTROINTESTINAL MEDICATIONS,,,Medicinal product categorized by therapeutic role;Antiemetic agent,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Apomorphine;Aporphines;Isoquinolines;Alkaloids;Heterocyclic Compounds;Substances and Cells (CHEM);Substances;Benzylisoquinolines;Heterocyclic Compounds, 4 or More Rings",,,,,,
273,149,43,Concomitant Medications,Generic Name,RxNorm,ofloxacin otic,Ofloxacin Otic Solution,377450.0,Ofloxacin Otic Solution,1160453.0,1160453.0,1160453,False,"Anti-Infective Agents;Enzyme Inhibitors;Topoisomerase II Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cytochrome P-450 Enzyme Inhibitors;Anti-Bacterial Agents;Topoisomerase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Antineoplastic Agents;Metabolic Side Effects of Drugs and Substances;Anti-Infective Agents, Urinary;Molecular Mechanisms of Pharmacological Action",Antiinfectives;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;OTOLOGICALS;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);Fluoroquinolones;QUINOLONE ANTIBACTERIALS,Medicinal product categorized by disposition;Fluoroquinolone antibacterial agent,Nitrogen and/or nitrogen compound-containing product;Fluoroquinolone antibacterial agent;Quinoline-containing product;Quinolone antibacterial agent;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Quinolones;Heterocyclic Compounds, Fused-Ring;Fluoroquinolones;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Ofloxacin;Quinolines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonorrhea;Otitis;Tuberculosis;Male Urogenital Diseases;Cystitis;Prostatitis;Proteus Infections;Otitis Media, Suppurative;Lung Diseases;Eye Diseases;Lung Diseases, Obstructive;Skin Diseases;Eye Infections;Conjunctival Diseases;Chlamydia Infections;Mycobacterium Infections;Suppuration;Epididymitis;Bacterial Infections and Mycoses;Bacterial Infections;Corneal Ulcer;Escherichia coli Infections;Salmonella Infections;Keratitis;Respiratory Tract Infections;Conjunctivitis, Bacterial;Pasteurellaceae Infections;Urologic Diseases;Gram-Positive Bacterial Infections;Urinary Bladder Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Bronchial Diseases;Sexually Transmitted Diseases;Urinary Tract Infections;Actinomycetales Infections;Tuberculosis, Pulmonary;Otitis Externa;Otitis Media;Pathological Conditions, Signs and Symptoms;Enterobacteriaceae Infections;Klebsiella Infections;Helicobacter Infections;Inflammation;Neisseriaceae Infections;Bronchitis;Genital Diseases;Ear Diseases;Infections;Pathologic Processes;Disease Attributes;Corneal Diseases;Urogenital Diseases;Staphylococcal Infections;Soft Tissue Infections;Conjunctivitis;Skin and Connective Tissue Diseases;Genital Diseases, Male;Skin Diseases, Infectious;Eye Infections, Bacterial;Skin Diseases, Bacterial;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Female Urogenital Diseases and Pregnancy Complications;Respiratory Tract Diseases;Female Urogenital Diseases;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;DNA Gyrase Inhibitors;Topoisomerase 2 Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Topoisomerase 4 Inhibitors;Topoisomerase Inhibitors;Mechanism of Action (MoA),Transcription to RNA Alteration;Nucleic Acid Replication Alteration;Cellular Activity Alteration;DNA Replication Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased DNA Replication;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;DNA Integrity Alteration;Decreased Transcription to RNA;Cellular Cycle Alteration;Decreased DNA Integrity,Established Pharmacologic Class (EPC);Anti-infective;Quinolone Antimicrobial;Chemical Structure;Antimicrobial,"ANTIBACTERIALS,TOPICAL OTIC;OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES","ANTIBACTERIALS,TOPICAL OTIC;OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,,Antiinfective agent;Fluoroquinolone antibacterial agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Quinolone antibacterial agent,,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Quinolones;Quinolines",,
274,149,43,Concomitant Medications,Generic Name,RxNorm,ofloxacin otic,Ofloxacin Otic Solution,377450.0,Ofloxacin Otic Solution,1160453.0,1160453.0,1160453,False,"Anti-Infective Agents;Enzyme Inhibitors;Topoisomerase II Inhibitors;Therapeutic Uses;MeSH Pharmacologic Actions (MESHPA);Cytochrome P-450 Enzyme Inhibitors;Anti-Bacterial Agents;Topoisomerase Inhibitors;Cytochrome P-450 CYP1A2 Inhibitors;Antineoplastic Agents;Metabolic Side Effects of Drugs and Substances;Anti-Infective Agents, Urinary;Molecular Mechanisms of Pharmacological Action",Antiinfectives;ANTIBACTERIALS FOR SYSTEMIC USE;ANTIINFECTIVES;SENSORY ORGANS;OTOLOGICALS;ANTIINFECTIVES FOR SYSTEMIC USE;OPHTHALMOLOGICALS;Anatomical Therapeutic Chemical (ATC1-4);Fluoroquinolones;QUINOLONE ANTIBACTERIALS,Medicinal product categorized by disposition;Fluoroquinolone antibacterial agent,Nitrogen and/or nitrogen compound-containing product;Fluoroquinolone antibacterial agent;Quinoline-containing product;Quinolone antibacterial agent;Medicinal product categorized by structure,"Heterocyclic Compounds, 2-Ring;Quinolones;Heterocyclic Compounds, Fused-Ring;Fluoroquinolones;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Ofloxacin;Quinolines","Chemically-Induced Disorders;Drug Hypersensitivity;Drug-Related Side Effects and Adverse Reactions;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Disease","Gonorrhea;Otitis;Tuberculosis;Male Urogenital Diseases;Cystitis;Prostatitis;Proteus Infections;Otitis Media, Suppurative;Lung Diseases;Eye Diseases;Lung Diseases, Obstructive;Skin Diseases;Eye Infections;Conjunctival Diseases;Chlamydia Infections;Mycobacterium Infections;Suppuration;Epididymitis;Bacterial Infections and Mycoses;Bacterial Infections;Corneal Ulcer;Escherichia coli Infections;Salmonella Infections;Keratitis;Respiratory Tract Infections;Conjunctivitis, Bacterial;Pasteurellaceae Infections;Urologic Diseases;Gram-Positive Bacterial Infections;Urinary Bladder Diseases;Diseases, Life Phases, Behavior Mechanisms and Physiologic States;Prostatic Diseases;Disease;Bronchial Diseases;Sexually Transmitted Diseases;Urinary Tract Infections;Actinomycetales Infections;Tuberculosis, Pulmonary;Otitis Externa;Otitis Media;Pathological Conditions, Signs and Symptoms;Enterobacteriaceae Infections;Klebsiella Infections;Helicobacter Infections;Inflammation;Neisseriaceae Infections;Bronchitis;Genital Diseases;Ear Diseases;Infections;Pathologic Processes;Disease Attributes;Corneal Diseases;Urogenital Diseases;Staphylococcal Infections;Soft Tissue Infections;Conjunctivitis;Skin and Connective Tissue Diseases;Genital Diseases, Male;Skin Diseases, Infectious;Eye Infections, Bacterial;Skin Diseases, Bacterial;Otorhinolaryngologic Diseases;Gram-Negative Bacterial Infections;Female Urogenital Diseases and Pregnancy Complications;Respiratory Tract Diseases;Female Urogenital Diseases;Sexually Transmitted Diseases, Bacterial;Chlamydiaceae Infections;Haemophilus Infections;Communicable Diseases",,,Nucleic Acid Synthesis Inhibitors;DNA Gyrase Inhibitors;Topoisomerase 2 Inhibitors;Enzyme Inhibitors;Enzyme Interactions;Topoisomerase 4 Inhibitors;Topoisomerase Inhibitors;Mechanism of Action (MoA),Transcription to RNA Alteration;Nucleic Acid Replication Alteration;Cellular Activity Alteration;DNA Replication Alteration;Physiologic Effect (PE);Generalized Systemic Effects;Decreased DNA Replication;Nucleic Acid Transcription Alteration;Cellular Synthetic Activity Alteration;DNA Integrity Alteration;Decreased Transcription to RNA;Cellular Cycle Alteration;Decreased DNA Integrity,Established Pharmacologic Class (EPC);Anti-infective;Quinolone Antimicrobial;Chemical Structure;Antimicrobial,"ANTIBACTERIALS,TOPICAL OTIC;OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES","ANTIBACTERIALS,TOPICAL OTIC;OTIC AGENTS;ANTI-INFECTIVE,TOPICAL OTIC;VA CLASSES",Anti-infective Agent;Antimicrobial Agent;Therapeutic Categories,,Antiinfective agent;Fluoroquinolone antibacterial agent;Antibacterial agent;Medicinal product categorized by therapeutic role;Quinolone antibacterial agent,,,,,"Heterocyclic Compounds, 2-Ring;Heterocyclic Compounds, Fused-Ring;Substances;Heterocyclic Compounds;Substances and Cells (CHEM);Quinolones;Quinolines",,
275,153,45,Concomitant Medications,Generic Name,RxNorm,Zinc,Zinc,11416.0,Zinc,11416.0,11416.0,11416,False,Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Trace Elements,,,Mineral-containing product;Zinc and/or zinc compound-containing product;Medicinal product categorized by structure;Metal and/or metallic compound-containing product,"Amino Acids;Amino Acids, Sulfur;Amino Acids, Neutral;Amino Acids, Essential;Inorganic Chemicals;Sulfur Compounds;Organometallic Compounds;Transition Elements;Substances;Substances and Cells (CHEM);Zinc;Metals;Organic Chemicals;Methionine;Metals, Heavy;Elements;Amino Acids, Peptides, and Proteins",,,,,,,,,,,,,,,,,,,
276,153,45,Concomitant Medications,Generic Name,RxNorm,Zinc,Zinc,11416.0,Zinc,11416.0,11416.0,11416,False,Physiological Effects of Drugs;MeSH Pharmacologic Actions (MESHPA);Micronutrients;Trace Elements,,,Mineral-containing product;Zinc and/or zinc compound-containing product;Medicinal product categorized by structure;Metal and/or metallic compound-containing product,"Amino Acids;Amino Acids, Sulfur;Amino Acids, Neutral;Amino Acids, Essential;Inorganic Chemicals;Sulfur Compounds;Organometallic Compounds;Transition Elements;Substances;Substances and Cells (CHEM);Zinc;Metals;Organic Chemicals;Methionine;Metals, Heavy;Elements;Amino Acids, Peptides, and Proteins",,,,,,,,,,,,,,,,,,,
